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SUMMARY
Davies and coworkers, in 1974, reported that levels of 
anti-(whole cows* milk) antibodies were significantly 
raised in patients who had suffered a Myocardial 
Infarction (MI), compared to controls. In 1982 Davies et 
al, described that such antibodies were more 
specifically directed to a component of cows' milk, the 
milk fat globule membrane (BMFGM). Davies et al (1982), 
further showed that a possible cross-reaction, between 
anti-BMFGM antibodies and the platelet membrane may 
exist, possibly providing a pathogenic mechanism 
contributing to MI.
The work in this thesis has examined in more detail;
1. Anti-BMFGM antibodies in MI and control patients.
2. The antigenicity of the BMFGM.
3. The cross-reactivity of the BMFGM and the platelet 
membrane.
Using an ELISA, developed to detect anti-BMFGM 
antibodies, it was found that IgM anti-BMFGM antibodies 
were raised in MI patients, compared with controls. IgA 
and IgG anti-BMFGM levels were also measured, but no 
significant differences were found between MI and 
control groups.
A method of affinity purifying anti-BMFGM antibodies 
was developed, and using these, together with human
sera, as immunochemical probes of the BMFGM, a protein 
of Mr 150-155kD, corresponding to xanthine oxidase (XO), 
was shown to be a major antigen of the BMFGM. XO was 
further purified, and used to detect anti-XO antibodies 
in serum. A strong correlation was shown between anti-XO 
levels, and anti-BMFGM levels in individual sera. On 
examination of anti-XO antibody levels in MI and control 
sera, significant elevations of IgM anti-XO antibodies 
were seen in MI sera*, compared to controls, but not with 
IgG or IgA.
No specific cross-reaction between anti-BMFGM 
antibodies and the platelet membrane was found. However, 
it was shown that anti-BMFGM antibodies may bind to 
platelets in the form of immune complexes.
These findings are discussed with reference to Davies' 
findings and with reference to the inability of other 
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One hundred years ago Coronary Heart Disease (CHD) was 
virtually unknown. By 1925 it was still being discussed, 
in the Lancet, as an obscure medical curiosity. Now it 
kills more people in Britain than cancer, or any other 
known cause of death.
At the start of the eighties, CHD appeared destined to 
become the country's disease of the decade. Comparisons 
between nations (Vemura and Pisa, 1985) revealed that 
the countries of the United Kingdom were becoming 
increasingly isolated at the top of the International 
League table for CHD mortality (see Table 1, p 2 ). 
Measures proposed to establish risk factors for the 
disease became a topic of concern. Epidemiological 
surveys (Dawber, 1980;Keys, 1980;Shaper et a l , 1981) 
established blood pressure, serum cholesterol, relative 
body weight, and cigarette smoking as major risk 
factors. Other investigators (Hopkins and Williams, 
1981) have added to this list which now contains over 
200 entries.
The heart is essentially a pump which circulates blood 
(about 7,000L/day) around the body. It does so by means 
of electrically stimulated contractions of its muscle, 
the myocardium, which receives its own blood supply from 
the coronary arteries (see Fig 1, p 3 ).
Table 1 Age-standardised mortality from ischaemic heart
disease in 1980. Rates per 100,000 population aged 40-69 
years.
Males JFemales
Northern Ireland 630 Scotland 208
Finland 599 Northern Ireland 191
Scotland 592 New Zealand 178
Eire 499 Eire 160
England and Wales 482 England and Wales 136
New Zealand 468 Hungary 134
Czechoslovakia 438 Australia 133
Australia 421 Czechoslovakia 132
Hungary 410 U.S.A. 130
U.S.A. 398 Israel 128
Denmark 392 Finland 121
Canada 390 Canada 118
Norway 390 Denmark 112
Sweden 386 Bulgaria 100
Netherlands 323 Romania 93
West Germany 314 Sweden 90
Israel 314 Norway 86
Austria 293 Austria 80
Poland 282 Netherlands 78
Bulgaria 268 West Germany 75
Belgium 264 Belgium 72
Switzerland 219 Yugoslavia 71
Italy 212 Poland 66
Romania 202 Italy 53
Yugoslavia 197 Switzerland 47
France 137 France 30
Japan 65 Japan 24
Vemura and Pisa (1985)
3Fig 1
circulation.
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Rank or riianhragm atir. v iew
From Bowman and Rand (1980), p22.4
In CHD, interruptions to the bloodflow result from a 
number of processes, including those which lead to a 
thickening of the artery walls, causing a narrowing of 
the arteries themselves. This process is known as 
atherosclerosis (see sect 1.2, p9). Uncertainty exists 
about the precise relationship between most CHD 
associated factors and the cellular development of 
atherosclerosis (Ross, 1986). Nevertheless it is 
indisputable that atherosclerosis can lead to severe 
occlusion of the coronary arteries (Gorlin et a l ,1986) , 
giving rise to the following three principal 
manifestations of CHD;
1. Angina Pectoris, a gripping pain experienced in the 
chest, often extending to the neck and left arm under 
physiological exertion or emotional stress. The pain is 
the result of an inadequate supply of oxygen reaching 
the myocardium when contraction is required.
2. Myocardial Infarction (MI). Normal contraction of 
the myocardium cannot occur because of sustained loss of 
blood supply. The lack of oxygen in a particular area 
results in muscle necrosis, the extent of which is 
thought to be an important factor in influencing 
survival.
3. Sudden Cardiac Death. Here, a patient, often in good 
health, collapses entirely without warning (Eisenberg et 
al , 1986). Death is usually the result of ventricular 
fibrillation leading to pump failure (Mitchell, 1978).
Fig 2 , p6, illustrates the large contribution (49%) 
that diseases of the circulatory system made to 
mortality in England and Wales in 1985. Conditions 
relating to the heart account for 67% of deaths within 
this group, the most significant disorder being CHD. 
Consequently, CHD caused 28% of the total mortality for 
England and Wales that year. Table 2, p7 , shows the age 
distribution of mortality from CHD. The majority (80%) 
of deaths from this occur in persons aged 65 or over. 
Nevertheless, the disease remains a significant cause of 
premature mortality. Overall, it accounts for one third 
of male deaths under 65, but reaching two fifths between 
the ages of 45 and 65 (see Fig 3,p8).
CHD during the middle decades of life is far more 
common in men than in women (Stamler,1963;Barrett-Connor 
and Khaw,1988). With increasing age, this sex diff­
erential disappears (Fig 3, p 8 ). One possible 
explanation is that increased endogenous oestrogen 
production may prevent development of the disease, and, 
after the onset of the menopause, this protection 
disappears (Oliver and Boyd,1959;Kennel et al ,1976). 
However, the incidence of venous thrombosis in younger 
women is higher than in men from the same age group 
(O.P .C .S .,1982) and angina is more frequently 
experienced than in men (R .C.G.P .,1986). Bradley et al 
(1978) have reported that HDL levels increase with 
increasing doses of oestrogen and fall with increasing 
progesterone doses when studying females taking oral 
contraception (in general high HDL levels are






















7Table 2 Age distribution of CHD mortality in England
and Wales, 1985.
Age group Males Females Total
Under 15 1 0 1
15-24 10 4 14
25-34 138 32 170
35-44 1,398 205 1,603
45-54 5,910 1,114 7,024
55-64 17,902 5,733 23,635
65-74 30,199 16,562 46,761
75 + 36,068 47,828 83,896
All Ages 91,626 71,478 163,104
From WeiIs (1986).
8Fig 3 Deaths from CHD as a percentage of all deaths at


















9considered to be protective against CHD (Gordon et al, 
1989)).
1.2 Atherosclerosis
In 1904 Marchand recognised the consistent association 
of fatty degeneration and vessel stiffening. The term 
atherosclerosis was reintroduced (Athera = gruel, 
Sclera = hardening). Atherosclerosis is often associated 
with narrowing of the arteries, affecting large and some 
medium sized arteries, mainly the aorta, femoral, 
popliteal, renal, carotid, coronary, vertebral, and the 
circle of Willis (Bowman and Rand,1980). It is only the 
internal lining of the arteries which is susceptible to 
atherosclerotic lesions.
Atheroma will not cause any problems if the lumen 
allows sufficient blood to get through to the heart 
muscle. Several factors are now thought to lead to 
accelerated occlusion. For example, local bends in 
arteries can influence exactly where plaques develop 
(Mitchell and Schwartz,1965), and real problems of MI 
develop when the coronary artery suddenly becomes 
blocked because of any combination of the following:-
1. Rupture of an atheromatous plaque.
2. Thrombus formation.
3. Coronary artery spasm.
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The walls of arteries contain three layers (see Fig 4, 
pll)
A.The Intima consists of a single layer of flattened 
endothelial cells lining the lumen, and mounted on a 
basement membrane. Beneath this is loose fibrous elastic 
connective tissue and a well developed internal elastic 
membrane.
B.The Media comprises circularly arranged smooth muscle 
cells, together with elastin fibres in all but the 
smallest arteries.
C.The Adventitia contains a fibro-elastic tissue with a 
nerve plexus under sympathetic stimulation. Fibroblasts 
are present in this layer also.
The lesions of atherosclerosis can take two major 
forms, the fatty streak and the advanced lesion or 
fibrous plaque. The fatty streak can occur throughout 
life from as early as infancy, and is a flat lesion. 
Cholesterol esters are present in appreciable amounts, 
intracellularly, in both smooth muscle cells and 
macrophages, which are thereby transformed into so 
called foam cells. The advanced lesion or fibrous plaque 
(see Fig 5,pl2) is found in young individuals with 
genetic forms of hyper1ipidaemia, but in the apparently 
healthy population is found to increase in frequency 
with increase in age (Woolf,1982).
The fibrous plaque has four dominant pathological 
characteristics, Fig 6,p 12:-
11
Fig 4 Transverse section through a normal artery,














Adapted from Taussig (1979) and Wells (1982)
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Fig 5 Transverse section through a diseased artery, 





Fig 6 The pathological characteristics of the fibrous 
plaque.














Adapted from Taussig (1979) and Wells (1982).
13
1 .Proliferation of smooth muscle cells, with variable, 
but large numbers of blood-derived macrophages, 
platelets, neutrophils, and lymphocytes.
2.The presence of the connective tissue matrix proteins 
and proteoglycans produced by smooth muscle cells.
3.Lipid accumulation in the form of foam cells within 
smooth muscle cells and macrophages.
4.Focal distributions of the lesions.
Later events in the history of the plaque may involve 
death of intimal smooth muscle cells and softening of 
the plaque base, possibly leading to ulceration, 
calcification, and lastly mural, or occlusive thrombosis 
(Forrester et a l , 1987). Controversy exists concerning 
the relationship of the fatty streak and the fibrous 
plaque (Woolf,1982; McGil1,1984). In recent years, 
another lesion, the gelatinous lesion, has also been 
implicated in the development of plaques (Haust,1971). 
It is generally considered to be a form of focal, 
intimal oedema.
1.3 The pathogenesis of atherosclerosis.
The processes involved in atherogenesis are still the 
subject of much debate. Table 3, pl4-15 summarises some
of the findings which have contributed to our current 
perception of the disease. According to our present 
understanding, atherosclerosis can be discussed under 
two headings; Hyper1ipidaemia and thrombosis.
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Table 3 Some major contributions of research into
atherosclerosis.
AUTHOR OBSERVATION
Crel1, 1740 Basal pool in atherosclerotic 
plaque is akin to pus and 
represents the end point of an 
inflammatory process.
Von Haller,1755 Similar to that of Crell and re­
introduced the term Atheroma.




Association between lesions in 
coronary arteries and at least one 
of the symptoms of myocardial 
ischaemia.
Von Rokitansky,1844 Plaques contain deposition of 
blood constituents, mainly fibrin, 
on the luminal surface of the 
arterial wall.
Vogel,1847 Plaques contain large amounts of 
cholesterol.
Virchow,1856 Lesion is subendothelial and 
arises from the loosening of the 
connective tissue ground 
substance of the lumen as a result 
of "imbibition" of constituents of 
passing blood.
Thoma,1883 Primary fault is a localised 
weakness in the media and the 
consequent aneurysmal dilation 




Fatty lesions in rabbits can be 
produced on provision of a diet 
rich in egg yolk.






Medial thinning is an accom- 
paniament of the athero­
sclerotic plaque.
Poole et al, 
1958
Removal of the endothelium gives 
rise to intimal lesions and smooth 
muscle cell proliferation.




Smooth muscle cell proliferation 
within fibrous plaques is 
monoclonal.
Ross et al, 
1974
Platelet-Derived growth factor 
causes smooth muscle cell 
proliferation.
Brown et al , 
1975
Free and esterified cholesterol 
is regulated by an LDL receptor.
Mustard and 
Packham,1975
Mural thrombi contain smooth 
muscle cells and lipids.
Wolinsky et a l , 
1975
Lysosomes in atherosclerotic 




Increase in cellular turnover in 
endothelial foci gives rise to an 
increase in trans-edothelial 
permeability.
Monacada et al, 
1976
Arterial walls are protected 
against platelet deposition by 
prostacyclin.
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The involvement of hyperlipidaeroia in atherosclerosis 
can be inferred from the following:-
(a) Atherosclerotic lesions contain more cholesterol 
than surrounding areas
(b) Genetic conditions, causing elevated lipid levels in 
serum, predispose certain individuals to premature heart 
disease (Brown and Goldstein,1984).
(c) Diets, high in cholesterol and saturated fats, are 
associated with populations in which heart disease is 
prevalent (Keys,1970;Shekelle et a l ,1981), and reducing 
plasma cholesterol levels in hypercholesterolaemic men, 
reduces their risk of having an MI
(L.R.C.P.,1984;Vines,1989) .
Involvement of thrombosis in atherosclerosis is 
suggested by the following observations:-
(a) Atherosclerotic plaques are associated with mural 
thrombi containing varying amounts of platelets and 
fibrin.
(b) Changes associated with early atherosclerotic 
lesions are influenced by platelets (Duguid,1948; Moore 
et al ,1976).
1.3.1 Lipids and atherosclerosis.
Lipids and cholesterol are carried in the bloodstream 
as complex lipoproteins, named according to their 
densities and with the compositions shown in Table 4, 
p 17. Various proteinaceous components of lipoproteins,
1 7
Table 4 Composition of the plasma lipoproteins
Type Density Major
(g/cm3) Polypeptides
Chylomicrons <0.94 apo A ,B ,C
Very Low Density
Lipoproteins (VLDL) 0.94 - 1.006 apo B ,C ,E
Low Density
Lipoproteins (LDL) 1.006 - 1.063 apo B
High Density
Lipoproteins (HDL) 1.063 - 1.210 apo A
From Stryer (1981), p470
lipoproteins, termed apoproteins, are designated A-E. 
The two lipoproteins most relevant to heart disease are 
Low Density Lipoprotein (LDL) and High Density 
Lipoprotein (HDL). The trafficking of lipoproteins in 
the body is explained in Fig 7, pl9-20. Briefly, the 
role of LDL is to transport cholesterol to peripheral 
tissues and regulate de novo cholesterol synthesis at 
these sites. One role of HDL is to transport cholesterol 
from peripheral tissues to the liver. Non-hepatic cells 
have specific LDL receptors on their surface. Following 
binding to the cells LDL is endocytosed and metabolised. 
Much of our current understanding of this phenomenon 
results from the work of Brown and Goldstein (1986), who 
have speculated that, if LDL receptors in arterial walls 
are saturated with LDL (i.e. there is an excess in the 
blood) then both cholesterol and its esters may
accumulate in arterial walls by non-physiological bulk
transfer systems. It is possible that an increase in the 
number of cholesterol molecules of the endothelial 
plasma membrane may affect its physical properties 
(Jackson and Gotto,1976). Evidence for the hypothesis 
stems from the genetic disorder, Familial 
Hypercholesterolaemia, in which there is a defect or 
absence of the LDL receptor. In addition, people
suffering from this condition are prone to heart 
attacks from as early an age as two. Diet induced
hypercholesteroleamia also leads to the characteristic 
lesions of the fatty streak (Gerrity,1981;Faggiotto et 
al,1984).
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Explanation of Fig 7
Dietary fat and cholesterol are absorbed through the 
wall of the gut and assembled there as chylomicra. 
Lipoprotein lipase, present on the capillary walls of 
fatty and muscle tissue, is activated by the apoprotein 
of the chylomicron and the free fatty acids and 
monoglycerides of the chylomicron, that are released by 
this action, are used by adjacent cells. The remaining 
components of the chylomicron form HDL, which in turn 
circulates in the blood and is captured by receptors in 
the liver. Cholesterol arriving at the liver in this 
way, or metabolised by the liver itself, is packaged 
into VLDL which, after circulation, is acted upon by 
another lipoprotein lipase to form HDL and LDL.
20
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The relationship of plasma concentrations of HDL and 
LDL to vessel wall disease has been studied by many
workers. Coronary artery angiography has suggested that
the severity of coronary artery disease increases with
increasing LDL concentrations, and decreases with 
increasing concentrations of HDL (Jenkins et a l , 1978). 
In vitro work has suggested a pathological mechanism 
for this (Bondjers and Bjorkerud,1973). Atherosclerotic 
regions of rabbit aorta, showed an increase in 
cholesterol when incubated in media containing L D L . In 
contrast, HDL promoted a slight decrease of
intracellular cholesterol. Heparin, exposed on 
disruption of endothelia can also bind LD L by means of 
its apoprotein (B and E) components (Weisgraber et 
a_l,1986). It is also apparent that many LDL forms exist 
among individuals and some may be more atherogenic than 
others (Sniderman et a l ,1980; Rudel et a l ,1985) . 
Recently Cathcart et al, (1985) have observed that LDL
exposed to macrophages is oxidised and is toxic to 
fibroblasts in culture, if oxidation occurs in vivo, it 
may be an important source of endothelial assault. It 
has been proposed (Wolinsky et al,1975) that a decrease 
in the activity of smooth muscle cell lysosomes, 
particularly the enzyme cholesterol ester hydrolase, may 
cause cholesterol accumulation. The cell may then die 
with the release of undegraded cholesterol into its 
environment.
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1-3.2 Platelets, thrombosis and atherosclerosis .
Platelets were described more than 100 years ago 
(Bizzozero,1882). In their normal state, they are convex 
discs, heterogeneous in size, but with an average 
diameter of 2.5y (Thompson et al ,1982). The larger
platelets are those that have been newly formed and, are
most active. Platelets are derived from large precursor 
sten cells, megakaryocytes (Levine,1982), under the
influence of the hormone thrombopoietin (Abildgard and
Simone,1967; Cooper,1970). Megakaryocytes are found in
the lung and bone marrow and it has been calculated that 
one megakaryocyte is capable of releasing between 2,000 
and 7,000 platelets in its lifetime (Thiery and 
Bessis,1956; Cronkite,1958).
Fig 8, p23-24, illustrates the ultrastructure of
platelets. Despite the absence of a nucleus, platelets 
possess many of the features of classic inflammatory 
cells (Page,1988). They are capable of phagocytosis and 
chemotaxis, and can release a variety of mediators that 
augment inflammatory recruitment (Nachman and 
Weksler,1980). A defence role in killing parasites has 
also been proposed (Copley,1979). However, their 
contributions to the above processes have been 
overshadowed by their involvement in Haemostasis.
Wintrobe (1974) describes how vascular injury results 
in adherance of platelets to the vessel wall. Activation 
occurs, and platelets change shape, spread, secrete the 
contents of their storage granules and aggregate. The
23
Key to Fig 8
E.C. - Exterior coat or glycocalyx
C.M. - Unit membrane
S.M.F - Microfilaments
O.C.S - Open cannalicular system 
M.T. - Microtubule bundles
Gly - Glycogen granules
M. - Mitochondria
G. - a-granules, lysosome-1ike organelles
containing platelet factor 4, and 
PDGF
D.B. - Dense bodies, containing ADP,
ATP, Calcium, Serotonin, 
Pyrophosphate, and Antiplasrain 
D.T.S - Dense-Tubule system akin to the
Endoplasmic or Sarcoplasmic reticulum
24
Fig 8 The ultrastructure of the human platelet.
From Johnson (1971), p48.
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adhesion of circulating platelets to subendothelial 
fibres is mediated by a receptor on the platelet 
surface, Glycoprotein lb (Gplb), which binds to 
collagen (George et al,1984) and Von Willebrand factor 
(VWF) (Jaffe et a l ,1973; Weiss et a l ,1973). Adherent 
platelets release ADP, from secretory granules, which 
promotes platelet aggregation. Aggregation reveals a 
phospholipid factor which is required for the conversion 
of prothrombin to thrombin, which further stimulates 
platelets, by hydrolysis of its own receptor
Glycoprotein V, on the platelet surface (Philips and 
Agin,1977). Thrombin helps to stabilise the platelets in 
a haemostatic plug. In addition platelets release the 
protein, Platelet Factor 4, which promotes clotting by 
neutralising the action of Heparin. Fig 9, p 26,
summarises the contribution of platelets to the blood 
clotting sequence.
In the normal response to endothelial injury, platelets 
quickly adhere to the damaged area, as already 
described. The healthy vessel wall is believed to be 
protected from such adhesion by the powerful
antiaggregator and vasodilator prostacyclin (PGI2). 
Thromboxane (TXA2), in contrast, is an aggregatory
substance, derived from platelet endoperoxides (Raz et 
al, 1977), and it is thought that there exists a
homeostatic balance between PGI 2 and TXA 2 in vivo. 
Interestingly, it has been reported (D'Angelo et 
























From Murano and Bick, 1980.
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generate PGI2 . Fig 10, p28, illustrates the pathways of 
PGI 2 and TXA2 production.
In atheroma, platelet deposition apparently fails to 
self-limit. Platelets and lipids infiltrate the inner 
layer of the vessel wall. LDL is known to bind to 
glcosylaminoglycans, particularly derroatan sulphate 
(Iverius, 1973). Smooth muscle cells (SMC), are seen to 
migrate from the media; mainly in response to PDGF, 
released by activated platelets. Although the process 
may stop at this stage and new endothelium can grow over 
any deposits, another plague will often form over the 
first one. The process is extremely complicated, 
probably involving also similar growth factors, released 
by monocytes (Shimokado et a l ,1985), endothelial cells 
(Leibovich and Ross,1976; Gajdusek et a l ,1980), and 
smooth muscle cells themselves (Seifert et a l ,1984), see 
Fig 11, p29. Moreover, the endothelium can release
heparan sulphate, a potent inhibitor of PDGF function 
(Rosenberg et al,1985). Clearly, we are dealing with a 
complex homeostatic mechanism.
The "Response to Injury" hypothesis of atherosclerosis.
The response to injury hypothesis proposed by Ross 
suggests that injury to the endothelium is the 
initiating event in atherogenesis and at least two 
different mechanisms may be in operation.
The first includes the hypercholesterolaemic and 
thrombotic elements already mentioned. Hyper-
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Fig 11 Possible pathways for stimulation of vascular
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C E L L S
1. Endothelial loss promotes platelet adherance with 
consequent release of PDGF.
2. Endothelial cells produce a PDGF mitogen which in vitro
stimulates smooth muscle cells, and release a factor which
inhibits PDGF action.
3. Intimal smooth muscle cell production of PDGF.
4. Blood monocyte production of PDGF
Reidy (1986), pll5.
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cholesterolaemia may lead to changes in the endothelium, 
as already stated, involving detachment of individual 
endothelial cells themselves, replacement occurring by 
spreading of adjacent cells (Reidy and Schwartz,1984), 
or by an increased turnover of adjacent cells (Bjorkerud 
and Bondjers,1972). This may result in monocyte 
adherance and subendothelial migration, accumulation of 
lipid to form foam cells and gradual accumulation of SMC 
to form fatty streaks (Faggiotto et a l ,1984) . At some 
sites endothelial cells may separate, exposing foam 
cells and connective tissue to which platelets may bind 
and initiate SMC migration (Faggiotto and Ross,1984), by 
the release of PDGF. However areas of denuded 
endothelium seem to be a rare occurrance in man (Bylock 
et a l ,1979; Reidy,1985). It has therefore been 
questioned whether endothelial denudation plays a 
significant role in the initiation of the
atherosclerotic process, but may be involved in its 
progression.
The second pathway involves direct stimulation of 
endothelium, which may release growth factors,
vasoactive agents, or growth inhibitors, possibly
inducing other cellular activities such as smooth muscle 
migration (Ross,1986).
The processes described above are summarised in fig 
12, p 31.
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The responses to injury hypothesis. Advanced intimal proliferative lesions of atherosclerosis may 
occur by at least two pathways. The pathway demonstrated by the clockwise (long) arrows to the right 
has been observed in experimentally induced hypercholesterolemia. Injury to the endothelium (A) may 
induce growth factor secretion (short arrow). Monocytes attach to endothelium (B ), which may continue 
to secrete growth factors (short arrow). Subendothelial migration of monocytes (C) may lead to fatty 
streak formation and release of growth factors such as PDGF (short arrow). Fatty streaks may become 
directly converted to fibrous plaque (long arrow from C  to F) through release of growth factors from 
macrophages or endothelial cells or both. Macrophages may also stimulate or injure the overlying en­
dothelium. In some cases, macrophages may lose their endothelial cover and platelet attachment may 
occur (D ), providing three possible sources of growth factors— platelets, macrophages, and endothelium 
(short arrows). Some of the smooth muscle cells in the proliferative lesion itself (F) may form and sec­
rete growth factors such as PDGF (short arrows).
An alternative pathway for development of advanced lesions of atherosclerosis is shown by the arrows 
from A  to E  to F. In this case, the endothelium may be injured but remain intact. Increased endothelial 
turnover may result in growth factor formation by endothelial cells (A ). This may stimulate migration of 
smooth muscle cells from the media into the intima, accompanied by endogenous production of PDGF  
by smooth muscle as well as growth factor secretion from the “injured” endothelial cells (£ ). These in­
teractions could then lead to fibrous plaque formation and further lesion progression (F).
From Ross (1986) p496
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1.3.3 Immunological aspects of atherosclerosis
In addition to the Ross hypothesis, the importance of 
the endothelium in the development of atherosclerosis 
was first suggested in animal experiments by Poole et al 
(1958), Baumgartner (1963) and Bjorkerud and Bondjers 
(1971). Removal of the endothelium led to development of 
intimal lesions resembling atherosclerotic lesions. 
These were characterised by SMC proliferation, 
connective tissue formation and lipid deposition. 
Experimentally it is possible to cause endothelial 
damage in a variety of ways, including immunologically 
(Levy,1967; Minick and Murphy,1973). Rabbits receiving a 
cholesterol diet, and injected with a foreign protein, 
which elicited immune complex formation, showed a rapid 
increase in arterial lesions. The resulting enhancement 
of lipid accumulations, within the arterial intima, was 
greater than with either insult alone (Levy,1967). In
the absence of cholesterol, however, immune complexes
(CICs), would only produce lesions if vasoactive amines, 
complement and leucocytes were present (Minick and 
Murphy,1973).
Any soluble or insoluble antigenic material can form 
CICs if it is released in sufficient quantities at a
time when specific antibodies are present in the plasma 
(Fig 77,p240). Generally, it is the IgG, IgA, and IgM 
classes which form complexes, very little is known about 
IgD, or IgE CICs. The nature and proportions of the 
antigen and antibody forming the complex determine its
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fate in the body (van Es et al,1984) . Larger complexes 
are cleared by macrophages, although precipitation may 
occur in the tissues. Very small complexes, on the other 
hand, pass harmlessly out through the urine. Inter­
mediate sized complexes, found in moderate antigen 
excesss, tend to stick to walls of blood vessels. Their 
size is favoured by low antigen valency and low amounts 
of low affinity antibodies (Playfair,1982) and have a 
size of l,000kD (Cochrane and Hawkins,1968). The latter 
group have also shown that CICs will only penetrate the 
endothelial lining of blood vessels if the vascular 
permeability is increased. The permeability of various 
blood vessels to CICs may vary with the haemodynamic 
forces within the blood vessel, and the structure of the 
internal endothelial lining of the blood vessels 
themselves. Post capillary venules are susceptible to 
CIC deposition, but it is less common in arterial walls 
where usually deposition is at sites of high shearing 
stress i.e. at arterial bends and bifurcations 
(Roitt,1988) .
Immune complexes can activate complement and cause 
release of inflammatory mediators and chemoattractants. 
Histamine and bradykinin (Arfors et a l ,1979) induce 
contraction of endothelial cells, causing transient 
endothelial gaps to develop. Material exceeding l,000kD 
can be trapped under the endothelium after the 
endothelial cells resume their original close 
apposition. These may attract Polymorphonuclear 
leucocytes (PMN), releasing destructive enzymes and oxy-
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species, which may damage surrounding tissue. The extent 
of the damage and the resulting symtoms will depend upon 
various factors including whether or not exposure to the 
offending antigen is brief or repeated. Recently 
vimentin, a cytoskeletal component of endothelial cells 
has been shown to bind IgG by an Fc reaction (Hannson et 
al,, 1980,1984) . Linder (1981) has pointed out the 
possibility of intracellular complement activation. 
Hannson et a l , (1981) have also shown that monocyte
adhesion to the vessel wall is reduced if IgG depleted
serum is used in the media. Fig 13, p 36, illustrates 
some of the consequences of CIC deposition in arteries. 
Inflammatory changes occur co-existant with
atherosclerotic lesions and inflammation or oedema of 
the vessel wall could provide an alternative mechanism 
for reduction in the arterial lumen (Shimamoto,1963; 
Shimamoto and Numano,1969). Virchow (1856) first 
suggested that atherosclerotic lesions were attributable 
to chronic irritation, and intimal oedema was observed 
by him too. Chronic inflammatory microlesions have also 
been documented in sudden unexpected heart attacks 
(Haerem,1975). Aortic and coronary arteritis are 
important consequences of serum sickness in man and 
animals (Saphir and Gore, 1950, Zak et a l ,1952). The
depositon of CICs in the arterial wall may lead to
inflammation which would increase endothelial 
permeability and possibly lead to lipid entry. Fig 13 
also illustrates some of the immune reactions possibly 
involved in atherosclerotic injury. The work of Levy
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(1967) showed that the atherosclerotic lesions of 
rabbits, pre-injected with foreign protein, were similar 
to that found in man. But, in humans, the most obvious 
association between immunologic injury and
atherosclerosis is found in coronary artery lesions that 
can occur in donor hearts after cardiac allo­
transplantation (Thompson,1969; Clark et a l , 1973).
Immune complexes may form from a variety of antigens 
which may include infecting micro-organisms (Cunningham 
and Pasternak,1988), vaccines, antibiotics, drugs, 
foodstuffs (Minick,1976),tobacco (Harkavy and Perlman, 
1964) and lipoproteins (Beaumont and Beaumont, 1978). A 
repeated or prolonged injury by formation of complexes 
from each of the above could illicit the local reactive 
changes mentioned above.
The involvement in atherosclerosis of pathogenic 
immune complexes, formed from dietary antibodies 
(particularly anti-milk antibodies) was proposed by 
Davies et al in 1969, he showed that anti cows1 milk 
antibodies were increased in patients with CHD and 
postulated that this was a consequence of an abnormal 
immune state, akin to immune complex disease 
(Davies,1969; Poston and Davies,1974).
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Fig 13 The effects of immune complex deposition in
blood vessel walls.
PMN chemotaxis
O \  m tfO th 'om b 
k \  (otmaiion
Deposition of immune complexes in blood 
vessel walls I. Antibody and antigen combineto form 
immune complexes (1). The complexes act orcom plement 
(to release C3a and C5a). which in turn acts onbasophils to 
release vasoactive amines. The complexes also act directly on 
basophils and platelets (in humans) to produce amine release. 
The amines released include histamine and 
5-hydroxytryptamine. which cause endothela! cell 
retraction and thus increased vascular permeability (2).
Deposition of immune complexes in blood 
vessel walls II. With increased vascular permeability, 
complexes become deposited in the vessel wall. The 
complexes induce platelet aggregation and complement 
activation. The platelets aggregate to form microthrombi on 
the exposed collagen of the basement membrane of the 
endothelium. Polymorphs (PMN) attracted to the site by 
chemotactic complement peptides cannot phagocytose the 
complexes and so release their lysosomal enzymes to the 
exterior of the cell causing damage to the vessel wall
1. complex formation








2. increased vascular 
permeability
From Roitt et al, (1985), p21.3
37
1.4 DAVIES HYPOTHESIS
Initial studies by Davies (1958), at Carmarthen, 
Wales, investigated the mobility of erythrocytes by 
using an Abrahamson electrophoresis cell. He concluded 
that electrophoretic mobility decreased with increasing 
age of the donor. However, when erythrocytes were washed 
in saline, this age-dependent phenomenon disappeared, 
and, moreover, it subsequently transpired that mobility 
was a function of atheroma-related disease rather than 
of age.
An investigation followed, looking at 20 coronary 
occluded patients, and 20 age-matched control patients. 
A significantly raised erythrocyte migration time was 
found in the coronary-occluded patients (see Table 5, p 
38, Davies,1958). Independent confirmation of this 
phenomenon followed (Begg et al,1966). Davies argued 
that the property of plasma that affects electrophoretic 
mobility of erythrocytes is likely to affect lipid 
particles in a similar fashion. This was reported to be 
the case (Davies,1959), see Table 6, p39, and it was
shown that the electrophoretic migration of erythrocytes 
was related to the migration of chlyomicra. Davies also 
showed, not only that the erythrocyte migration time did 
not relate to plasma cholesterol levels (see Fig 14, p40 
), but also that such migration gave a much more 
satisfactory index of atheroma than did cholesterol 
levels (Davies and Clark,1961).
Further studies in 1967, showed a highly significant
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Table 5 Comparison between erythrocyte migration times 
of coronary heart disease and control patients.













1 38 Coronary ocdusioo 81 25-8 6
2 42 • t at 79 183 6
3 50 *• II 105 44 0 9
4 50 • • II 96 26-0 5
5 .  51 H  aa 95 157 5
6 52 • • at 102 24 0 10
7 52 at a* 77 21 0 4
8 52 aa 86 14 3 5
9 53 aa aa 78 16 6
10 54 aa at 87 170 5
11 54 aa aa 91 123 5
12 55 100 8 7 5
13 55 84 24 3
14 56 79 14 0 5
15 59 93 120 5
16 60 74 15 4
17 61 aa at 93 13 6 5
18 64 aa a* 91 14 6 5
19 67 aa aa 77 204 6
20 67 aa aa 70 175 6
Mean age =  54-6 yr..
















1 38 M itral stenosis 78 8 0 6 3
2 42 Normal 85 7-5 5 - 6
51 Normal 80 18 3 6 25
4 53 Normal 64 7 0 5 32
5 56 Gastric ulcer 96 17 3 6 - 1
6 51 Hypertension 67 16-0 6 35
7 52 Duodenal ulcer 69 19 3 6 8
s 48 Duodenal ulcer 76 13 1 5 10
9 53 Normal 73 108 5 5
10 57 Cholecystitis 56 5 1 5 31
11 58 Normal 99 242 4 - 8
12 60 Gastric ulcer 77 105 5 23
13 55 Cor pulmonale 89 156 4 - 5
14 57 Gastric ulcer 65 4-2 5 14
15 62 Chronic bronchitis 75 22-1 5 18
16 62 Pulmonary embolism 73 9-8 6 1
17 58 Hypertension 86 205 5 7
18 59 Pulmonary embolism 71 1 0 0 5 2 0
19 63 Normal 82 140 6 - 5
20 72 Normal 63 3-6 4 7
Mean age =  55-3 yr.. Total =  214.
Mean difference in erythrocyte
214 S.E. of
migration times between pairs =  - =  10-7 =  dfc 3 01
mean
" t "  =  3-55, degrees o f freedom - 19
. . 0 01 >  p >  0 001
From Davies (1958).
Table 6 Comparison between chylomicron and erythrocyte
migration times on samples obtained from 25 hospital in­







Mean Standard Error Mean Standard Error
1 52 1.1 49 3.1
2 53 3.3 56 2.4
3 55 3.7 52 2.7
4 57 3.6 55 1.6
5 58 2.4 60 3.5
6 60 4.7 54 4.2
7 63 3.6 65 3.8
8 64 5.0 56 2.9
9 66 4.5 61 2.2
10 73 2.0 61 4.9
11 75 6.1 68 3.2
12 77 4.5 74 3.7
13 79 1.5 65 2.7
14 80 3.9 79 3.9
15 82 2.8 70 5.1
16 84 5.1 81 2.7
17 85 2.6 70 4.2
18 92 4.1 85 2.9
19 93 3.3 83 3.2
20 97 3.1 85 2.5
21 100 4.3 97 5.2
22 101 6.8 89 2.4
23 102 5.7 82 4.6
24 102 7.1 89 4.1
25 103 2.5 97 4.6
From Davies (1959).
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Fig 14 Variations in erythrocyte migration time and serum 
cholesterol about the mean level characteristic for each 
patient.
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correlation between erythrocyte migration times and 
platelet adhesiveness (Davies and Lloyd,1967), see Fig
15, and Table 7,p 42), a factor known then to be 
associated with CHD (Florey,1960;McDonald,1960).
The next series of investigations were designed to 
discover the nature of the plasma agents that were 
affecting the above factors in CHD patients. It was 
found that IgG was raised in a series of 50 patients, 
compared to 78 controls (Davies and Clark,1968) (see Fig
16, p43). Furthermore, of the heart diseased patients
examined serially, the increase was not secondary to 
infarct itself i.e. antibodies were not being formed to 
neo-antigens. An independent group, Gray et al, (1978),
also confirmed Davies' findings. The results of these 
findings suggested that the mechanism reducing the 
plasma surface activity was immunological in nature and 
that the tendency for circulating blood particles to 
adhere together and to blood vesssel walls could be the 
expression of immunoadherence.
Davies decided to look at possible exogenous antigens 
to which CHD patients were being sensitised and focussed 
on food antigens which were, by then, known to be 
intestinally absorbed in macromolecular form 
(Schloss,1924/25; Gunther et a1,1960; Parish et a l ,1960; 
Taylor and Truelove,1961, see also Introduction, 
Sect.3, p60). He found that antibodies to cows' milk 
were elevated in CHD (Davies et a l ,1969) . This was 
extremely interesting considering milk itself has long
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Fig 15 The relationship between erythrocyte migration








Erythrocyte miration time (sec)
Table 7 Erythrocyte migration time (EMT), and platelet 
adhesiveness as indices in patients with coronary artery 
disease.
EMT (sec) Platelet adhesiveness (%)
Controls Mean = 61.43 Mean = 29.05
n = 21 S.D. = 7.01 S.D. = 16.37
MI patients Mean = 78.14 Mean = 42.2900CMIIc S.D. = 11.07 S.D. = 15.87
Difference= 16.71 13.24
t = 6.45 2.85






Fig 16 Total IgG levels in 45 Control and 50 MI patients.
Normal f~J n « 45  






2 3 4 5 61
Serum IgG Levels
laG level m g / 1 0 0  ml
1 6 0 0 — 6 9 9
2 700 — 799
3 800 - 89 9
4 900 - 9 99
5 1000 - 10 99
6 1 100 - 1 199
7 1200 — 1299
8 1300 - 139 9
9 1400 - 1499
10 1500
Adapted frora Davies and Clark (1968).
been implicated in CHD (Annand,1967;Segal1,1977;Seely,
1981).
Following this initial report, collaborative studies, 
with the MRC Epidemiology unit at Cardiff, were 
initiated. Four comparative matched case-controlled 
studies were made. The first of these was hospital based 
and showed a significant difference in antibody levels, 
to dried cows' milk, between CHD patients and controls. 
The remaining three community based studies showed that, 
although the levels of antibodies were significantly 
raised in CHD patients, the differences were not 
statistically significant. These community-based studies 
were on patients who had survived an infarct for up to a 
year or more and the suspicion arose that that elevated 
antibody levels were merely sequential to infarction, 
decreasing with time. However, serial studies on 
individual patients showed that this was not the case 
(reviewed by Davies,1984). An alternative explanation 
was provided in 1971, when the MRC analysis of the data 
suggested that patients with higher antibody levels were 
dying earlier; a factor that would tend to decrease 
average antibody levels in the community-based patients.
A further paper published in the Lancet (Davies et 
a_l,1974) showed conclusively that antibodies to dried 
cows' milk in CHD patients were raised compared to an 
age-matched control group (see Fig 17,p45). The 
difference was much more striking when the levels were 
analysed from patients who had died within six months, 










Fig 17 Comparisons of milk antibody titres in ;
a) Controls and MI patients, and
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Adapted from Davies et al (1974).
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Up to this the point, work had been concerned with 
dried whole cows' milk and it was clearly essential to 
determine the individual milk antigens responsible for 
eliciting the antibody response. The first steps in this 
direction were reported, in 1980, by Davies et a l , who 
showed an excellent correlation between anti-(whole 
dried milk) antibodies and anti-(washed cream), 
antibodies, but not with anti-(skimmed milk antibodies), 
see Fig 18, p47. It appeared, therefore, that the
antibodies of interest were directed against some 
component of the cream and these studies were extended 
to show that Bovine Milk-Fat Globule Membrane (BMFGM- 
see sect 2, p52) was, in fact the relevant antigen 
(Davies et a1,1982; Rees 1985).
Thus, by the early 1980's, Davies had established a 
link between BMFGM antibody and CHD. Rees and coworkers 
then proceeded to examine more closely why this 
antibody, in particular, might be implicated. On the 
premise that common antigens may be shared by membranes 
of diverse cells and, in view of the generally accepted 
importance of platelets in CHD, they decided to examine 
the possibility that anti-BMFGM antibody might cross- 
react with human platelets. Antibodies to a preparation 
of BMFGM were raised in laboratory rabbits and linked to 
a fluorescein probe. Cross-reaction with human platelets 
was demonstrated by marked platelet-membrane bound 
fluorescence of the post-immune sera, but not the pre- 
immune sera (Davies 1984, Rees, 1985). Platelet clumping
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Fig Comparisons of reconstituted dried whole bovine
milk (RDWBM) antibody with; a) washed cream antibody 

































From Davies et al (1980)
48
and aggregation were also marked with post-immune sera 
but not with pre-immune sera. Davies and co-workers 
concluded that anti-BMFGM antibody could be atherogenic 
because of its anti-platelet activity (Davies et 
al,1982).
Rees has further discussed this connection. He noted 
that a higher percentage of MI patients, compared to 
normals, had an excess of active platelets in their 
blood. Moreover, platelets which have been newly formed 
in the blood, have higher amounts of vasoactive amines 
and ADP and so aggregate more readily. Rees hypothesised 
that BMFGM antibody bound to platelets caused their 
removal from the circulation, by the reticulo­
endothelial system. Such a reaction would be followed by 
an increased platelet turnover, resulting in a greater 
proportion of newly formed active platelets (Rees,
Davies thus proposed that anti-BMFGM antibody was 
atherogenic, and the fact that it could be demonstrated 
in the umbilical cord bloods of newly born babies led
deaths and still-births (Davies, 1984).
1.5 Literature Response To Davies* Hypothesis.
The paper published by Davies et al in the Lancet
(1974) aroused a great deal of interest. Initial 
reaction was enthusiastic. Ellis (1974) suggested that 
Davies' findings could possibly be the most important
1985) .
him to suggest that it may also be pathogenic
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nutritional discovery of the century. He went on to 
propose that the milk of the mother was the best food 
for an infant, and if not, then a vegetable based infant 
formula may be a better source of food.
Davies* results were confirmed by Oster et a l , (1974) 
who, like Davies et al, used the tanned red blood cell 
haemagglutination assay (Boyden,1951; Rees,1973) for 
anti-cows' milk antibodies. Oster and coworkers 
confirmed that antibody levels were raised in patients 
with atherosclerotic disease. They also measured the 
antibody response to Xanthine Oxidase (XO), a major 
protein of the BMFGM and again found a statistically 
significant elevation of antibodies to XO in those 
subjects with demonstratable atherosclerotic
manifestations. In fact, there appeared to be better 
correlation with antibodies to XO than to cows* milk. 
Oster's paper was used by him to support his theory that 
bovine milk XO was a causative factor in CHD. This 
hypothesis was the subject of a report by the Division 
of Nutrition, Bureau of foods, Food and Drug 
Administration (FDA), Washington, D.C. (Carr et al, 
1975)
Following Oster's confirmatory report, three papers 
(Toivanen et al,1975a, Scott et al ,1976, Gibney et 
al,1980) were published all of which failed to show 
statistical difference in milk antibody levels between 
MI patients and controls. Toivanen et a l , compared IgG 
and IgM anti-cows' milk antibodies of MI and control 
patients by using a radioimmunoassay, they reported no
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difference between MI and control patients. Their data 
are, however, confused. Titres presented in the Table of 
their paper, show average antibody levels for all sera 
within each group, while a separate set of average 
titres in their Text exclude sera from samples showing 
zero antibody levels. The mean levels shown in the text 
are accordingly raised compared to those of the Table. 
However, when values are calculated for the Table from 
the text and vice versa, there are wide discrepancies 
(see Table 8, p51). Poston (1975) comments upon this 
fact and states that the figures of the text concerning 
IgM actually support the Davies' hypothesis. In a reply 
to Poston, Toivanen et al (1975b), reiterated their 
conclusion that there was no difference between MI and 
control patients, and if anything, that IgM was higher 
in the controls, when all sera were examined.
Davies et al, (1980) offered a further comment on the 
equivocal results of Toivanen et al (1975a). Davies and 
co-workers compared levels of antibodies to re­
constituted dried whole bovine milk (RDWBM), to washed 
fresh bovine cream and to skimmed bovine milk (see Fig 
18, p47. Anti-RDWBM antibody levels correlated with
anti-cream but not with anti-skim milk antibody levels. 
They pointed out that the data of Toivanen et al were 
obtained with fat free milk whereas those of Davies and 
co-workers themselves and those of Oster et al (1974) 
were obtained by using RDWBM as antigen. Scott et al 
(1976) who also refuted Davies conclusions used 
"National Dried Milk" as antigen. This was
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IgG [45] 7.38 (8.30) [381 8.46 (8.46)
IgM [42] 3.20 (3.30) [40] 3.88 (2.44)
Figs in [ ] = no. of patients




IgG [50] 6.64 (5.90) [47] 6.84 (6.84)
IgM [50] 2.62 (2.56) [47] 2.18 (3.47)
Figs in [ ] = no. of patients
Figs in ( ) = theoretical values for Table calculated
from Text.
52
Table 9 A summary of the literature response to 
Davies' hypothesis.
AUTHORS Total No MI samples Total No Control samples
Male Female Total Male Female Total
Davies et al 213 0 213 143 0 143
Oster et al 25 9 34 22 19 41
Toivanen et aJ 47 0 47 50 0 50
Scott et al 90 0 90 36 0 36
Gibney et al 33 4 37 25 12 37
Assay used Antigen source






Toivanen et a] Radioimmunoassay Fat-Free Dried Milk
Scott et al Haemagglutination National Dried Milk




Davies et al 
Oster et al 
Toivanen et al 
Scott et al 
Gibney et al





unfortunately withdrawn in 1977 and, while, it was known 
to differ from other infant formulas, was not available 
for further study. Gibney et al, (1980), the third
dissenting group, used a spray dried milk, source 
unknown.
The results of these surveys are summarised in Table 
9, p52.
Not withstanding the subsequent discussions, the 
result of the refuting publications was to effectively 
discredit the Davies hypothesis; a situation that has 
remained largely unchanged until now.
2.0 THE BOVINE MILK FAT GLOBULE MEMBRANE (BMFGM).
2.1 Introduction
During lactation, milk fats are secreted from mammary 
epithelial cells into the mammary gland lumen. They are 
in the form of globules, with diameters ranging from 0.1 
- 20ym (Walstra,1966), surrounded by a surface layer of 
membrane, the BMFGM (see Figs 19,20, p54). At least 98% 
of the core of each globule is composed of 
triglycerides, 60% of which is phosphatidylethanolamine 
and phosphatidyl serine (Patton and Keenan,1975). 
Immediately surrounding this is a layer of materials 
which appears to be absorbed from the cell prior to 
secretion, and may, in part, be derived from the 
endoplasmic reticulum of the cytoplasm. Finally, the
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Fig 19 A milk secreting alveolus.
M y o e p i t h e l i a l
Cell
Alveolar Cell
Milk expelled Into duct
From Alberts et al (1983), p917.
Fig 20 Milk protein and fat production from a milk
secreting cell, showing formation of the BMFGM.
Milk Fat Globule Membrane
Milk Fat droplet







From Bloom and Fawcett (1975).
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apical membrane of the secretory mammary cell (see Fig 
20,p54). During the secretion process, fat droplets 
within the mammary secretory cells approach the apical 
membrane, and are progressively enveloped by it before 
being expelled into the gland lumen. Some of the BMFGM 
may also be acquired directly from the Golgi apparatus 
within the cell, but the extent of this contribution 
remains controversial (Keenan et al,1970; Wooding 1971, 
1973; Keenan and Huang,1972; Matel et al ,1973;Keenan, 
1974; Powell et al,1977). Nevertheless it is generally 
agreed that the BMFGM is largely derived from the 
plasma membrane; a fact supported by biochemical 
analyses (Keenan et al,1970).
Table 10, p56, gives an historical perspective of the
discovery of the membrane, the overall composition of 
which is shown in Table 11, p57.
2.2 BMFGM Lipids
The lipidic fractions of the BMFGM were first 
characterised by Thompson et al (1961) who showed that 
individual phospholipids were similar to those of the 
plasma membrane. There is however, some contamination of 
the BMFGM by triglycerides of the inner core (Keenan and 
Huang,1972; Newman and Harrison,1973; Walstra,1974). 
Interestingly, various gangliosides of BMFGM, presumably 
derived from the plasma membrane are known to act as 
receptors for bacterial adhesion and may act to prevent 
infection of the newborn (Huang,1973; Keenan,1974; 
Laegrid et al,1986).
Table 10 Major contributions to BMFGM Study
AUTHOR CONTRIBUTION
Van Leeuwen hoek,1674 Discovered fat globules in milk




First to isolate and partially 
characterise the membrane
King,1955 Summarised all evidence to 




Showed progressive emergence of 
BMFGM from apical cell membrane 
by electron microscopy
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Table 11 Gross composition of BMFGM
Constituent Amount
Proteins 25 to 60% of dry weight
Total lipids 0.5 to 1.1 mg/mg protein
Neutral lipids 56 to 80% of total lipids
Hydrocarbons 1.2% of total lipids
Sterols 0.2 to 5.2% of total lipids
Sterol esters 0.1 to 0.8% of total lipids
Glycerides 53 to 74% of total lipids
Free fatty acids 0.6 to 6.3% of total lipids
Cerebrosides 3.5 nmol/mg protein
Gangliosides 6 nmol/mg protein
Sialic acids 63 nmol/mg protein
Hexoses 0.6 ymol/mg protein
Hexosamines 0.3 ymol/mg protein
From Patton and Keenan (1975).
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2.3 BMFGM Proteins
Separation of the proteins of the BMFGM by SDS-PAGE 
leads to the resolution of 8-14 major components 
(Anderson and Cheeseman,1971; Keenan and Huang,1972; 
and Kobylka and Carraway,1973). Over 40 polypeptides can 
be identified after electrofocusing in the presence of 
urea (Mather,1978)• Fig 21, p59, shows a typical SDS-
PAGE profile of the membrane, and the molecular weights 
of the major proteins. The apparent protein composition 
of the membrane does however depend upon the method of 
preparation (Basch et al,1985) and molecular weights of 
the bands vary slightly from paper to paper (Anderson et 
a l ,1974).
In all surveys it is clear that two proteins Xanthine 
Oxidase and Butyrophilin account for nearly 50% of the 
total Coomassie staining of the membrane:- 
Xanthine Oxidase (Mr 150-155KD) costitutes some 8-10% of 
the BMFGM protein (Morton,1954; Zittle et al, 1956; 
Briley and Eisenthal,1974) and its degradation products 
(e.g. with Mr 43KD and 90KD (Mather et al,1982)) may 
also be detected. Some XO may also occur in mitochondria 
and microsomes (Dowben et al,1967)♦ The function of XO 
in the membrane is unknown, but roles have been proposed 
for it in microbial defence, and vesicle 
formation(Jarasch et al,1981).
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From Mather and Keenan (1975)
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Butyrophilin (Mr 60-65 KD) is an acidic glycoprotein 
forming a major part of the dense, fuzzy coat of the fat 
globule. Immunolocalisation shows it to be present 
exclusively at the apical, and not the basolateral 
surface of the mammary epithelial cell (Franke et 
a_l,1981). It is suggested that this protein provides a 
specific marker for the apical surface of the milk 
secreting cell and its vectorial discharge of lipid 
globules.
Other proteins known to be present in the membrane 
include; HLA-Dr antigens (Wiman et a l ,1979), Acid and 
Alkaline Phosphatases (Dowben et al,1967), Mg2*-
activated ATPase (Nielson and Bjerrum,1977), 5'-
Nucleotidase (Patton and Trams, 1971, Huang and 
Keenan,1972), a glycoprotein PAS IV (Greenwalt et 
a_l,1985) and a b-type cytochrome (Jarasch et al, 1977) .
3.0 ANTIGEN ABSORPTION
Inherent in the Davies' hypothesis is the concept that 
the antigen, BMFGM, must be present in the blood, to 
generate an immune response. Many common dietary 
macromolecules (particularly proteins) can be antigenic. 
According to Wiseman (1964) nearly all ingested protein 
is absorbed rapidly and efficiently from the gut lumen 
following the action of gastric and pancreatic enzymes.
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However complete breakdown of protein into amino acids 
requires about 200 hours (Fisher,1954), and it is likely 
that most proteins reach the intestinal mucosa in the 
form of both oligopeptides and amino acids (Silk,1974). 
Amino acids are taken up in the ileum by specific 
transport mechanisms. Oligopeptides may bind to specific 
receptors (secretory IgA molecules (s.IgA)) and be 
degraded by brush border amino peptidases (Underdown and 
Schiff,1986). Alternatively, they may be taken into 
vacuoles for intracellular hydrolysis. Should any 
oligopeptide escape degradation, it is possible that it 
may be antigenic as 3-6 amino acids are the optimal size 
for antigenic determinants (Kabat,1968).
In the fetal and neonatal intestine there is a 
maturational delay of the gut mucosa, rendering it more 
permeable to food antigens than in later life (Eastham 
et a l ,1978; Rothberg,1969; Walker 1985). Studies with 
fetuses have shown uptake of large molecules by 
intestinal epithelial cells (Lev and Orlic,1973; Moxey 
and Thier,1975), and the neonatal small intestine has a 
capacity to ingest macromolecules and possibly even 
cells (Weiler et al ,1983) by an endocytotic mechanism, 
this is of particular importance in animal species that 
depend, for their passive immunity, on maternally 
transmitted immunoglobulins via colostrum during the 
first few days after birth (Clark,1959). The phenomenon, 
known as "closure" is the result of intestinal 
maturational events i.e. the glycocalyx development,
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which is facilitated by colostrum itself (Heird and 
Hansen,1977).
Despite the commonly held notion that the adult gut is 
an impenetrable barrier to the uptake of luminal 
antigens, experimental and clinical evidence suggests 
that this is not so. Macromolecules may be absorbed in 
healthy adults, not in sufficient quantities to be of 
nutritional importance, but, nevertheless, enough (up to 
2% of ingested protein) to be antigenically or 
biologically active (Wilson and Walzer,1935; Lippard et 
ad,1936; Walker and Isselbacher,1974). The absorption of 
antigen in healthy adults was first documented at the 
beginning of the century by Uhlenhuth (1900) who 
reported the formation of circulating antibodies in 
rabbits fed on ovalbumin. Korenblat and co-workers 
(1968) demonstrated precipitins in some humans after 
ingesting milk, and Paganelli et al (1979) showed that 
consumption of high levels of milk, in a single feed, 
was followed by a transient rise in levels of serum 
immune complexes. These subsequently fell to levels 
below those normally associated with tissue damage. It 
is possible that the immune system, in a novel role, is 
aiding the removal, from the bloodstream of small v 
quantities of undigested or foreign protein (Hamburger 
et al ,1987). Certain disease states, such as Ulcerative 
Colitis (Jewell and Truelove,1972), gastro-intestinal 
allergy, inflammatory bowel disease (Ferguson,1977), 
Coeliacs disease (Shiner and Ballard,1972) and some
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immune complex mediated disease (Walker,1975) may be 
caused by absorption of intraluminal antigens, 
particularly food derived, resulting in the triggering
of allergic type responses (Hutchins and Walker Smith,
1982) .
Antigen absorption in the healthy individual can
occur at three levels:-
1. The M-cell is a specialised epithelial cell, 
overlying the gut-associated lymphoid tissue (GALT) in 
the ileum. The whole comprises the Peyer's Patches (see 
Fig 22, p64). M-cells are specially adapted for antigen
transport (LeFevre and Joel,1984), and delivery to 
subepithelial lymphocytes and are known to be penetrated 
by various colloids and protein antigens (Joel et
a_l,1970; Owen,1977). It is not known whether these cells 
act merely to "sample" antigens present in the gut lumen 
or whether they may also process them, as do macrophages 
(Richman et al,1981).
2. The normal epithelial cell, as already mentioned, 
possesses receptors for oligopeptides (s.IgA). However, 
they also seem to possess a non-specific uptake' 
mechanism whereby molecules are adsorbed on their 
luminal surface and endocytosed. The resulting small 
intracellular vesicles fuse to form phagosomes, which 
fuse further with lysosomes so effecting intracellular 
digestion (see Fig 23, p64). This may represent the
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Fig 22 Diagrammatic representation of a Peyers' patch, 
consisting of two follicles (the M-cells are enlarged 
for emphasis).
I N T E S T j N A L  L U M E N
VILLI
M C E L L M C E L L
D O M E
B C E L L  
AREAT C E L L  
A R E A
E L L  I G E R M I N A L
c e n t e r
g e r m i n a l
c e n t e r
c r y p t s
s m o o t h
m u s c l e
From LeFevre and Joel (1984).
Fig 23 Possible routes of transmission of intact and
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residual of the primitive absorptive mechanism found in 
the gut of the neonate. Undigested or partly digested 
breakdown products may be released into the interstitial 
space, where they are presented to the subepithelial 
immune system or transported in immune-complex form to 
the liver (Walker,1978).
Histochemical studies have shown that small quantities 
of antigen are uptaken preferentially by M-cells, but 
larger quantities by epithelial cells (Walker,1979)• 
Various factors influence particle uptake by cells. 
Particles more hydrophobic than the surface of the cell 
are selectively phagocytosed (LeFevre and Joel,1984). 
This may be of relevance when considering uptake of 
BMFGM. Homogenisation of milk breaks up fat globules 
from an average diameter of 3.5ym to lym and increases 
the number of globules 100-fold. Ross et a l , (1980),
have compared the uptake of such globules to that of 
liposomes which are used for transporting therapeutic 
substances across the intestinal barrier
(Gregoriadus,1976).
3. Intra-cellular junctions can be widened in certain 
disease states i.e. inflammation or surgical 
intervention of the gut. This can result in enhanced' 
uptake of luminal antigen (Rhodes and Kornovsky,1971; 
Reinhardt et al,1983).
The normal consequences of antigen absorption involve 
local production, in the intestine, of s.IgA which acts
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to exclude dietary antigens (Walker and Isselbacher, 
1977). In patients with selective IgA deficiency, uptake 
of bovine antigens is increased (Cunningham-Rundles et 
a_l,1978). A systemic immune response may occasionally 
arise, but, most commonly, a state of tolerance develops 
determined principally by T-cell unresponsiveness 
(Challacombe and Tomasi,1980; Mowat,1987).
AIMS
The major aims of this thesis were as follows:-
1. To verify and expand on the observation of Davies, 
that anti-milk antibodies are elevated in MI patients. 
However, anti-BMFGM, (rather than anti-milk), antibodies 
are measured specifically by means of an ELISA, 
developed for routine assay.
2. To investigate, in more detail, the antigenic 
determinants of the BMFGM itself.
3. To establish whether or not a true cross-reaction 




1.1 Chemicals and reagents
Column resins and immunochemicals were provided by the 
Sigma Chemical Company (Poole, Dorset, U.K.), unless 
otherwise stated.
All buffering reagents were supplied by either Fisons 
pic. (Loughborough, Leics., U.K.) or BDH Chemicals Ltd. 
(Poole, Dorset, U.K.). Phosphate buffered saline (PBS) 
was supplied in tablet form by Oxoid Ltd (Basingstoke, 
Hants, U.K.).
Chemicals for SDS-PAGE gel electrophoresis were 
supplied by BDH Chemicals Ltd. (Poole, Dorset, U.K.), 
and were of the Electran range.
All other chemicals were provided by Sigma Chemical 
Company (Poole, Dorset, U.K.) or BDH Chemicals Ltd. 
(Poole, Dorset,U .K .).
1.2 Serum samples
Normal rabbit serum and normal goat serum were provided 
by Sera-Lab Ltd (Crawley Down, Sussex, U.K.).
Human serum samples came from the following sources.
1. Control samples for MI samples were provided by the 
MRC Epidemiology Unit in Cardiff. The samples were from 
males of age 49-64 and were collected from Caerphilly 
(Wales, U.K.) mainly, and Speedwell (Bristol U.K.) as' 
part of a survey, examining known risk factors for Heart 
Disease (Caerphilly and Speedwell Collaborative group, 
1984).
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2. MI samples were provided by the same MRC unit, as 
part of a survey examining diet in secondary prevention 
of MI. These cases came from areas all over South Wales 
(Swansea to Newport), with a few from Gloucester and 
Bristol, and were males of ages 45-80.
3. Myasthenic sera had been collected from the Royal 
United Hospital (Bath, Avon, U.K.), the Royal Infirmary 
and Southmead (Bristol, Avon, U.K.). Samples were stored 
at -40°C.
4. Serum samples from Motor Neurone Disease sufferers 
was provided by Charing Cross Hospital (London, U.K.), 
as were those from migraine sufferers sera (provided by 
D r .P . Davies).
5. Immune Thrombocytopenic sera were provided by the 
Haematology Department of the West Wales Hospital 
(Carmarthen, Wales, U.K.), and had been characterised by 
positive immunofluorescence on Megakaryocytes.
6. All other human serum was provided by the South West 
Regional Blood Transfusion Service. This serum was from 





2.1 Preparation of BMFGM
The method was followed according to Mather and Keenan
(1975), except for the inclusion of protease inhibitors 
during the washing stages of cream. Their inclusion was 
found to give clearer SDS-PAGE profiles of BMFGM.
Cream was separated from fresh uncooled milk (12 L ) f from 
Friesian cows in mid-lactation, kindly provided by Bassett 
farm (Claverton Down, Bath, U.K.). Milk (12L) was 
centrifuged (170q, 15min) , at 37°C and the fat globules 
were washed with an equal volume of distilled water 
(37*C), containing 0.15mM-phenylmethylsulfonyl fluoride 
(PMSF), lOm-ethylenediaminetetraacetic acid, disodium 
salt (EDTA), and 2mM-benzamidine, before centrifugation 
at 37°C (250q,lOrain). The washing of the cream was
repeated 3-4 times until a clear wash was obtained and the 
final wash was performed at 4°C. The cream was resuspended 
(5:1 v/v) in 50mM-Tris/HCl, pH7.5 and chilled to 4*C in 
an ice-bath before churning to butter in a Waring blender 
(5-10 min). The butter was collected and liquified at
v
37#C, in order to release trapped BMFGM. This was further 
separated from the fatty mixture by centrifugation 
(100,OOOq,lh) at 20#C.
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The brown-white pellet of BMFGM was collected (see Fig 2 4 )  
and stored at -80°C. Yields varied from 2-6g wet weight of 
BMFGM from 12L of milk, depending upon the time of year.
Fig 24 BMFGM purification, after centrifugation of







Brown + White pellets = BMFGM
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2.2 Preparation of platelet membrane.
Platelet Rich plasma (PRP) was obtained from the South- 
West Regional blood transfusion service. Blood group "O" 
platelets were used in order to minimise cross-reaction 
of sera with membrane antigens.
(i ) Preparation according to Winiarski and Ekelund
(1986), modified from Kaser-Glanzmann et al, (1977).
PRP was centrifuged (1300c[,lOmin) , and the platelet
pellet was resuspended in PBS buffer containing 0.33%
EDTA, pH 7.4. The pellet was washed three times by 
centrifugation (1300cj, lOmin) and was then resuspended in 
EDTA-PBS. The platelets were adjusted to a concentration 
of 109/ml (counted by means of an improved Neubauer 
counting chamber) and sonicated (Model 180 sonicator, from 
Ultrasonics Ltd., Shipley, Yorks., U.K.) in 25ml batches, 
surrounded by ice. 100W was delivered in 2 x 30s bursts 
with a 30s interval during which the probe was retuned,
within the sample. Batches of sonicated platelets were 
pooled and centrifuged (10, 000c[, 15min) at 4*C. The pellet 
was discarded and the supernatant was collected and 
recentrifuged (100 , 000c[, lh) at 4#C. The pellet, containing 
platelet membrane, was resuspended by homogenisation in 
EDTA-PBS and stored at -80#C.
(ii) Platelet membrane preparation according to Barber 
and Jamieson (1970).
PRP was centrifuged (1300cj,lOmin) and the pellet was 
resuspended in 0.OlM-Tris/HCL, pH7.5, containing lmM- 
EDTA, and 0.15M NaCl before recentrifuging as above. In
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this way, platelets were washed three tiroes. The 
intracellular glycerol concentration of the platelets was 
then raised to 4 . 3M by centrifuging them (1, 465cj, 30roin 
followed by 5,860cj, lOmin) through an isotonic glycerol 
gradient (0-40%) at 4°C. The supernatant glycerol 
solutions were removed and Tris-sucrose buffer (Washing 
buffer above containing 0.25M sucrose) was added to the 
remaining platelet pellet (5:1 v/v), which was immediately 
vortexed. The lysed platelet suspension was layered onto a 
sucrose solution (27% w/v) and centrifuged (25,000£,5h) at 
4°C, when subcellular components and debris sedimented to 
the bottom of the tubes and the membrane fraction 
remained as a narrow band above the sucrose interface. The 
membranes were isolated, diluted in cold Tris-sucrose 
buffer (1:10 v/v) and centrifuged (106 , OOOcj, lh) at 4°C. 
The membrane pellet was resuspended in cold Tris-sucrose 
buffer, layered on a linear sucrose density gradient (15- 
40% w/v) and centrifuged (63,500cj, 18h) at 4#C. Two 
membrane bands were separated, diluted (1:10 v/v) in cold 
Tris-sucrose buffer and centrifuged (106,000£,lh) at 4°C. 
Platelet membrane was resuspended, by homogenisation in 
Tris-sucrose buffer, and stored at -80#C.
Membrane protein, for both procedures, was estimated by 
using the SDS-Lowry method (Methods Sect 3.1 (ii), p 85 ).
2.3 Preparation of washed platelets.
The protocol of Tangen et al (1970) was followed.
(i ) Centrifugation
PRP was centrifuged (1,300cj, lOmin) , and the platelet 
pellet was resuspended in 0.154M-Tris buffer, pH 7.4 (5 x
the original volume) containing 0.154M NaCl, and 0.077M 
EDTA before centrifuging as before. This process of 
washing the platelets was repeated twice. The platelet 
pellet was finally resuspended in 5mM-Tris/HCl, pH 7.4, 
containing 0.154M NaCl, 50yM CaCL2 and 1% w/v glucose.
(ii) Gel filtration
A silanised glass column (1.5 x 30cm) was prepared 
containing Sepharose 2B-300 (200ml) (Sigma Chemical
Company, Poole, U.K.) in the above buffer. A slurry was 
poured into the column and allowed to settle overnight, 
under gravity, before washing with the same buffer (2.5 
bed volumes). A sample of PRP (l-5ml) was layered on top 
of the gel, under buffer, and was allowed to flow through 
at 25ml/h. Platelet peaks (detected visually, or by A 2 8 0 ) 
emerged well ahead of the plasma peak and were collected 
in silanised tubes, pooled, and counted.
2.4 Preparation of Bovine Xanthine Oxidase.
(i ) The method according to Nakamura and Yamazaki (1982) 
was followed.
Buffer B - 0. 2M--K2HPO 4 , containing 2.5mM-DTT, ImM-EDTA,
and 1.25mM-salicylate.
Buffer A - As buffer B, but using 0.2M-Na2HPO4 in place 
of the potassium salt.
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2.5mM-DTT, ImM-EDTA, and 1.25mM-salicylate were added to 
fresh milk (9L), and cooled to 4°C. All further steps
were carried out in a cold room at 4°C. The solution was 
centrifuged (3, OOOq, 30min) and an equal volume of Buffer B 
was added to the supernatant followed by slow addition of 
cold butanol (-20*0,(15% v/v), and 15% w/v ammonium
sulphate. The resulting slurry, was stirred for lhr, 
removing all lumps of cream, before centrifuging
(13,OOOq,20min). 15% Ammonium sulphate (w/v) was added
slowly to the lower aqueous phase and the solution was
stirred for 30min then left to separate for 2h. The upper 
phase was centrifuged (10,OOOq,30min) and Buffer A was
added to the supernatant, to give a final volume of
approximately 30ral, which was dialysed overnight against 
a large volume of Buffer A. The dialysate was centrifuged 
( 20 , OOOcj, lh) and applied to a calcium phosphate column, 
prepared as follows.
Calcium phosphate gel was suspended in Buffer A (1:4 
v/v), washed five times in the same buffer, packed into a 
column (3cm x 25cm) and washed with Buffer A (2.5 x bed 
volume).
The dialysate was applied to the column, eluted (lOml/h) 
with Buffer A and collected (7.5 ml fractions), until 
A 2 s o returned to < 0.005. Bound XO was eluted from the
column by Buffer A containing 5% ammonium sulphate. XO was 
dialysed overnight at 4°C, into a suitable buffer, to 
remove ammonium sulphate.
(ii) Purification by Molecular Exclusion.
A Sephacryl G-200 column (2cm x lm) was used in an
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attempt to further purify XO as prepared from the calcium 
phosphate method (See Results Sect 5,3, p167 ). XO mixture 
(20-25 m g ), dialysed into running buffer was applied to
the column and allowed to elute through overnight
(40ml/hr) in 7.5mM-KH2P04/20mM-Na2HPO4, pH 7.3. Fractions 
(10ml) were collected and assayed for protein at 280nm.
(iii) The method according to Nishino et al (1981). 
AH-Sepharose 4B folate was a gift from Dr Bray, Department 
of Molecular Sciences, University of Sussex, U.K. The 
general procedure for covalently coupling AH-Sepharose 4B 
with folate is described by Nishino et al, (1981). The 
column matrix was stored in the dark, with 0.02% azide 
when not in use. The gel was poured into a column (1.5cm 
x 9cm), covered in aluminium foil and allowed to settle 
overnight, under gravity.
Buffer A contained O.IM-sodium pyrophosphate buffer,
pH8.5, (20%) and 0.05M-Tris/HCl, pH7.8 (80%), together
with 0.2mM-EDTA.
Buffer B contained O.IM-sodium pyrophosphate buffer,
pH8.5, (30%), and 0.05M-Tris/HCl, pH7.8, (70%),
containing 0.2mM-EDTA and 0.05mM-hypoxanthine (final
concentrations).
The folate column eluted with buffer A (2.5 x bed vol) 
and XO (prepared from method (i) above, was loaded onto
the column (column binding capacity 3-4 mg protein/ml 
gel). The sample was eluted with buffer A at 25ml/hr and 
collected in 5 ml fractions,until no absorbance at A 2 8 0  
was detected. Bound XO was then eluted with buffer B and 
dialysed into a suitable buffer, at 4°C.
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2.5 Preparation of IgG from serum.
The method according to Johnstone and Thorpe (1982) was 
followed. All operations were carried out at 25*C. Human 
serum (usually 5-10 ml) was warmed to 25#C and sodium 
sulphate was added to make an 18% w/v solution, which was 
then stirred for 30min and centrifuged (3, OOOcj, 30min) . The 
supernatant was discarded and the volume of the 
precipitate noted. The precipitate was redissolved in 
distilled water (£ volume of the original serum),and 
sodium sulphate was added again to make a 14% w/v 
solution. The solution was stirred for 30 min, then 
centrifuged as before. The process of sodium sulphate 
addition, stirring and centrifuging was repeated until a 
clear supernatant was obtained, when the precipitate was 
redissolved in distilled water and dialysed against 20mM- 
sodium phosphate buffer, pH8.
For the preparation of rabbit IgG the procedure above was 
followed, but the final precipitate was dialysed against 
20mM-sodium phosphate, pH 7.5.
For the preparation of goat IgG, serum was treated with 
14% w/v sodium sulphate for the initial addition, and the 
final precipitate was dialysed against 20mM-sodium 
phosphate buffer, pH 7.5.
The above dialysa.tes were further purified on a DE-52 
ion-exchange column.
Pre-swollen DE-52 (diethylaminoethyl cellulose anion
exchanger), Whatman Chemical Separation Ltd., (Maidstone, 
Kent, U.K.) was equilibrated with 20mM-sodium phosphate, 
pH8 at 20ml/g DE-52. Fines above the slurry were removed
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by aspiration and the slurry was washed 3 times with 
buffer. After each wash, fines were removed and the 
resulting slurry was stored at 4*C with 0.01% azide, until 
required.
DE-52 was packed into a column (1.5 x 17cm) and 
equilibrated with the required phosphate buffer (i.e. the 
buffer into which the final precipitate had been 
dialysed). The sample was applied to the column, and IgG 
was eluted through with equlibrating buffer (30ml/h). 
Absorbance was monitored at 280nm, and fractions (5ml) 
were collected. Impurities were subsequently removed by 
elution with 0.5M NaCl.
2.6 Preparation of F(ab')2 r Fab1, and Fc fragments from 
human IgG.
The method according to Hudson and Hay (1976) was
followed.
(i) Preparation of F(abf)2 and pFc fragments.
Pepsin digests human IgG into one F(ab)2 fragment and 
smaller Fc fragments, pFc.
An IgG solution (prepared as described in Methods 2 * 5 ,  p 
77, was concentrated to at least lOrag/ml and dialysed 
against O.OlM-sodium acetate and the pH of the dialysate 
was adjusted to pH 4.5 with acetic acid. Pepsin (from 
porcine stomach mucosa, 2500-3500 units/mg (from Sigma 
Chemical Company, Poole, Dorset, U.K.)) was added
(lmg/50mg IgG) to the dialysate and was left to stir at 
37*C for 24h. The solution was then centrifuged
(3,000q,15min) and any precipitate formed was discarded.
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The pH of the supernatant was adjusted to pH 7.4 and the 
latter was further dialysed against lOmM-sodium phosphate 
buffer, pH7.4.
(ii) Preparation of Fab' and Fc fragments.
Papain digests IgG into two Fab' fragments and one Fc 
fragment.
IgG was concentrated, to at least lOmg/ml, in 20mM-sodium 
phosphate buffer, pH7.4 and lOmM-cysteine, 2mM-EDTA, and 
papain (from papaya latex, 16-40 units/mg, (Sigma Chemical 
Company, Poole, Dorset, U.K.)) were added (lmg/lOOmg IgG). 
The solution was stirred at 37#C for 4h (transparency 
indicated completion of reaction). 20mM-Iodoacetate was 
added and the solution was left on ice for one hour, then 
dialysed against sodium phosphate buffer, pH 7.4.
Separation of fragments
a ) Protein A affinity chromatography.
F(ab )2 fragments could be separated from undigested IgG 
and pFc fragments, likewise Fab from IgG and Fc by use of 
a Protein A column (provided by Dr.A.Jehanli, Bath Univ., 
Bath,U.K.). Digests were applied to the column and eluted 
with lOmM-sodium phosphate buffer, pH 7.4. F(ab )2 and Fab 
fragments pass through unbound, whereas IgG, pFc and Fc 
fragments, which bind to the column, are eluted with 0.1M- 
glycine/HCl, pH2.8.
b ) Molecular exclusion chromatography.
Digests were applied to a Sephacryl G-200 column (2 x 
100cm) and eluted, overnight, in lOmM-sodium phosphate 
buffer, pH7.4 at a flow rate of 40ml/h. Fractions (10ml)
80
were collected and assayed (A2 8 0 ) for protein content. 
Fractions were then pooled (according to MWt) and 
concentrated i.e. IgG (150kD), F(ab >2 (lOOkD), Fab and Fc 
(50kD).
Protein A chromatography does not allow separation of Fc 
fragments from IgG and Molecular exclusion does not allow 
separation of Fab and Fc fragments, so a combination of 
both methods was used.
Fragments were tested for homogeneity by immuno- 
electrophoresis (see Methods Section 4.3, p 95 ), then
concentrated to at least lmg/ml and stored at -40°C.
2.7 Preparation of goat anti-(human-IgG) IgG horseradish 
peroxidase conjugate (IgG-HRP).
Horseradish peroxidase (HRP, 4mg/ml H 2O was stirred for 
20 min at room temperature with freshly prepared O.IM- 
sodium periodate (0.2ml). The greenish/grey solution was 
dialysed overnight in ImM-sodium acetate, pH4.4, and the 
resulting orange solution was titrated, to pH9.5, with 
0.2M-NaOH followed by the immediate addition of goat anti- 
(human IgG) IgG, [8-10mg in 50mM-sodium carbonate buffer 
pH9.5, (lml)l. The goat IgG was prepared from goat anti­
serum (provided by Dr.A.Jehanli, Bath Univ.,Bath,U.K.) 
according to the method described in Methods Sect 2.5, p  
77.The solution was stirred at room temperature for 2h 
followed by the addition of freshly prepared sodium 
borohydride (4mg/ml in H 2O ) . The solution was allowed to 
stand for 2h at 4#C, was then dialysed overnight against 
PBS.
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Unconjugated HRP and IgG were removed by chromatography 
on a Sephacryl G-200 column (0.75 x 100cm), collecting 
fractions (7.5ml) at a flow rate of 30ml/h in 20mM sodium 
phosphate buffer, pH7.4.
The IgG-HRP was concentrated, to 5mg/ml, in equal volumes 
of PBS and glycerol, and stored at -40°C for further use.
2.8 Preparation of rabbit immune-sera•
Antigen (lOOyg protein) was made up in sterilised PBS 
(0.5ml), homogenised if necessary, then mixed with an
equal volume of Freunds Complete Adjuvant. Blood (10ml) 
(for pre-immune sera) was taken from the ears of
Californian rabbits, (Animal house, Bath Univ.), which 
were then injected (2 x 0.5ml) in their hind limbs. Two 
weeks later the rabbits were given the same injection, but 
this time antigen was prepared in sterilised PBS alone. 
The same injection was again delivered one-month later. 
Approximately 5 days after this final injection, a small 
sample of blood (0.5ml) was taken from an ear vein and 
tested for reactivity toward antigen. If positive the 
animal was then sacrificed, and blood was collected (60- 
100ml).
Blood was left to clot at 37°C for lh, then overnight at 
4*C. The suspension was centrifuged (30,000q,lOmin) and
the supernatant was collected as serum.
2.9 Affinity purification of anti-BMFGM antibody.
The development of these methods are described in,
Results Sect 5.1, p152.
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I ) Batch absorption
BMFGM was homogenised in human serum (25mg/ml) and left to 
stir at 37°C for lh. The suspension was then centrifuged 
(100,000g, lh), and the BMFGM pellet was resuspended in 
PBS, containing 0.75M NaCl incubated at 37*C for lh and 
then centrifuged as above. The BMFGM pellet was then 
resuspended in 0.05M Gly/HCl, pH2.8, (1ml), incubated at 
37°C for lh while stirring, and recentrifuged. The 
supernatant was decanted, neutralised by the addition of 
4M NaOH, dialysed into a large volume of 0.1% ammonium 
acetate overnight at 4#C and then lyophilised. The 
affinity-purified antibodies were redissolved in PBS.
II) Preparation of affinity column
Concanavalin A - Sepharose 4B (ConA-Sepharose), (5ml), 
was washed with PBS (5:1 v/v) three times, separating, 
each time, by decantation. BMFGM suspended in PBS 
(5ml,0.lg/ml) was stirred overnight with washed ConA- 
Sepharose. The slurry was centrifuged (10,OOOg,lOmin) 
and the supernatant, containing unbound BMFGM was removed. 
The remaining slurry was washed by the addition of PBS 
(5:1 v/v) and recentrifuged. This process was continued 
until a clear supernatant was obtained. The slurry,
containing BMFGM bound to ConA-Sepharose, was poured into
\
a small column and allowed to settle overnight under 
gravity. BMFGM was then cross-linked covalently to the 
column by using Dimethylsuberimidate (DMSI), (Lang et a l , 
1982). DMSI (0.17-0.2mg/ml) in 0.2M triethanolamine, pH 
8.4, was passed through the column (15ml/h) for 3h and 
the reaction was terminated by recirculating 0.5M lysine
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through the column overnight, in the same buffer. The 
column was then washed with PBS for 2h at 10ml/h, and for 
lh at 20ral/hr.
Before the column was used for affinity purification, it 
was washed with 0.05M ammonium hydroxide, pHll, to remove 
any non-specifically bound protein from the BMFGM. The 
column was stored at 4*C with 0.02% azide.
Ill Affinity purification of anti-BMFGM antibodies using 
the above column.
Bovine Serum Albumin (BSA), (lOmg/ml PBS) was passed, at 
a flow rate of 15 ml/h, for lh, through the column which 
was then washed through with PBS until A 2 8 0  < 0.005. IgG, 
from which anti-BMFGM antibody was to be prepared, was 
then allowed to circulate through the column overnight at 
10ml/h. Unbound IgG was then eluted with PBS (30ml/h; 5ral 
fractions) until absorbance at A 2 8 0 was negligible. The 
column was then washed with PBS containing 0.85M-NaCl, 
0.2M a-methyl mannoside and 0.2M a-methylglucoside, until 
the absorbance at A 2 8 0 returned to <0.005. 0.05M-ammonium 
hydroxide, pHll, was then passed through the column 
(30ml/h), and the fractions (2ml), containing affinity 
purified anti-BMFGM antibody, were pooled and immediately 
neutralised with 2M-acetic acid, dialysed against 0.1^ 
ammonium acetate, and lyophilised.
Antibody was either stored, lyophilised, at -40°C, or 




(i ) Soluble protein 
Method 1
An estimation of protein concentration was made, by 
measuring the absorbance (280nm) of a suitably diluted 
protein solution against a diluent blank.
Concentrations of samples were then calculated from their 
known extinction co-efficients.
For mixtures of unknown proteins or proteins with unknown 
extinction coefficients, the absorbance of the solution 
was measured at both 260nm and 280nm (Warburg and 
Christian, 1940) and the protein concentration was 
calculated a follows;
(O.D«2 8 0 nn x 1.55) - (O.D.2 6 0 nm x 0.76) = mg/ml protein. 
Method 2
The method is based on the binding of Coomassie Brilliant 
Blue dye to proteins, in the presence of ethanol and 
phosphoric acid (Bradford,1976).
a) Microassay (For samples containing less than or equal 
to 25yg/ml protein)
Duplicates of samples containing protein were made up in 
either water or phosphate buffer (0.8ml). To this was 
added Bio-Rad protein assay dye-reagent (0.2ml), Bio-Rail 
Laboratories GmbH, (Munich, West Germany) and the 
solutions were mixed by inversion.
A standard curve was prepared from duplicate samples (1- 
25yg) of BSA in the corresponding solvent (0.8ml). A 
standard curve was prepared every time.
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The samples containing dye were left for 5-60 min, then 
read at 595nra.
b) Standard assay (For samples containing 20 - 140yg
protein)
Unknown samples were made up as above, but in 0.1ml 
volumes, and mixed with dye reagent (5ml). A standard 
curve was prepared by using BSA (0.2-1.4 mg/ml). The 
procedure was then as for the microassay.
(ii) Membrane protein.
The method used was a modification of the Lowry method 
(Lowry et al , 1951), futher developed by Markwell et al,
(1981) and Carruthers and Melchior (1983).
Solution A - 2% (w/v) Na2CC>3 in 0.4% (w/v) NaOH, 0.16% 
(w/v) KNa Tartrate and 3% (w/v) SDS.
Solution B - 4% (w/v) CuSCU.
To unknown samples diluted in water or phosphate buffer 
(200yL) a mixture of solutions A and B (100:1 v/v), were 
added (1ml). The resulting solution (1.2ml) was mixed by 
inversion and left for lOmin. Folin and Ciocalteau 
reagent (1:1 H 2O v/v) was then added at equal volumes to 
each sample, mixed by inversion and left for 30min. 
Absorbance was read at 750nm.
A standard curve was prepared from 0-100yg BSA,' 
dissolved in the same buffer as the samples being 
assayed.
3.2 Assay of XO activity 
XO exists in two forms, an oxidase (XO), and a 
deydrogenase (XD). Inclusion of DTT in buffers favoured
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preparation of the dehydrogenase form. Activities were 
measured according to the method of Nakamura and Yamazaki
(1982).
Reaction mixture (2ml) contained 
70yM Xanthine (first solubilised in a minimal volume of 
4M NaOH) and O.IM-sodium pyrophosphate, pH8.3.
0.5mM-NAD+ - was additionally present for the Dehydrogenase 
assay.
A suitable amount of enzyme contained in a volume of no 
greater than lOOyl, was added to reaction mixture (2ml) in 
a cuvette, and mixed by inversion.
Xanthine Oxidase activity was measured spectro-
photometrically by the increase in absorbance at 292nm 
under aerobic conditions, corresponding to the oxidation 
of Xanthine to Uric acid.
[A unit of XO activity was measured as the amount of 
enzyme yielding lymole of uric acid/min, E for Uric acid 
at 292nm is 12.2mM~1cm_1, (Dawson et al,1974).]
Xanthine Dehydrogenase (XD) activity was measured as the 
increase in absorbance at 340nm corresponding to the 
reduction of NAD+.
[ A unit of XD activity is defined as the amount of enzyme 
yielding lymole NADH/min, E for NADH at 340nm = 6.22mM- 
^•cmr1, (Dawson et al ,1974).]
3.3 Enzyme Linked immunosorbent assays (ELISAs)
(I) BMFGM
The development of this ELISA is described in more detail
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in Results Sect 1.1, p101.
BMFGM was prepared as described in Methods Sect 2.1 and 
used to coat raicrotitre wells. BMFGM was homogenised in 
50mM-sodium carbonate buffer, pH9.6 at a concentration of 
lOyg BMFGM protein /ml carbonate buffer. Suspension 
(lOOyl/well) was added to polystyrene microtitre plates, 
(Flow Laboratories Ltd., Rickmansworth, Herts., U.K.) 
which were then left to incubate at 4°C overnight or for 
3h at 37#C, washed with washing and blocking buffer 
(200yL/well) (PBS containing 0.05% (v/v) Tween 20), for 3 
x lOmin. Serum or IgG, diluted appropriately in 
PBS/Tween, was added (lOOyl/well) and left to incubate 
overnight at 4#C, or for lh at 37#C. Wells were then 
washed as before and conjugate was added (1:1000 in 
PBS/Tween, lOOyl/well) and was allowed to incubate at 
room temperature for l-2h. Wells were then washed as 
before and stain was applied. 0.OlM-sodium acetate/citrate 
buffer, pH6 containing 0.3mM-H2C>2 and 420yM-tetramethy 1 
benzidine (TMB) was added (lOOyl/well) and allowed to 
incubate at room temperature until a suitable colour 
developed, as judged by eye. The reaction was then stopped 
by the addition of 2 M-H 2 SO4 , (50yl/well). The absorbance 
(450nm) was read by using a Titertek Multiskan MCC (Flow 
Laboratories, Rickmansworth, U.K.).
For human sera or IgG, conjugate was either laboratory- 
prepared goat anti-(human IgG) IgG-HRP (see Methods Sect 
2.7, p 80 and Results Sect 1.1b, p102), or commercially
produced goat anti-(human, IgG, IgA, or IgM) IgG-HRP 
conjugate.
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For assay of rabbit anti-sera, goat anti-(rabbit 
immunoglobulins) IgG-HRP was used.
"Carmarthen” antigen, Dried milk (Oster Milk Two, Farley 
Healthcare Products Ltd, Notts., U.K.) was prepared as 
follows. Dried milk (3g) was added to the coating buffer 
(20ml) which was vortexed then centrifuged (30,000cj, 
15min). The supernatant was diluted (1:100) in the same 
coating buffer and used to coat the microtitre wells 
(lOOyL/well) which were then incubated overnight at 4#C, 
or for 3h at 37#C.
(II) Xanthine Oxidase
The procedure was identical to that of the BMFGM ELISA 
above except that XO, prepared according to Methods Sect
2.4 (iii),p76 , was used to coat the microtitre wells at a 
concentration of 15yg/ml of sodium carbonate buffer.
(III) Platelet membrane
The development of this ELISA from the method of 
Winiarski and Ekelund (1986), is discussed in Results Sect 
6.1, p184. Microtitre wells were coated with platelet
membrane, prepared according to Method Sect 2.2 (ii).
\
Platelet membrane was homogenised in 50mM-sodium carbonate 
buffer,pH 9.6 at a concentration of lOyg platelet
menbrane protein/ml carbonate buffer, the suspension 
CDOyL) was added to each well and left to incubate at
4°C overnight or at 37°C for 3h. Wells were then washed (3
x L0 min) with PBS/Tween. Serum, or IgG (5mg/ml in PBS),
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was diluted in Incubation buffer [PBS/Tween containing 4% 
(w/v) BSA, and 5% (v/v) Normal rabbit serum (NRS) v/v], at 
dilution factors of 1 : 1 0 0  and 1 : 2 0 0  respectively, and 
added to the wells (lOOyl/well). After incubation 
overnight at 4 #C or for 2h at 37#C, wells were washed (3 x 
lOmin) with PBS/Tween. Conjugate, diluted in Incubation 
buffer, was then added, (lOOy1/wel1), and left to incubate 
at room temperature for 2h. Wells were washed (3 x 10 min) 
and stained as for the BMFGM ELISA, (Methods Sect 3.3 
(I). Conjugates used were approprate for the serum being 
assayed, (see BMFGM ELISA, Methods Sect 3.3 (I), p 8 6 ).
4.0 TECHNIQUES
4.1 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE).
SDS-PAGE was carried out as described by Laemmli (1970). 
Separating gel was prepared the day before the gel was 
run. The stacking gel used was of 5% polyacrylamide, and 
the separating gel of 10% polyacrylamide. Gel compositions 
are described in Table 12. Separating gel was poured 
between two glass plates and overlayed with water- 
saturated butanol, to allow polymerisation.After 
polymerisation, butanol was washed fom the surface of the 
gel with distilled water, the surface was blotted dry, and 
the stacking gel was then poured onto the separating gel.
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Acrylamide stock (25% w/v,
24.5% Acrylamide, 0.62% Bis- 
acrylamide•
16 2
lM-Tris/HCl, pH 8 . 8 15 -
lM-Tris/HCl, pH 6 . 8 - 1.25
Distilled H 2O 7.7 6.3
The reagents overleaf were mixed, degassed, and the 
following reagents were then added:-
10% SDS (w/v)
N,N,N',N '-Tetramethylethylene-
0.4 0 . 1
diamine (TEMED) 0.025 0 . 0 1
1.5% Ammonium persulphate (w/v) 0.9 0.35
\
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A well comb was inserted and again the surface of the 
gel was overlayed with water-saturated butanol. After 
polymerisation, (approximately 40min), the comb was 
removed and the gel was placed in an electrophoresis 
tank, (Protean II, Biorad Chemical Division Richmond, 
California, U.S.A.). Electrophoresis buffer was poured 
into the tank and the samples were loaded into the 
buffer filled wells with an Hamilton syringe. The gel 
was run at 70-80V (no greater than 30mA) until the dye 
front had reached the separating gel. The voltage was 
then increased to 150-200V, (again the current did not 
exceed 30mA), and allowed to run until the dye front had 
reached the bottom edge of the separating gel. The gel 
was then removed from the tank and treated accordingly. 
Electrophoresis buffer contained, 0.192M-Glycine, 0.025M 
Tris, and 0.01% (w/v) SDS, final pH 8.3.
Generally, this buffer was made as a 10-fold 
concentrated stock. The buffer could be used to run 3 
SDS-PAGE gels before disposal and approximately 2.5L 
were used in the tank.
Preparation of samples
Sample buffer contained 50% (w/v) glycerol, 10% (w/v)
SDS, 10% (w/v) 2-mercaptoethanol, 0.01% (w/v)
bromophenol blue, in 0.125M-Tris/HCl.
Samples, prepared in lM-Tris/HCL, pH 6 .8 , were diluted 
in the above buffer (4:1 v/v), membranes being
homogenised in sample buffer. Samples were then either 
incubated at 37°C for 2h, or boiled for lmin to ensure 
complete denaturation. It was also ensured that all
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samples contained at least a 5-fold excess of SDS by 
weight over protein.
Molecular weight markers, SDS-6 H (Sigma Chemical Co, 
Poole, U.K), were prepared as instructed using the above 
sample buffer.
50yl wells contained approximately 75yg protein for 
membrane samples, and 2 0 yg for a single protein.
Staining of SDS-PAGE gels for protein
(i ) Coomassie Brilliant Blue
Gels were fixed in 45% methanol/10% acetic acid in 
distilled water for 40 min, followed by staining with 
0.1% Coomassie Brilliant Blue in the fixing solution for 
1 h. Gels were then destained in 5% methanol/7.5% acetic 
acid in distilled water overnight,followed by fresh 
changes of destain until the gel background was 
transparent.
These processes were carried out at room temperature, 
with constant gentle agitation.
(ii) Silver Staining (for samples containing < lOyg 
protein).
The method used was that according to Morrisey (1981), 
which is a modification of the original method by 
Switzer et al (1979).
Slab gels were incubated succesively, for 30min each, 
in 50% methanol/10% acetic acid; 5% methanol/7% acetic 
acid and finally 10% glutaraldehyde. The gels were then 
washed overnight in a large volume of distilled water 
and incubated for 30 min in dithiothreitol (5yg/ml). 
Excess solution was removed and immediately, without
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rinsing, silver nitrate (0 .1 % w/v) was added, and left 
to incubate for 30rain.
The gel was then rinsed with developing solution [3% 
sodium carbonate (80ml) and 37% formaldehyde (20ml)] and 
soaked in developer until the desired level of staining 
was obtained. The reaction was stopped by the addition 
of 2.5M citric acid (5ml) directly to the developer, and 
mixing by agitation. The solution was discarded and the 
gel was washed 5 times with distilled water, then soaked 
in 0.3% sodium carbonate for 10 min. Finally, the gel 
was washed in distilled water and stored in the dark at 
4°C.
4.2 Western-blotting of SDS-PAGE gels.
The method according to Towbin et al (1979) was 
followed.
SDS-PAGE slab gels were overlayed on nitrocellulose 
paper, ( 0.2y, from Sartorius, Belmont, Surrey, U.K),
pre-soaked in transferring buffer, ensuring that no air 
bubbles were present between the layers. The filter and 
gel were then sandwiched between blotting paper (Whatman 
3M) and Scotch-brite pads (on both sides), before being 
clamped into a plastic holder.
The holder was inserted into a transfer tank, ' 
containing 2.5L of transfer buffer, 25mM Tris/HCl, 20% 
methanol, pH 8.3, ensuring that the nitrocellulose was 
adjacent to the anode and the slab gel was adjacent to 
the cathode. Protein was transferred from the gel to the 
nitrocellulose for lOh, at 60mA, and at 4°C.
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The nitrocellulose filter was washed with distilled 
water, to remove any traces of SDS. Tracks were 
highlighted by immersion of the filter in 0.1% Ponceau 
S, in 3% TCA, when protein was stained as red bands 
(Coudrier et al , 1983). Tracks were cut with a sharp 
scalpel blade into 0.5cm widths and placed in incubation 
chambers. Residual Ponceau S was washed from the gels by 
incubation in PBS/Tween and the nitrocellulose strips, 
containing protein transferred from SDS-PAGE tracks, 
were then stained.
I Protein staining
The method according to Hancock and Tsang (1983) was 
followed. Indian ink (lyl/ml in PBS/Tween) was applied 
to each strip, ensuring complete immersion. When protein 
bands were visible, the ink was removed by aspiration, 
and the strip was incubated in PBS/Tween.
II Immuno-staining
Detection was according to the method of Towbin et al 
(1979, 1984), with some modifications.
Nitrocellulose strips were soaked, with gentle shaking, 
in blocking buffer (PBS/Tween, containing 0.1% (v/v) 
fish-skin gelatin) for 2h at room temperature. Strips 
were then treated with appropriate antibody i.e. human 
or rabbit serum (1:100), or IgG (1:200), diluted in ' 
incubation buffer (blocking buffer containing 5% Normal 
goat serum, and 4% BSA). Strips were incubated overnight 
at room temperature, then washed (4 x 15 min) with 
blocking buffer. A suitable conjugate was added see 
BMFGM ELISA Sect 3.3 (I),p87 , at 1:1000 dilution in
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incubating buffer and left to shake at room temperature 
for 2h. Strips were washed as before, then stained as 
follows.
Stain for HRP conjugated IgG,
3-Amino-9-ethylcarbazole (AEC) [4% in dimethylformamide 
(DMF)] was diluted (1:20 v/v), with 50mM-sodium acetate
buffer, pH5 to which 30% H 2O 2 (lyl/ml) was added. The 
inclusion of 0.05% Tween in this stain was found to 
prevent precipitation of AEC. Each strip was submerged in 
stain and was allowed to incubate, while shaking until, 
the strips showed brown/orange bands. The strips were 
washed in 50mM-acetate buffer, pH 5, then dried, and 
covered with film. Photographs were taken as soon as 
possible as the stain was found to fade with time.
Stain for Alkaline Phosphatase conjugated IgG.
To 10% diethanolamine buffer, pH9.8, containing 4mM- 
magnesium chloride (9vol), Nitroblue tetrazolium (lmg/ml 
in diethanolamine buffer (lvol) was added. In addition, 5- 
bromo-4-chloroindolyl phospate(5mg/ml in DMF) was added at 
lOyl/ml of stain. Nitrocellulose strips were submerged in 
stain, until blueish purple bands were visualised. The 
stain was then removed, and strips were immersed in 
distilled water and treated as above.
4.3 Immunoelectrophoresis 
Barbitone buffer was prepared by adding barbital (5'-5' 
diethyl barbituric acid), 4g dissolved in distilled H 2O 
(150ml) heated to 95°C, to sodium barbital (5'-5' 
Diethylbarbituric acid, Sodium salt), 12g dissolved in 
distilled H2o (800ml). The solution was made up to 1L,
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and the pH adjusted to 8.2.
1.5% Agarose, (Electophoresis grade, Bethesda Research 
Laboratories, Gaithersburg, U.S.A) was made up in the 
barbitone buffer. Agarose gel (15ml) was melted, and 
poured onto a 1 0 cm 2 agarose gel support medium, 
(Gelbond, FMC corporation, Maine, USA).After gelling, 
wells were punched (3mm diameter), and troughs were 
marked between the wells. The wells were then filled 
with 5yl serum or IgG (lmg/ml). One well contained serum 
to which a few grains of Bromophenol Blue had been 
added. The flat bed electrophoresis tank was filled with 
barbitone buffer, and the gel was placed on a glass 
slide, connected to the buffer by a strip of filter 
paper, making contact with the complete edge of the gel 
and the buffer. A current of 20mA was applied until 
Bromophenol Blue had migrated to the edge of the gel.
The gel was then taken out and troughs were filled with 
an appropriate antiserum and left to incubate in a humid 
chamber until precipitin lines appeared. The gel was 
rinsed succesively in PBS and H 2O for 24h each, then 
stained by immersion in 0.1% (w/v) Ponceau S in 3% (w/v) 
TCA. The gel was then dried to a film by incubation at 
370C for 24h.
4.4 Platelet aggregation
Preparation of Platelet Rich Plasma (PRP)
Fresh blood was collected in heparinised vacutainers, 
from hospitalised patients at the West Wales Hospital 
(Carmarthen, Wales, U.K.). Blood group "O" samples were
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detected as follows. One drop of a murine monoclonal 
anti-(human A and B blood group) antibody 
(Orthodiagnostics, New Jersey, U.S.A) was added to a 
sample of blood (approximately 1ml). The samples were 
shaken gently, then centrifuged (I6 O3 ,2min). Samples 
which showed agglutination were discarded. The remaining 
blood group “0 " samples were centrifuged (160c[, lOmin) and 
the supernatant was collected as PRP. If any red blood 
cell contamination was present, the solution was 
recentrifuged for another few minutes. Platelet Poor 
plama was prepared by re- centrifugation of the 
remaining blood specimen ( 30 , OOOcj, lOmin) .
Platelet aggregation
Platelet aggregometry was performed using a whole blood 
aggregometer from Coulter Electronics Ltd. (Luton, Beds. 
U.K.). Platelet aggregation denotes the adherance of 
platelets to each other. The phenomenon can be induced 
by adding aggregating agents to PRP or washed platelet 
suspensions. The process of aggregation is measured 
spectro-photometrically, using light transmittance 
through PPP, as a measure of 100% aggregation. The 
instrument develops a voltage proportional to the 
transmittance of light through PRP, and the voltage is 
recorded on a strip recorder as a function of time. 
Aggregation of PRP 
Each batch of PRP, prepared from fresh platelets as 
described above, was first tested for its ability to 
aggregate with collagen, a known aggregant. PRP (0.5ml)
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of platelet count 2-7 x 1012/L, was added to the 
aggregation chamber and left to reach 37°C. Collagen (2- 
4 yg/ml) was added, the solution stirred by means of a 
magnetic stirrer, and aggregation was observed. If the 
PRP did aggregate, then the test aggregant, in this case 
pre-, and post-immune sera, would be added (50-100vL 
aliquots),to a fresh aliquot of the same batch of PRP. 
Every 30 min, PRP would be re-tested with collagen, and 
it was noticed that generally, freshly prepared PRP was 
viable for up to 3h.
Aggregation of washed platelets 
In the same way as PRP, washed platelets (10-50 x 
1010/L), prepared according to Methods Sect 2.3,p74, 
were placed in the aggregating chamber and tested for 
their ability to aggregate with collagen. Another sample 
of the same washed platelet suspension was then treated 
with test aggregant i.e. serum, or IgG (5mg/ml), in 50- 
lOOyL aliquots.
Aggregation was usually observed within 5 min.
5.0 STATSITICAL ANALYSES.
5.1 Kolmogorov - Smirnov test
This method of analysis was used when comparing 
antibody levels in two populations (e.g. control and MI 
sera).
The Kolmogorov-Smirnov two tailed test (Siegel,1956) 
considers the difference between cumulative frequencies 
of two samples of populations. The test identifies the 
part of the distribution, in which maximum difference
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occurs, and a value (Ks) is directly derived from it. This 
is compared with a theoretical value Ks, dependant upon 
the numbers of each sample, and the required level of 
significance. If the observed Ks is less then the 
theoretical value of Ks, then the null hypothesis holds 
true, that the two samples have been drawn from the same 
population, and are not significantly different. 
Conversely, if the observed Ks is greater than or equal to 
the theoretical Ks, then the two samples are sufficiently 
different to suggest that they are from two different 
poulations.
5.2 Chi2 "Goodness of fit" test.
This test was used when comparing frequencies of antibody 
distributions within different categories, such as age 
group.
This analysis (Parker,1973; Hayslett,1976; Robson,1979) is 
used to test the significance of deviations between 
observed (0), and (E), expected frequencies. The chi2 
statistic computed is a goodness of fit between 
observations and theoretical values.
The test of association between frequency distributions in 
different categories is considered by looking at each 
individual frequency within a particular category as a 
cell in a Table of columns (i.e.categories), and rows 
(i.e. frequencies). Chi2 is calculated in the form:- 
( 0 - E ) 2
E for each cell, then summed, and is
compared with tabulated values, dependent upon the degrees 
of freedom for each analysis.
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5.3 Rank correlation 
This test was used, for example, to compare results 
from two assays carried out on the same set of samples. 
If a random sample of n members and two characteristics, 
x and y of each member are measured, a random sample of 
n pairs of observations is obtained. Under the
assumption that the distribution of x and y are normal, 
the sample correlation co-efficient is a measure of the 
linear relation between the two variables. If, however, 
the values of x and y are not normally distributed, then 
the rank-correlation co-efficient can be calculated, 
which depends upon the ranks of values, rather than
actual measurements. Values in the sample are ranked
from 1 to n, and for samples of the same value, then
their average rank is allocated to each. The Spearman 
rank-correlation co-efficient, Rs, is calculated as 
follows:-
Rs = 1- 6 (Xi - Yi )2
n (n 2 - 1)
Where n = Number of pairs of observations.
Xi = rank of xi 
Yi = rank of yi 
A value of Rs = i, indicates perfect agreement between 
the ranks: a value of -1 indicates that the ranks of x 
are exactly opposite to those of y,(Parker, 1973).
RESULTS
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1.0 DEVELOPMENT OF AN ELISA TO DETECT ANTI-BMFGM 
ANTIBODIES.
1.1 Design of a BMFGM ELISA 
The design of the above ELISA system was based upon 
the following protocol used in most ELISA systems. 
Microtitre plate wells were coated with antigen (i.e. 
BMFGM, Methods Sect 2.1, p70) suspended in 50mM-sodium
carbonate buffer, pH 9.6, and incubated overnight at 4#C 
or for 2h at 37°C. Wells were washed, (3 x 10 min), with 
washing buffer [0.05% Tween 20 in PBS, 200yl/well] and 
incubated with human serum, at an appropriate dilution 
in washing buffer, overnight at 4#C or for 2h at 37#C. 
Wells were then washed as above and incubated with goat 
anti-(human IgG)-HRP conjugate (Materials and Methods 
Section 2.7,p80), at an appropriate dilution, in washing 
buffer for 2h at room temperature, before washing as 
before. Finally, enzyme substrate (420yM-
tetramethylbenzidine in 0.01M sodium acetate/citrate 
buffer,pH6, containing 0.3mM H 2O 2 > was added and allowed 
to incubate until a blue colour developed, when the 
reaction was stopped by the addition of 2M H 2SO4 
(50yl/well) and absorbance was read at 450nm. All 
additions were at lOOyl/well unless otherwise stated.
The following parameters were investigated to optimise 
this ELISA:-
a. Coating conditions
ELISA plates were coated with various concentrations 
of BMFGM, to find the optimal coating concentration for
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the assay. Pooled high titre (anti-BMFGM antibodies) 
human serum, diluted 1/200, was assayed using laboratory 
prepared goat anti-(human IgG)-HRP conjugate (1:1000). 
Fig 25, pl03, illustrates that maximum absorbance was 
reached between 8-12 yg BMFGM protein /ml coating 
buffer. A coating concentration of 10 yg BMFGM protein 
/ml was used routinely in the BMFGM ELISA.
b. Conjugate concentration
Horseradish Peroxidase (HRP) conjugated to goat anti- 
(human IgG), prepared in the laboratory (see Methods 
Sect 2.7, p80), was titrated at various concentrations
on ELISA plates, coated with lOyg BMFGM protein/ml, and 
incubated with a pooled high titre (anti-BMFGM 
antibodies) human serum, diluted 1/100. A conjugate 
concentration of lyl/ml provided a sufficient 
colouration, after a period of incubation of 10 min (Fig 
26, pl03). Any subsequent conjugate preparation was
compared directly to previous batches, to maintain 
consistency.
c. Serum dilution
Plates were coated at lOyg BMFGM protein/ml, and human 
sera at dilutions ranging from 1/25 to 1/800 were 
assayed using laboratry prepared conjugate, diluted 
1/1000.
Because so many different sera had to be assayed, only 
one dilution of each serum was made; a 1/200 dilution 
was used. This was the minimum dilution necessary to 
give consistent titres, particularly for higher titre 
sera (see Table 13, pl04).
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The absorbance values, quoted above, represent the mean 
of 8 readings obtained on a particular day.
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Table 13 Effect of serum dilution on resultant antibody 
titre.
Serum Serum dilution
No 1/25 1/50 1/100 1/200 1/400 1/800
1 5.3 5.1 4.5 4.7 4.7 4.5
2 5.9 6.0 5.2 5.0 3.7 6.5
3 6.3 6.7 9.3 10.0 11.2 10.8
4 8.9 17.0 19.9 20.0 21.4 21.0
5 16.4 17.7 19.0 21.6 22.4 22.6
6 37.0 22.3 20.9 21.5 23.4 22.0
7 42.1 65.9 53.7 51.4 49.2 50.6
8 64.6 52.4 56.2 59.0 55.2 48.2
9 93.3 69.0 48.7 61.8 64.6 63.5
10 104.0 99.8 58.9 79.6 78.0 71.3
11 64.2 81.4 70.8 120.5 132.5 142.3
12 89.4 120.6 150.7 168.6 173.1 169.4
Titre is expressed as a percentage of the standard.
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d. Blocking conditions
Various blocking conditions are commonly used to 
minimise non-specific binding (Ruttenberg et a 1,1976; 
Lin and Kasamatsu,1983;Johnson et a l , 1984 ) , which can 
occur in either of two ways. The first is that 
conjugate may bind to the antigen coating the plate, 
thus an absorbance would be detected with no sera 
present: the second is that antibodies, which are not 
specific for antigen, may bind, thus the conjugate would 
detect both specific and non-specific antibody binding.
Conditions were tested using a coating concentration 
of BMFGM at lOyg/ml, pooled human serum was diluted at 
1/200, and laboratory prepared conjugate was diluted 
1/1000. Fig 27a, pl06, illustrates that including 5%
normal goat serum (NGS) in the washing buffer (with or 
without 1% BSA), reduces the absorbances of both the 
high and low titre sera. However, as both high and low 
titre sera were equally affected, it did not seem 
crucial to include either of these blocking agents in 
the BMFGM ELISA, as the relative differences between 
antibody titres would still be the same. This was also 
obvious from other sera tested (results not shown).
The effect of casein (1% in the washing buffer, and 0.1% 
during incubation of both sera and conjugate), assayed 
using the same conditions as for the blocking agents 
above, was to diminish the absorbance produced in all 
sera assayed (e.g. see fig 27b, pl06), thus it was not
included in the assay. When PBS containing 0.05% Tween 
was used as a blocking and incubating
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Fig 27 Effect of using a) NGS (5%) ± BSA (1%) and b)
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buffer, blank wells i.e. with buffer alone, had zero 
absorbance. Various sera gave rise to a range of 
absorbances, from values greater than 2 (high titre 
sera) to absorbances comparable with those of the blank 
wells (low titre sera). Blocking with PBS/Tween alone 
was accordingly used in the BMFGM ELISA.
The finalised protocol for the BMFGM ELISA is described
in Materials and Methods Sect 3.3, p 86.
1.2 Nature of binding of anti-BMFGM antibodies to the 
membrane
To examine whether the binding of anti-BMFGM antibodies 
to the membrane was specific or non-specific, F(ab*)2, 
Fab*, and Fc fragments were prepared from two high and
two low titre sera.The fragments were assayed according 
to the ELISA system (Methods Sect 3.3 (i), p86),using a
1:50 dilution of a lmg/ml solution of each,in place of 
sera. For high titre sera, binding of IgG, F(ab')2, and 
Fab* fragments gave high absorbances (Figs 28a, 28b and 
28c, pl09), whereas that of Fc did not (Fig 28d). Low
titre sera IgG, F(ab*)2 , and Fab' fragments gave low
x
absorbances, which were nevertheless higher than these 
produced by high titre sera Fc fragments. Low titre sera 
Fc fragments produced similar absorbances to those of
high titre Fc fragments.
For 50 samples, anti-BMFGM antibody levels were compared 
to total IgG levels (measured at BATH RUH), in the same 
serum sample* Fig 29, pllO, shows the results of this
108
Fig 28 Diagrams showing titration of :
a) IgG,
b) F (ab ')2 t
c) Fab' and
d) Fc fragments, prepared from high and low titre 
anti-BMFGM serum.
Key:-
A - High titre serum 100% Std
O  - " 75% Std
■ - Low " 5% Std
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comparison. The rank correlation coefficient (Rs) 
calculated for these data is 0.220. For p=0.05, only 
values of 0.273 or above show a significant correlation 
i.e. the results indicate that anti-BMFGM antibody 
levels are independent of total IgG levels.
1.3 Routine assay of samples
An important requirement of the ELISA is that the 
results be directly compared from day to day. To ensure 
this:-
1. A number of high titre sera were pooled and samples 
were used to derive a standard curve for each assay 
plate. Titres of test sera could then be expressed as a 
% of the standard serum (% Std).
2. A second pooled serum was prepared and assayed on 
every plate. If its titre deviated greatly from the 
mean, the samples contained on that plate would be re­
assayed (see Fig 30, pll2).
Each test sample was assayed in triplicate and the mean 
value was quoted. If the range of triplicate absorbances 
varied by more than 0.05 units that sample would be re­
assayed .
Table 14, pll3, shows the results of titrations of 5 
different sera, assayed on 10 separate occasions and the 
variation to be obtained within each of these ranges.
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Fig 30 Diagram showing the standard curve used in routine 
ELISA*s, prepared from pooled sera, and the value expected 
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Absorbance values of the Standard Curve are ± Standard
Error (n = 4).
Internal Standard = 50.2 ± 4.6 %Std (n = 10)
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Table 14 Variations present in anti-BMFGM titres
Serum number
1 2 3 4 5
1 5.3 11.4 19.2 70.4 139.8
2 5.2 10.8 21.6 100.2 120.4
3 5.1 13.2 25.4 86.4 160.2
4 6.0 10.2 22.4 96.3 125.6
Assay 5 3.6 11.0 21.3 90.2 186.4
number 6 4.5 11.6 18.4 86.4 140.4
7 4.6 12.1 19.8 86.1 140.3
8 4.9 10.5 22.0 70.8 160.9
9 2.3 13.4 21.6 100.0 133.6
10 3.4 9.6 21.6 69.2 154.2
Mean 4.5 11.4 21.3 85.6 146.2











Titres are expressed as a % of BMFGM Std.
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2.0 ASSAY OF MRC MI AND CONTROL SERUM SAMPLES.
1.Serum samples were assayed from three sets of male MI 
patients:-
a). 2-5 weeks post infarct (termed new)
b). 6 months post infarct
c ). 2 years ,, ,,
and from control patients (for further details see 
Materials Section 1.2, p69).
2.1 Comparison of "New" MI with control samples
Fig 31, pll5, shows the results of a comparison of New 
MI samples (< 65yrs of age), with control samples. There 
is no obvious difference between the two populations. A 
Kolmogorov-Smirnov (K-S) analysis shows that the 
greatest difference between the two populations occurs 
above 10-20% of the Std (i.e. 28.6% of MI, and 32.7%
control samples have values greater than this). However, 
this difference is not significant.
2.2 Comparisons of "New", 6-roonth, and 2-year samples. 
Fig 32, pll6, illustrates anti-EMFGM antibody levels
in each of the categories of MI patients listed in 2.0 
above. There appears to be little difference in antibody 
distribution between new, 6-month, or 2 year patients. A 
chi2 analysis of the different MI categories with Ab 
ranges of 0-10,10-20,20-30,30-40,40-50, and 50+% of Std 
give a calculated value of 13.694 (18.307 is necessary
for significance at p=0.05), showing that anti-BMFGM
115
Fig 31 Distribution of anti-BMFGM antibodies in 462
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Fig 32 Distribution of anti-BMFGM antibodies in:- 
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antibodies are similarly distributed within each of the 
three groups.
Investigation of changes in anti-BMFGM titres (new - 6- 
months, and 6-months - 2-years) post infarct.
Patient antibody levels were compared directly in 
pairs of time intervals after infarct. Figs 33a and b, 
pll8, show that there is a significant correlation 
between both new and 6-month antibody levels, and 6- 
month and 2-year antibody levels, suggesting that the 
anti-BMFGM titre after infarction is constant for up to 
2 years (For new and 6-month samples Rs calculated = 
0.947, values above 0.3 are necessary for a significant 
correlation at p = 0.05 and for 6-month and 2-year
antibody levels Rs calculated = 0.957, values above
0.352 are necessary for a significant correlation at p = 
0.05)
2.3 Comparisons of "new", 6-month, and 2-year MI with 
control samples (considering only titres of less than 
10% of Std).
Approximately 50% of all of the groups of samples 
assayed have a titre of below 10% of the standard, and 
it is possible that any difference present between the 
groups may be present in this range. Fig 34a, pll9, 
shows the results of a comparison between control 
samples and new MI samples. A K-S analysis shows that 
the two populations differ most above 3.0-4.0% of the 
Std (i.e. 67.9% of MI and 70.2% of control samples
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Fig 33 a comparison of anti-BMFGM antibody levels in MI 
patients:-
a) First sample after infarct, with 6-month sample after 
infarct. ( 2 2 9  samples)
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Fig 34 A comparison of anti-BMFGM antibody levels of less
than 10% of the Std in:-
a ) New MI patients with control
b) 6-month and 2-year MI patients with control
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considered have values greater than 3.9% of the Std). 
This difference is not significant. Fig 34b, shows a 
similar comparison between control samples, 6-month and 
2-year MI samples. Here, using the same analysis, a 
significant difference was obtained between both 6-month 
and 2 year samples and controls. A K-S analysis showed a 
maximum difference between both sets of samples to occur 
above 3.0-4.0% of Std (i.e. 59.3% of 6-month and 78.1% 
of control samples had titres of greater than 4.0% of 
the Std, as did 59.5% of 2-year and 78.2% of control 
samples. The difference however demonstrates a higher 
level of anti-BMFGM antibodies in the control samples.
2.4 Regional variation in anti-BMFGM titres of new MI 
samples
MI samples were collected from various regions of 
Wales and South-West England. To examine whether there 
was any regional variation, titres obtained from "new" 
samples were examined according to their area of origin. 
These are compared in Table 15a, pl22, and 15b which 
also compares the results when patients of >65 years of 
age are excluded.
A chi2 goodness of fit analysis of all regions against 
antibody levels (in the ranges 0-10, 10-20, 20-30, 30-
40, and 40+ (%Std)) showed that antibody frequencies are 
not significantly different in any region. Chi2 values 
were calculated to be 7.648 (all samples) and 4.593 (<65 
yrs of age). A value of 26.3 (p=0.05), is the minimum 
value necessary to show a significant difference.
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Table 15a The regional distribution of anti-BMFGM
antibodies (expressed as a percentage of the regional 
total (n) ), considering all samples within the region
and those of less than 65 yrs of age.
Key: -
A= all samples.
B= samples < 65yrs of age.
AREA 1 Cardiff and Newport
2 Swansea
3 South Wales Valleys
4 Bristol and Bath
5 Gloucester
Table 15b A comparison of the weighted mean for all 
regional new MI samples and those below 65 yrs of age 
with control samples.
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REGION 1 2 3 4 5
%Std A B A B A B A B A B
0-10 46.0 47.3 46.3 46.6 51 .1 50.3 53.2 52.8 48.3 50.0
10-20 23.6 25.0 23.2 24.1 22.3 24.8 14.9 16.7 24.1 15.0
20-30 10.8 10.6 11.6 13.8 13.3 10.6 10.6 11.1 13.8 8.3
30-40 4.4 4.3 4.3 5.2 3.2 3.5 6.4 5.6 0.0 0.0
40-50 3.6 2.7 2.9 0.0 2.7 2.8 0.0 0.0 3.4 4.2
50-60 1.6 1.6 2.9 1.7 1.1 1.4 2.1 2.8 3.4 4.2
60-70 3.2 2.1 0.0 0.0 1.1 0.7 2.1 2.8 3.4 4.2
70 + 6.8 6.4 8.7 8.6 5.3 5.7 10.6 8.3 3.4 4.2
n = 250 188 69 58 188 141 47 36 29 24
All titres are 




0-10 48.4 48.7 46.2
10-20 22.5 24.1 21.1
20-30 11.8 10.9 11.2
30-40 3.9 4.0 4.6
40-50 2.9 2.2 3.1
50-60 1.7 1.8 2.1
60-70 2.1 1.6 1.5
70 + 6.7 6.5 9.9
n = 583 447 517
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Table 15b, pl22, shows that when the weighted means of
titre categories within each of the regions (with and 
without considering samples of >65 years of age) are 
compared with each other and with the control group there 
are in fact very similar in distributions.
2.5 Distribution of anti-BMFGM antibodies within age 
groups of New MI samples.
Table 16, pl24, shows a comparison of anti-BMFGM antibody 
levels within age groups. Although a statistical analysis 
shows no relation between age group and antibody levels it 
is worth noting that the age group containing the largest 
deviations from the expected results are in the 56-60 year 
age group. A chi2 analysis comparing the age groups (as 
shown in Table 16), with anti-BMFGM antibody titres (in 
the range; 0-5, 5-10, 10-15, 15-20, 20-30, and 30+ % Std)
gave a calculated value of 22.158; values of above 37.653 
(p=0.05),are necessary to show that there is an 
association.
2.6 Comparisons of anti-BMFGM titres in other disease 
states.
Sera in the department were available from disease states 
in which there is an immunological disturbance; Myasthenia 
Gravis (MG) (Vincent,1979;Harrison and Behan 1986), Motor 
Neurone Disease (MND) (Digby et al,1985;Rutter et a l ,1986) 
and Idiopathic Thrombocytopenic Purpura (ITP) (Kelton and 
Gibbons, 1982; MacDonald and Savoca,1985). Anti-BMFGM 
levels of antibodies were assayed in each of these, and 
were compared
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Table 16 Distribution of anti-BMFGM antibody levels
within age groups.
Ab Titre Age Group (years)
(% Std) <45 46-50 51-55 56-60 61-64 65 +
0-5 21.2 20.9 15.5 16.7 22.8 19.1
5-10 25.6 27.6 27.8 32.5 26.0 26.1
10-15 15.2 13.6 13.4 20.0 8.7 14.8
15-20 4.5 15.5 8.2 10.0 11.8 8.7
20-30 13.6 12.1 16.5 6.7 11.8 11.3
30-40 7.6 3.4 6.2 2.5 5.5 4.3
40-50 1.5 3.4 4.1 0.0 3.9 3.5
50-60 1.5 0.0 1.0 5.0 2.4 0.9
60-70 1.5 0.0 2.1 1.7 0.8 2.6
70 + 7.6 3.5 5.2 5.0 6.3 8.7
n = 66 58 97 120 1 127 115
Frequencies are expressed as a % of total number of 
samples within each age-group.
to the same controls as used in the comparisons with MI 
samples (Figs 35a, b and c, pl27). MND samples showed no 
deviation from control subjects. However, although ITP and 
MG sera both appeared to show elevated levels of anti- 
BMFGM antibodies, the Kolroogorov-Smirnov analysis showed 
that there was only a significant difference in the MG sera 
compared to controls.
[A K-S analysis comparing MND sera with controls showed 
that the region of greatest difference occurred above 5-10% 
of the Std,(56.8% of MND, and 47.5% of control samples had 
titres of greater than 9.9% of the Std). However the 
calculated K-S value of 9.3 was less than the theoretical 
value of 30.4 (p=0.05) necessary to show a significant
difference. Comparing ITP sera with control sera ,again the 
point of greatest differnce between the two sets of samples 
occurred above 5-10% of the Std (77.5%, and 50% of ITP and 
control sera, respectively, had anti-BMFGM titres greater 
than this). A calculated K-S value of 27.5 was less than 
the necessary value of 30.4 as above.
Comparing MG sera with control sera, the region of maximum 
difference was above 10-15% of the Std (82% of MG samples 
and 37.1% of controls had values greater than this). A 
calculated K-S value of 44.9 was greater than the 
necessary value of 30.4, showing that anti-BMFGM titres 
were significantly raised in MG sera compared to controls 
(see Fig 35c,p 127)1.
Milk and dairy products have often been implicated as 
migraine triggers (Egger et a l ,1983; Monro et al,1984)
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Fig 35 A comparison of anti-BMFGM antibody titres in 
control samples with a) MND
b) ITP
c) MG sera.
Key to anti-BMFGM antibody titre ranges:-
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and it was considered worthwhile to investigate the 
levels of anti-BMFGM antibodies in the sera of migraine 
sufferers.
Sera were assayed blind and the results were then 
compared to the migraine trigger source (if known), see 
Table 17, pl28. Of the known triggers those associated
with dairy products had both high and low BMFGM titres.
3.0 COMPARISON OF ASSAY METHODS USED AT BATH AND 
CARMARTHEN
3.1 Comparison of ELISA techniques.
The results discussed in Section 2 show no significant 
differences between IgG anti-BMFGM antibody levels of 
control and MI patients (a possible difference may be 
detected at very low values, but would suggest an 
increase in titre of control samples, see Sect 2.3, 
pll7). At the time of these studies, Rees and Thomas, in 
Carmarthen were finding an elevation in antibody levels 
in MI patients compared with controls (Rees and Thomas, 
personal communication).
It seemed appropriate, therefore, to compare the assays 
used at Bath and Carmarthen. The assay used by Carmarthen 
differed from the Bath assay in two major respects:-
1. The antigen used was a Dried Milk extract [previous /  
work however, had shown titres using this to give an 
excellent correlation with those obtained using BMFGM as
an antigen (Rees,1985)].
2. The conjugate used was commercially produced goat
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anti-(human polyvalent immunoglobulin) antibodies which 
would detect IgG, IgA, and IgM.
35 samples were assayed by using the Bath ELISA system 
(see Sect 1.1, plOl) but varying the antigen and 
conjugate as follows:
i). No change,i .e . original Bath assay.
ii). Dried milk extract as antigen (see Methods Sect 3.3 
(i), p87), in place of BMFGM.
iii). Carmarthen conjugate, in place of the Bath 
conjugate, at a dilution of 1:1000.
iv). A combination of ii and iii above i.e. dried milk 
extract as antigen and Carmarthen conjugate. This 
is essentially the Carmarthen assay.
The mean values of 5 separate experiments were 
recorded. The results are compared in Fig 36a (i v ii), 
Fig 36b (i v iii), and Fig 36c (i v iv), pl31, and show 
highly significant correlations in all three cases (Rs = 
0.976, 0.942, and 0.936, respectively. Values greater 
than 0.325, p=0.05, show a significant correlation). The
effect of changing the conjugate was greater than that 
resulting from variation in antigen.
Another cruder way of comparing data was explored. 
Titres were classified as low, medium and high and the 
mean was calculated for each:- 
High titres are where, x > or =, 70% Std,
Medium titres, 70 > x < 10% Std and 
Low titres, where x < or = 10% Std
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Fig36 A comparison of:-
a) Bath and Carmarthen antigens, using Bath conjugate
b) , ,
c )
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Again, changes in conjugate seemed to have more effect 
than changes in antigen (Table 18, pl33).
A series of 5 sera, used by the Carmarthen group as 
standards in their assay, were provided. They were 
assayed using BMFGM as antigen, and with both 
conjugates. The results are shown in Table 19, pl33. 
Again, this shows that the use of different conjugate 
rather than antigen is causing discrepancies between 
results obtained at Bath and at Carmarthen.
3.2 Effect, of freeze-thawing of sera, on IgG, IgA, IgM 
and Polyvalent anti-BMFGM titres.
An alternative explanation for differences between 
results obtained at Bath and Carmarthen could lie in 
differences in the number of times that sera had been 
frozen and thawed. Three different sera were divided 
into 10 aliquots (0.5 ml). Nine of the aliquots were 
frozen at -40#C (approx 45 min), the 10th aliquot was 
reserved for analysis of an unfrozen sample. The frozen 
aliquots were allowed to thaw at room temperature 
(approx 15 min),and another aliquot of each serum was 
retained while the remaining eight aliquots of each 
serum were re-frozen at -40°C as above. The process was 
continued until 10 samples (frozen and thawed 0-9 times) 
were available for each of the three sera. IgG, IgA, 
IgM, and Polyvalent anti-BMFGM antibodies were detected 
using commercially produced conjugates, specific for 
each antibody type. Fig 37, pl34, shows that freezing 
and thawing appears not to affect the titre.
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Table 18 Average values for high, medium, and low titre 
samples in the BATH ELISA compared with the average 
values of their corresponding titres when varying antigen 
and conjugate
Antigen BMFGM DRIED MILK

















Table 19 Effect of conjugate on titre of Carmarthen 
standards, using BMFGM as antigen.
Conjugate Source
Carmarthen Bath Carmarthen
Titre, % Carm. Std Titre, % Carm. Std,
quoted by Carm. calculated at Bath.
84 93.3 ± 5.6 77.6 ± 9.4
43 20.9 ± 2.3 46.7 ± 3.8
21 8.3 i 1.4 19.0 ± 2.1
20 15.0 ± 3.4 21.0 ± 3.5
14 6.8 ± 2.2 16.0 ± 1.8
(n = 5 )
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Fig 37 The effects of freeze thawing on anti-BMFGM
antibody levels with respect to; a) polyvalent, b) IgG,
c) IgA, and d) IgM antibodies.
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3.3 Analysis of the laboratory prepared goat anti-human
IgG conjugate.
The conjugate prepared in the laboratory was compared 
to a commercially available conjugate specifically 
raised to IgG (i.e. directed against the Fc portion of 
IgG). Fig 38f pl36, shows that while both conjugates
detect IgG molecules, the Bath conjugate detects an F 
ab* fragment whereas that of the commercial conjugate
does not i.e. Bath conjugate is possibly detecting light /
chain as well as heavy chain fragments.
4•0 Analysis of IgG, IgA, IgM, and Polyvalent anti- 
BMFGM antibodies in MI patients and controls.
4.1 Preliminary analysis
Fig 39, pl37, shows the results of titration of the 
standard sera, using the BMFGM ELISA, with different 
conjugates (goat anti-human IgG, IgA, IgM and Polyvalent 
conjugated to HRP (1:1000 in PBS/Tween 0.05%). It can be 
seen that slightly lower dilutions of sera are necessary 
to detect IgA, and IgM, compared with IgG. Nevertheless, 
it is clear that IgG, IgA, and IgM molecules are being 
measured in the serum. In subsequent assays, IgG and 
Polyvalent antibodies were measured at 1:200 dilution of 
serum, IgM, and IgA were measured at 1:50 dilution of 
serum.
Two sets of 65 control and 65 ’’New" MI patients were 
chosen randomly and assayed for the above antibodies, 
see Figs 40 (a-d), pl39-143. A K-S analysis was
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Fig 39 Standard curves produced from the standard sera 
already in use (BMFGM ELISA Results Sect 1.1) but using:-
a) anti-polyvalent, anti-IgG, and
b) anti-IgA, anti-IgM, commercially available conjugates.
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performed on each set of jesults. There was no 
significant difference between M3 and control titres of 
Polyvalent, IgG or IgA anti-BfFGM antibodies, but IgM 
antibodies were significantly raised in MI patients 
compared to controls.
[ For polyvalent anti-BMFGM antibody detection the 
greatest difference between Ml and control samples 
occurred above 5-10% of the Stc (65.1% of MI and 55.5% 
of control had values greater tlan 9.9% of the Std in 
set 1, and 65.1% and 48.5% respectively in set 2). K-S 
values of 0.136 and 0.167 were calculated for each set 
respectively, 0.237 is the minimum value necessary to 
show a significant difference atp=0.05.
For IgG comparisons, the greatest difference between 
the two populations occurred at 5-10% of Std (53% of MI, 
and 59% of controls had values greater than 9.9% of Std 
in set 1, and 53% and 58% respectively in set 2). K-S 
values of 0.061, and 0.045 were calculated for set 1 and 
set 2, values above 0.237 bsing necessary for a 
significant difference.
For IgA, the greatest differencs occurred above 30-40%
of the Std (21.2%of MI and 7.6% of control in set 1 and
22.7% and 9% in set 2). K-S values for set 1 and set 2
were both 0.136; 0.237 or above is necessary to show a
significant difference.
For IgM, the greatest difference between the two 
populations occurred above 10-20* of the Std (82% of MI 
and 44% of control,in set 1 and 85% and 60% respectively 
in set 2), giving K-S values of 0.379 and 0.257 for sets
Fig 40 Distribution of anti-BMFGM antibodies in two
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1 and 2, both values of which are above the value of
0.237 necessary to show a significant difference between 
MI and control samples.]
4.2 Assay of 100 v 100 MI sample with controls
The next investigation was to compare a larger set of 
MI patients and controls. This time however, the MI 
patients were selected from a specific area, that of the 
South Wales Valleys, which was most compatible with the
area of collection of the controls (Caerphilly and
Speedwell). As all control samples were from men of < 65 
years of age, all MI samples > 64 years of age were 
excluded•
The results of measuring Polyvalent, IgG, IgA, and IgM 
anti-BMFGM antibody levels are shown in Figs 41 (a-d), 
pl45-147. As in the previous section (4.1, pl35), no
significant differences were observed when considering 
polyvalent, IgG or IgA antibodies. Differences were 
however, significant with IgM.
(For polyvalent antibody measurement, the greatest 
difference between MI and control samples occurred above 
5-10% of the Std (70% of MI and 56% of controls).A K-S
value of 0.14 calculated was below the value of 0.192
necessary to show a significant difference at p=0.05.
For IgG, the greatest difference occurred above 5-10% 
of the Std (52% of MI and 63% of control samples were 
above this). A K-S value of 0.11 was below the value of
0.192 necassary for significance at p=0.05.
For IgA, the greatest difference occurred above 0-5.0%
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Fig 41 A comparison <of anti-BMFGM antibodies in 100 MI 
samples sets of 100 ”N<ew" MI samples (region and age 
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of the Std (79% of MI and 91% of control samples were 
above this). A K-S value of 0.12 was again below the 
necessary value of 0.192 to show significance.
For IgM, the greatest difference occurred above 50-60% 
of the Std, although the difference above 20-30% of the 
Std was only slightly lower, (32% of MI and 10% of 
controls had values of greater than 59% of the Std). A 
K-S value of 0.220, greater than that necessary to show 
significance, 0.192 at P=0.05, indicated a significant 
elevation of IgM anti-BMFGM antibodies in MI patients 
compared to controls.
5.0 ANTIGENIC DETERMINANTS OF THE BMFGM
5.1 Affinity purification of anti-BMFGM antibodies
To facilitate characterisation of antigenic determinants 
of the BMFGM, serum anti-BMFGM antibodies were affinity 
purified. These were then used as tools in further
immunochemical analyses (see Results Sect 5.2, pl60, 
6.2.1, pl97 and 6.4, p210).
a) Batch adsorption method
This method had been described by Freed (personal 
communication). It entailed mixing BMFGM with serum,
centrifuging to remove BMFGM, adding 0.05M Glycine/HCl
buffer pH 2.8 to the BMFGM, which was removed leaving 
the affinity-purified antibodies in Glycine/HCl buffer. 
Experimental details were sparse, so the following 
protocol, based on the above, was used initially.
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A suspension of BMFGM in pooled human serum, was
incubated at 37#C and centrifuged (100,000 lh). To
avoid any non-specific binding of antibodies or other
proteins to BMFGM, a wash step was included at this 
point. BMFGM was resuspended in PBS/0.75M NaCl and 
centrifuged as before. The BMFGM pellet was then
resuspended in 0.05M Gly/HCL, pH 2.8 for lh at 37°C, and 
centrifuged as above. The supernatant was decanted, 
neutralised, by the addition of 4M NaOH and dialysed 
against a large volume of ammonium acetate (0.1%) at 4#C 
overnight. The dialysed solution was then lyophilised, 
and redissolved in PBS.
To maximise anti-BMFGM binding to the BMFGM, the
following conditions were investigated:-
1. The amount of BMFGM required to absorb out total 
anti-BMFGM activity was investigated. Varying amounts of 
membrane were incubated for lh at 37°C with three 
different sera, of varying titre, to discover how much 
BMFGM was required to completely absorb out anti-BMFGM 
antibodies
Fig 42, pl50, shows that for a very high titre serum
25mg / ml of sera will absorb out all anti BMFGM 
antibodies.For a mid-titre and low titre serum the 
amount of BMFGM required to produce the same effect was 
less. For subsequent experiments 25mg of BMFGM/ ml of 
sera was used.
2. The time for maximal binding of antibody to BMFGM was 
investigated. BMFGM was incubated with serum (25mg/ml),
150
Fig 42 Absorption of anti-BMFGM activity in 3 different 
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by stirring at 37#C. At various time intervals (0- 
60min), an aliquot (5ml) of suspension was taken, 
centrifuged and treated as for the method outlined 
above.
Fig 43, pl50, shows that almost all (95%) antibody has 
bound to the BMFGM after 50 min, under the conditions
used for incubation. For further experiments an
incubation time, for BMFGM with sera, of 60 min, was
allowed.
The activity recovered by the above process was poor 
(0.1 ± 0.1% of original activity, n=3).
The following experiments were designed to try to
optimise recovery of anti-BMFGM antibodies from a 
pooled, high titre serum.
1. The volume of Gly/HCl used in incubation of antibody 
bound BMFGM was varied 100-fold (l-100ml). This had no 
significant effect on activity recovered (0.1 ± 0.1% 
orig. serum., n=3).
2. The time of incubation of Gly/HCl with BMFGM was 
varied between lh and 24h. This also had no effect on 
recovery of activity (0.1 ± 0.1% orig.serum., n=3).
3. It was considered possible that the denaturing agent 
Gly/HCL may have been interfering with either the 
activity of the antibody itself, or the antigenic 
structure of the BMFGM. Incubation of serum with Gly/HCl 
(37#C, lh), had the effect of reducing the activity of 
the sera to 85.3 ± 7.2% of the original, n=3. The
i
activity of the sera was, „ in fact, reduced by
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incubation of the sera at 37'C, lh (to 95.4 ± 5.5% of 
original activity). A similar experiment was performed, 
treating BMFGM with Gly/HCl. BMFGM was used to coat 
ELISA plates (as in Results Sect 1, plOl), after 
incubation with and without Gly/HCl (37*C, lh).
Treatment of BMFGM at 37*C alone had no effect on the
antigenicity of the membrane (100 ± 6.1% original),and
treatment with Gly/HCl reduced the activity of the
membrane to 91.6 ± 4.3% of original activity, (n=3). The
effect of Gly/HCl on both BMFGM and sera did not reduce 
the activity of either sufficiently to account for the 
poor recoveries of anti-BMFGM antibody.
4.The eluting agent was varied. In place of Gly/HCl, 3M- 
potassium thiocyanate, O.IM-sodium borate, pHIO, and 
0.05M-ammonium hydroxide, pHll were investigated. Some 
improvement was noted using ammonium hydroxide (0.3 ± 
0.1% original, n=3) therefore this was the choice
eluting agent in all subsequent experiments. Potassium 
thiocyanate, and sodium borate showed no improvement
over Gly/HCl (0.1 ± 0.1% original activity, n=3).
The final experimental protocol for affinity 
purification of anti-BMFGM antibodies by a batch 
absorption method is described in Materials and Methods 
Sect 2.9, p81.
b) Design of an affinity column
An affinity column Was prepared by a combination of the 
methods of Sela and Edelman, 1977; and Steiner 1985, as
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follows.
The column matrix, Sephadex G-50 (50ml) was stirred at 
room temperature with Concanavalin A (Con A) (50mg in 
PBS). Excess Con A was removed by decantation and the 
ConA- Sephadex was stirred with a BMFGM suspension (5ml,
O.lmg/ml) overnight at 4#C. This mixture was degassed 
and poured into a column (2.5 x 25cm). The column was 
washed for 30min with glutaraldehyde (30% in PBS, at 
30ml/h for 2h) and then equilibrated with PBS. Before 
passing serum through the column (10ml,30ml/h), 1% BSA 
in PBS was passed through, (lh, 30ml/h). This was 
followed by exhaustive washing with PBS until the
optical absorbance of the column effluent, measured at 
280nm, was < 0.005. Material bound to the column was
then eluted in 0.5M ammonium hydroxide pHll, at 40ml/h. 
The eluate was immediately adjusted to pH 7 with 2M- 
acetic acid, and lyophilised, giving anti-BMFGM 
antibodies representing 5.2 ± 3.4%, n=3 of those loaded 
onto the column.
A second commercially-available matrix, Sepharose-4B, 
to which Con A was already bound, was used in place of 
Sephadex G-50 (5ml instead of 50ml). Preparation of the 
affinity column and purification then proceeded in the 
same way, using the same quantities of serum. Using this 
matrix, activity recovered was 12.2 ± 4.4% of the
original activity n=3.
The above experiment was repeated except that a wash 
step was included to remove non-specifically bound 
material from the column. This buffer contained PBS,
154
0.75M NaCl, 0. 2M a-methylmannoside and 0.2M a-methy1
glucoside. Table 20, pl55 shows a purification profile 
of anti-BMFGM antibodies from serum.
The wash step acts to remove some BMFGM activity, 5.3
± 2.6% of original activity, but this does not detract 
from the activity recovered in the final affinity 
purification stage (14.2 ± 3.6 %, n=3). Table 20, also 
shows the control experiment of passing PBS through the 
column in place of serum. This shows that no anti-BMFGM 
activity is recovered at any of the stages. Some protein 
recovered after the wash stage may be due to the BSA 
bound to the column.
The following experiments were designed to optimise 
recovery of anti-BMFGM antibody from the affinity column 
using a batch of pooled human sera.
1. Serum was passed through the affinity column, once,
twice, and recirculated through the column overnight. 
Repeated passage through the column resulted in an 
increase of recovered activity from 10.2 t 4.3 % to 15.8 
± 2.7 % of the original activity.
2. A second cross-linking agent, dimethylsuberimidate, 
used to covalently attach BMFGM to the column, was 
investigated. The method of preparation was according to 
Lang et al (1982). Dimethylsuberimidate (0.17-0.2 mg/ml) 
in 0.2M triethanolamine, pH 8.4 was passed through the 
BMFGM — ConA Sepharose column, in place of glutar- 
aldehyde. After 3h, the reaction was terminated by 
recirculation through the column overnight of 0.5M
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Table 20 Affinity purification of anti-BMFGM
antibodies from serum using an affinity column (see 













Orig. 100 82.2 ± 5.6 0 0
N B 28.2 ± 6.6 78.4 t 8.2 0 0
N S B 5.3 ± 2.6 8.1 t 4.2 0 4.3 ± 1.8
S B 14.2 ± 3.6 0.02 ± 1.0 0 0
n = 3
Key to above table:-
Orig. - Original serum applied to column 
N B - Material not binding to column
N S B - Non-specifically binding material eluted after 
washing with salt
S B  - Specifically binding material eluted after
Ammonium Hydroxide treatment
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lysine, in the same buffer. Activity recovered was
increased from 14.7 ± 3.3 % (using glutaraldehyde as a 
cross-linking agent) to 20.4 ± 3.6 % of the original
antibody activity (n=3), when dimethylsuberimidate was 
used.
3. Immunoelectrophoresis of the affinity purified anti- 
BMFGM antibodies had shown that they were largely IgG. 
Anti-(human polyvalent) antibody gave a very similar 
result compared to anti-(human IgG) when used to detect 
affinity purified anti-BMFGM antibodies), see Fig 44, p
157. When serum (1ml) or the equivalent amount of IgG 
(lOmg,approx) was applied to the column, the final
recovery of activity was similar (13.9 ± 2.6% for serum, 
and 14.5 ± 2.0% for IgG, n=3).
In all further experiments, IgG was used as the source 
of antibodies for purification.
In all of the experiments outlined, antibody activity 
of 25-35% was lost in the flow-through serum. Attempts 
were made to optimise the amount of IgG applied. The 
results (Table 21, pl58) show that the anti-BMFGM 
activity present in the flow through does not result 
from an excess of anti-BMFGM antibody. There appears to 
be an anti-BMFGM antibody population which does not bind 
to the column. This is indicated by the similar amounts 
of activity in the flow through from the application of 
2-16 mg IgG/ml of PBS. However, on analysis of the 
affinity purified fraction,the optimum loading of IgG 
appears to be lOmg/ml of PBS.
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Fig 44 Immunoelectrophoresis of two preparations of









2. Affinity anti-BMFGM I
3. Affinity anti-BMFGM II
Trough
X. Goat anti-(human IgG)
Y. Goat anti-(human polvalent antibodies)
Z. Goat anti-(human IgG)
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Table 21 Optimisation of antibody purification from
varying amounts of IgG, prepared from a pooled serum, 
(per 5 ml affinity column).
N B N S B S B
IgG Act • Prot. Act. Prot. Act. Prot.
(mg/ml) (% Orig) (mg) (% Orig.) (mg) (% Orig) (mg)
2 23.2 1.2 2.1 3.1 8.5 0.05
4 28.5 3.8 5.2 3.2 10.6 0.09
6 26.1 5.5 4.8 4.4 15.4 0.17
8 25.9 7.6 3.7 6.5 20.1 0.20
10 32.9 9.6 6.8 6.2 19.7 0.24
16 33.1 15.5 9.4 4.2 22.9 0.25
(NB, NSB and SB, as for Table 20 ,p 155)
Table 22 Results of affinity purification of 10
different human sera, and an immune sera raised in 









BMFGM Ab level 
(mg/ml serum)
1 100 (Pooled) 20.6 0.24 1.17
2 123 21.4 0.19 0.89
3 89 19.6 0.20 1.02
4 82 18.3 0.16 0.87
5 46 15.6 0.14 0.90
6 32 16.1 0.10 0.60
7 20 14.3 0.06 0.40
8 10 9.9 0.04 0.40
9 5 12.3 0.01 0.08
10 2 13.2 0.01 0.07
RABMFGM 31.6 0.69 2.18
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The final protocol for preparing a column and 
purifying anti-BMFGM antibodies is described in 
Materials and Methods Sect 2.9, p 8 .2.
Table 22, pl59 shows the results of affinity 
purifications from 10 different human sera, of varying 
titres, and cf anti-serum to BMFGM raised in rabbit.
It can be seen that the % recoveries of the affinity 
fraction are similar in all, apart from the rabbit anti- 
BMFGM sera which shows a recovery of 31.6% . The
difference between titres is represented by the protein 
recovered in each i.e. high titre sera have a higher 
recovery of protein associated with the affinity 
fraction. Assuming 100% activity in the original serum 
it is possible to estimate the total amount of anti- 
BMFGM specific IgG present per ml of each individual 
serum, the results of which are also shown in Table 22.
5.2 Western blotting of SDS-PAGE patterns of BMFGM, 
followed by immunoblotting.
BMFGM, prepared as described in Materials and Methods 
(Sect 2.1, p70), was subjected to SDS-PAGE and then 
polypeptides were transferred to nitrocellulose sheets 
,Materials and Methods (Sect 4.1 and 4.2, p89, 93). The
transferred bands were incubated with either serum 
(1:50), or IgG (1:200), prepared from it, followed by an 
appropriate conjugate (1:1000), Materials and Methods 
(Sect 4.2, p94).
Figure 45, pl62, shows the results of immunoblotting 
of 9 different human sera. One band at approximately
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150 kD appears to be consistently present. Fig 47, pl63, 
shows an immunoblot of human sera on the BMFGM in more 
detail. Although the 150 kD is present in all sera, 
other bands, at 28, 36, 45, 59, 66, and 170kD occur in 
some gels. All of the bands are noticeably more intense 
in the high titre sera. Fig 47, pl64, shows the results 
of immunoblotting of affinity purified IgG anti-BMFGM 
antibodies from different human sera. Again the band at 
150 kD is detectable in all preparations. Bands of MWt 
28, and 94 kD are detectable in the pooled sera and a 
band of 45 kD is seen in the high titre preparations. In 
the two high titre sera (lanes 1, and 4), the bands of 
150 kD are enhanced.
Fig 48, pl65, shows the results of immunoblotting of
affinity purified rabbit anti-BMFGM antibodies together 
with the unpurified rabbit IgG and flow-through 
fractions (containing 25% of the original activity of 
the IgG). All gels show a band at 150kD. It is 
noteworthy that most transferred protein bands are also 
stained, in contrast to results with human sera, 
indicating that human anti-BMFGM antibodies may be more 
specific in their binding.
Fig 49, pl66, shows an SDS-PAGE pattern of dried whole 
milk (as used in the Carmarthen assay). Two regions of 
low MWt proteins are shown , both of which also stain 
when immunoblotted with sera.
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Fig 45  An immunoblot profile of the BMFGM treated with 9 
different human sera.
150 kD
Lane 1 - BMFGM stained for protein
2,3,4,7 and 9 - High titre anti-BMFGM sera
5,6 and 8 - Medium titre sera
10 - Low titre sera
11 - No sera
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Fig 46 Immunoblotting profile of human sera against
BMFGM.
1 2  3 4
1. Low titre sera
2. Medium titre sera 
3f4. High titre sera
(Low, medium, and high, as defined on p130)
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Fig 47 Immunoblotting profile of affinity purified anti- 
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1. Pooled sera 
2,3. Low titre sera 
4,5. High titre sera 
6,7. Medium titre sera 
8. No sera
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5.3 Preparation of Xanthine Oxidase for immunochemical 
analysis of anti-XO antibodies.
XO was initially purified from bovine milk according 
to the method of Nakamura and Yamazaki, 1982 (Materials 
and Methods, Sect 2.4 (i), p74). However, of the five
preparations made (45.6 t 10.2 mg protein, 5.29 ± 0.95 
IU/mg) from 9L fresh Bovine Milk), only one was suitable 
for assaying IgG, IgA, and IgM anti-XO antibodies, in 
an ELISA. The other four preparations caused a 
background to anti-XO IgM detection see Fig 50, pl68. 
The background was present when sera was assayed, but 
not in the control with no sera. This background was not 
eliminated by use of enzyme prepared in the presence of 
protease inhibitors and was not affected by the 
proportion of oxidase form of the enzyme (results not 
shown).
SDS-PAGE profiles of two different preparations of the 
enzyme, one of which did and one of which did not show a 
background in IgM ELISA, are shown in Fig 51, pl69. A 
contaminant (83kD) is present in the preparations 
creating the background to IgM. This was found to be 
always the case.
Attempts to separate the preparation containing the 
150kD and 83kD polypeptides, by gel-filtration on G-200 
Sepharose, were unsuccessful (Materials and Methods, 
Sect 2.4 (ii), p75).
A further attempt to separate these bands was made by 
using a folate column (folate is an affinity ligand for 
XO); for further details of this column see Materials
168
Fig50 Standard curves showing the presence of IgG, IgA, 
and IgM anti-XO antibodies in a pooled serum , using two 
different preparations of XO, in the XO ELISA (Sect 5.4).
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Fig 51 SDS-PAGE profile of two different preparations
of XO , purified from cows' milk, by the method of 








2. Non-binding extract of XO from BMFGM (20yg)
3. XO -no background (30yg)
4. XO -background (30yg)
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and Methods Sect 2.4 (iii), p76). The sample of XO 
(containing 150kD and 83kD polypeptides) was applied to 
the column (10ml) which was washed with Buffer A, until 
the column eluate A 2 8 0 was < 0.005. Protein remaining on 
the column was affinity eluted by Buffer B. Of 25.4 ±
2.3 mg protein loaded onto the column, a colourless 
fraction of protein content 3.1 ± 0.7 mg passed through 
the column unbound, (no XO, or XD activity was recorded 
in this fraction), and an orange-brown fraction of 
protein content 20.4 ± 1.6 mg, of specific activity, 6.5 
± 0.3 IU/mg, was eluted by Buffer B (n=2).
Fig 52, pl71, shows SDS-PAGE patterns of the fractions 
collected. It can be seen that the folate column 
effectively removes the 83kD band, which passes through 
unbound. When tested as antigens on an ELISA (lOyg/ml 
carbonate buffer, the original sample and the unbound 
fraction (lanes 2, and 3, Fig 52, pl71), gave high
backgrounds, whereas the affinity eluted XO did not.
5.4 Design of an ELISA to detect anti-Xanthine Oxidase 
antibodies•
The ELISA protocol was similar to that of the BMFGM 
ELISA, described in Methods Sect. 3.3, p86. The main 
difference was that XO was suspended in carbonate 
coating buffer, in place of BMFGM as the antigen. All 
incubation, wash and staining steps were the same.
XO (prepared from the folate column) coating 
concentrations were optimised for the ELISA (as with 
BMFGM see pi03).
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5 4 3 2 1
1. BMFGM (50yg)
2. XO applied to folate column (30yg)
3. Run through folate column (30yg)
4. XO specifically eluted from folate column (20yg)
5. XO after 2 days at 40°C ( + inhibitors)
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Fig 54 Standard curves produced from the detection of 
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The results of this are shown in Fig 53, pl72.
Fig 54, pl72, shows the results of anti-XO IgG, IgA, and
IgM detection in pooled sera, using goat-anti human 
IgG, IgA, and IgM (1:1000) conjugated HRP. The pooled 
sera which had been used to generate a standard curve in 
the BMFGM ELISA (Results Sect 1.3, pll2), contained very 
little anti-XO IgA, or IgM. A second set of sera in 
which these antibodies were high were pooled and used
for the standard curves shown in Fig 54. Anti-XO IgG
samples were assayed at 1:200 as before, and anti-IgA-, 
and IgM were assayed at 1:100.
The final protocol is described in Materials and Methods 
Sect 3.3, p88.
5.5 Comparison of anti-XO antibody titres with anti- 
BMFGM antibody titres.
IgG, IgA, and IgM anti-XO antibody levels were assayed 
in 198 human serum samples and compared, in each sample 
with the corresponding anti-BMFGM antibody titre (see 
Fig 55, pl74-177). Significant correlations were
obtained for all antibody types.
[ The Rs calculated when comparing anti-XO antibody 
titres with anti-BMFGM levels were 0.894 (IgG), 0.894 
(IgA) and 0.599 (IgM). Values above 0.14 are necessary 
to show a significant correlation for p=0.05.]
5.6 A comparison of IgG, IgA, and IgM anti-XO
antibodies in MI and Control samples.
The 100 MI samples, age and region matched with 100
174
Fig 5 5 Comparisons of anti-BMFGM antibody titres with 
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controls, used to compare anti-BMFGM antibody levels 
(Results Sect 4.2, pl44) were assayed for anti-XO
antibodies using the ELISA system described in Results 
Sect 5.4. Fig 56, pl80, shows the results of these 
comparisons; only IgM anti-XO antibodies are 
significantly raised in MI patients.
[ For IgG anti-XO antibodies the point above which the 
MI samples and controls differ most is at 20-30% of the 
Std (11% of MI, and 9% of control samples had values 
greater than this). A K-S value of 0.02 is well below 
the theoretical value of 0.192, necessary to show a 
significant difference between the two populations at 
p=0.05.
For IgA, the region of maximum difference was above 0- 
5.0% of the Std (39% of MI and 50% of control samples 
had values greater than this). A K-S value of 0.11 
calculated for this difference was again below the value 
of 0.192, necessary to show a significant difference.
For IgM, there were two places above which the two 
populations of MI and controls were equally different, 
these were at 50-100% of the Std, and 100-150% of the 
Std (50% of MI and 30% of contol samples had values 
greater than 150% of the Std; 69% MI and 49% control 
were above 100% Std). A K-S value of 0.2, was greater 
than the necessary value of 0.192 to show a significant 
difference between the two populations at p=0.05]
A second series of MI patients whose sera was 
available 1-2 days after infarction was available from 
the Royal United Hospital (Bath, Avon, U.K.). Anti XO
179
Fig 56 Distribution of XO antibodies in 100 MI
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levels were similarly measured in these and compared to 
age matched hospitalised (same hospital, Bath RUH) 
patients who had no known history of heart disease. The 
results of this study are shown in Fig 57, pl83. Again, 
IgM anti-XO antibodies are raised in MI patients.
[For IgG a maximum difference between the two 
populations occurs above 0-5.0% of the Std (48% of MI, 
and 61% of control are greater than 5.0% of the Std). A 
K-S value of 0.136 was below that necessary for 
significance, 0.274 for p=0.05.
For IgA, the maximum difference occurred at 0-5.0% of 
Std also (16% of MI, and 30% of control were above 
this). A K-S value of 0.243 was again below 0.274.
For IgM, the greatest difference occurred above 100-150% 
of the Std (54% of MI and 11% of control samples had 
values greater than this). A K-S value calculated at 
0.42 was much greater than that necessary for 
significance at p=0.05, 0.274.
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Fig 57 Distribution of XO antibodies




c) anti-XO IgM antibodies.
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6.0 IMMUNOLOGICAL CROSS-REACTIVITY OF BMFGM WITH
PLATELET MEMBRANE.
6.1 Design of an ELISA to measure anti-Platelet 
membrane antibodies.
a) The method of Horai et al (1981) was first 
investigated•
A platelet suspension (50yl, 10*/yl), was added to 
microtitre wells and the trays were centrifuged (5min, 
200cj av. ) . Formaldehyde (50yl, 2% in PBS) was added to 
each well and left for lh at room temperature. The wells 
were then washed (4 x 10 min) with PBS/Tween (0.05%). 
Serum was then added to each well (appropriately diluted 
in washing buffer). After incubation (lh, 37#C), wells 
were washed as before, then incubated (45min, 37°C) with 
goat anti-human IgG-HRP conjugate (as in Results Sect 
1.1, pl02, 1:1000 in PBS/Tween 20, 0.05%). Wells were
washed again and stained as described in the BMFGM 
ELISA, Materials and Methods sect. 3.3 (i), p87.
Table 23, pl87, shows the results obtained when a 1:50 
dilution of serum was coated onto 75 wells. There were 
essentially two problems 1. A wide variation in
replicates of the same sample, and 2. A high background 
reading in the blank well.
Poly-l-lysine was used to pre-coat microtitre wells 
(lOOyl/well,50yg/ml PBS, lh at 37#C), before coating 
with platelets and calcium was included in the buffer 
(lOmM in TBS, not PBS) to try to improve the binding of
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the platelets to the roicrotitre plates. But, as is 
obvious from Table 23, pl87, no significant improvements 
were made. Table 24, pl87, shows the results of addition 
of various blocking agents to the buffer used in the 
ELISA. Again, no significant reduction was made in the 
background levels.
To try to eliminate background absorption, presumably 
arising from platelet bound IgG, the platelet
monolayers were incubated and washed with buffer for 
various times, at 37#C. Table 25, pl87 shows that, 
again, this had no effect in reducing the background 
absorption•
b) The method according to Winiarski and Ekelund,(1986) 
was followed.
Platelet membrane, prepared by sonication (100W, 60s), 
of a washed platelet suspension, Materials and Methods 
Sect 2.3, p74, was suspended in PBS (50yg membrane
protein/ml) and then added to microtitre wells 
(lOOy1/wel1). Formaldehyde (lOOylr 2% in PBS) was added 
to each well and allowed to stand for lh at 25*C. Plates 
were washed ( 5 x 5  min) with PBS/Tween 20, 0.05%. Serum 
was added to each well (1:100 diluted in PBS/Tween, 
4%BSA). The plates were incubated (lh, 37#C) and washed 
as before. Conjugate (as, Sect 6.1.a, pl84) was added to 
each well (lOOyl, 1:1000 PBS/Tween). After incubation 
(45min, 37*C) wells were washed, as above, stained and 
read for the ELISA, as in Materials and Methods sect. 
3.3, p87.
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Table 23 Effect of different coating conditions of
platelet monolayers on the reproducibility of the ELISA.
Table 24 Effect of different blocking conditions on the 
platelet ELISA background (i.e. wells with no serum). 
PBS/Tween with asein (1% for washing, and 0.1% when 
incubating with serum and conjugate), Gelatin (0.1% in 
all buffers), Normal goat serum (NGS), and Normal rabbit 
serum (NRS), (5%, with incubation buffer).
Table 25 Effect of pre-incubation of platelet
monolayers with buffer, to remove surface bound IgG, on 
absorbance of wells with no sera.
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Coating of microtitre wells - serum + serum
Platelet Monolayer (PM) 
PM + poly-L-lysine 
PM +poly-L-lysine + Ca2+
0.210 t 0.180 
0.192 ± 0.089 
0.280 ± 0.120
0.361 i 0.284 









0.150 ± 0.101 
0.175 ± 0.162 
0.206 t 0.189 
0.183 ± 0.146
n = 3
Incubation time of platelet monolayer A 4 5 0
with buffer (min)
1 x 3 0 0.193 ± 0.120
3 x 30 0.184 ± 0.131
10 x 30 0.190 ± 0.096
n = 3
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Fig 58, pl89, shows a standard curve obtained by using
the BMFGM standard serum. This is compared to the 
"standard curve" generated by the method of Horai et a l . 
Table 26, pl90, shows a range of titres produced from 12 
different sera of known anti-BMFGM titre. As can be 
seen, the anti-platelet titres range between 11-26% of 
the Std, unlike the BMFGM titres which range from 2.3- 
102% of the Std. Further attempts were accordingly made 
to try to improve the ELISA, by eliminating some of what 
was probably non-specific binding of the serum to 
platelet membrane. A number of parameters were further 
investigated. These were:- 
i_ Platelet membrane preparation
The method of membrane preparation used by Winiarski 
and Ekelund (1986) involves sonication. However, it was 
noticed that certain batches of membrane produced a very 
high background with no serum. Fig 59, pl91, shows that 
this background varies with the time of sonication, 
leading to inconsistencies and probably involving some 
structural damage to the membrane. Fig 60, pl91, shows a 
change in the SDS-PAGE profile of platelet membrane 
after different times of sonication, most noticeably a 
mass of proteinaceous material appears around 60kD, 
after longer sonication times. An alternative method of 
membrane preparation was examined (Barber and 
Jamieson,1970, Materials and Methods Sect 2.2, p72). 
This preparation involves loading platelets internally 
with glycerol, then subjecting them to osmotic lysis.
189
Fig 58 Standard curve obtained by using the BMFGM Std 
serum on a platelet ELISA performed; a) according to the 
method of Winiarski and Ekelund (1986), and b) according 
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Absorbance values are ± Standard Error (n = 4).
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Table 26 A comparison of BMFGM titres with Platelet 
membrane titres, using the platelet membrane ELISA of 








1 2.3 ± 1.2 19.1 ± 3.2
2 4.1 ± 0.6 16.2 ± 1.3
3 6.5 ± 1.7 11.2 ± 2.1
4 8.1 ± 1.9 20.4 ± 5.2
5 12.8 ± 3.4 20.4 ± 6.3
6 15.8 ± 1.6 26.3 ± 4.7
7 30.7 i 5.5 19.0 ± 3.9
8 42.4 ± 8.1 24.6 ± 5.9
9 75.5 ± 9.7 26.3 ± 4.8
10 79.1 ±10.6 19.1 ± 2.2
11 100.0 ± 9.3 26.0 ± 4.3
12 102.5 ±14.6 24.6 ± 6.2
n = 3
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Fig 59 Effects of different sonication times (for the 
preparation of platelet membrane) on the background 
absorbances of the platelet membrane ELISA i .e . 
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Platelet membranes are then recovered on a sucrose 
density gradient. SDS-PAGE profiles (Fig 61, pl93) of
membrane preparations from the two techniques, are very 
similar. However, membrane prepared without sonication 
gives lower background levels.
Fig 62, pl94, shows the absorbances produced when
various concentrations of platelet membrane were used to 
coat the plates. The optimum coating concentration was
10 yg protein / ml carbonate coating buffer.
11 Coating medium
Formaldehyde (2% in PBS) was used by Winiarski and 
Ekelund to fix platelet membranes onto the raicrotitre 
wells. This was compared to coating with carbonate 
buffer, as used in the anti-BMFGM antibody ELISA 
(Materials and Methods Sect. 3.3, p86). Carbonate buffer 
was found to increase the range of absorbance values 
(Fig 63, pl95), and was accordingly used subsequently, 
iii Blocking agents
Table 27, pl96, compares the antibody titres of 10 
serum samples obtained in the presence and absence of 
NRS (5%). Its effect varies for each serum suggesting 
that it has a specific effect in reducing antibody 
titres, e.g. the titre of serum sample 4 is 
dramatically reduced, whereas that of sample 1 is not. 
NRS was included in all subsequent ELISAs.
The finalised Platelet Membrane ELISA is described in 
Materials and Methods Sect 3.3 (iii), p88.
Fig 61 SDS-PAGE profile of two different platelet
membrane preparations, which react differently as 
antigens on a platelet membrane ELISA.
Lane 1 - Winiarski and Ekelund, 1986. 






Fig 62 Optimisation of platelet membrane coating
concentration for the ELISA.
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Fig 63 Optimisation of membrane coating conditions for 
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Table 27 The effect of including NRS in the platelet 
ELISA.
Serum Sample % Std %Std + NRS
1 30.1 ± 4.6 29.2 ± 3.1
2 25.2 ± 2.3 10.4 ± 1.2
3 18.3 ± 2.3 15.5 i 1.9
4 16.2 ± 2.4 8.3 ± 1.6
5 15.5 ± 1.9 14.1 ± 0.8
6 13.9 t 3.2 14.4 ± 1.2
7 12.4 ± 1.4 12.1 ± 2.6
8 10.9 i 2.1 6.3 ± 1.4
9 11.4 ± 1.3 10.1 ± 0.4
10 8.2 ± 1.4 7.1 ± 1.4
6.2 Comparison of anti-BMFGM antibody titres with anti­
platelet membrane titres.
The ELISA developed in Sect 6.1.b was used to compare 
anti-Platelet membrane antibody titres with anti-BMFGM 
antibody titres.
6.2.1 Comparative assays
Fig 64, pl98, shows a comparison of anti-BMFGM titres
with anti-Platelet membrane titres, measured in 50 serum 
samples. The average titres (of three separate 
measurements) are shown. The rank correlation 
coefficient (Rs = 0.088) calculated is below that
necessary to show a significant correlation (Rs = 0.273) 
for p = 0.05.
Table 28, pl99, shows the results of assaying
affinity-purified anti-BMFGM antibodies for anti­
platelet membrane activity. No absorbance was shown by 
any sample. In contrast, IgG purified from rabbit anti­
platelet membrane serum (Materials and Methods Sect. 
2.5, p77), did produce a high titre.
Control sera from healthy donors (as used in the BMFGM 
ELISA) were compared with Immune Thrombocytopaenia (ITP) 
sera, using the anti-platelet membrane ELISA (Fig 65,
p200).
A maximum difference was obtained above 15- 
20% of the Std (34% of the controls and 56% of ITP sera 
had titres above this.) A K-S value calculated for this 
difference of 0.2 was below that necessary (0.289 for 



























4 0  - X  
X *
20
6 0 100 2001 5 0





2.01.0 1 .5 2.50.5
L O G ( % B M F G M  Std)
199
Table 28 Affinity purified anti-BMFGM antibodies assayed 







1 123.4 ± 12.2 0
2 100.3 t 9.6 0
3 89.6 ± 7.1 0
4 82.5 + 8.0 0
5 46.9 ± 5.8 0
6 32.7 ± 4.3 0
7 20.4 t 5.1 0
8 10.6 ± 4.3 0
9 5.7 ± 2.5 0
10 2.2 ± 1.6 0




Fig 65 Comparison of ITP sera with normal sera using the 
anti- platelet membrane antibody ELISA.
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Platelets were used as competitors in the BMFGM ELISA as 
follows. Platelets were either used directly, as PRP, or 
washed as described in Materials and Methods Sect 2.3, 
p74, and those pre-blocked were incubated in PBS/Tween, 
NRS(5%) (lh, 37#C). Platelet suspensions (0.125-64 x 
106/ml) were mixed with an appropriate amount of diluted 
serum (1:100), in order to give the required final 
concentrations of PBS/Tween and serum, and added to 
microtitre wells (lOOyl/well)• After incubation, plates 
were washed, and the ELISA was followed according to 
Materials and Methods Sect 3.3, p88.
Table 29, p202, shows the effects of using different
concentrations of platelets as competitors using a 
sample of pooled human serum by BMFGM ELISA for anti- 
BMFGM antibodies. Far from inhibiting the assay as 
expected, all additions led to an apparent increase in 
anti-BMFGM levels measured.
An alternative means of assaying platelet incubated 
sera was examined. Platelets (blocked and non-blocked as 
above) were incubated with a pooled serum, (undiluted) 
(lh, 37#C), to give final concentrations of 0.15-5.00 x 
106/ml of serum. Platelets were then separated from the 
serum by centrifugation (lOmin, 12,000q av) and the 
remaining serum was assayed using the BMFGM ELISA, 
Materials and Methods Sect. 3.3, p86, and the Platelet 
Membrane ELISA, Materials and Methods, Sect 3.3, p88.
Incubation of the serum with washed platelets caused 
up to 30% inhibition of ELISA for anti-BMFGM antibodies
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Table 2 9 Effect on anti-BMFGM antibody titres of
platelets (Platelet rich plasma (PRP),washed, washed and 
blocked) used as competitors in the BMFGM ELISA.
Platelet type
Platelet conc. PRP Washed Washed +
x 106/ml blocked
64 190 ± 10 142 ± 20 161 ± 21
32 192 ± 6 150 ± 18 158 1 18
16 190 ± 10 136 ± 25 169 ± 4
8 180 ± 15 147 t 8 174 ± 36
4 195 ± 25 120 ± 15 180 ± 24
2 170 ± 30 148 t 21 161 ± 17
1 200 ± 27 119 ± 30 193 ± 31
0.5 198 ± 17 120 ± 25 158 ± 3
0.25 194 i 36 143 ± 8 169 ± 16
0.125 184 ± 9 143 ± 11 149 ± 15
(n = 3)
Titres are expressed as a % of the BMFGM Std.
Original serum titre = 105% of the Std.
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Fig 66 Levels of anti-BMFGM antibodies in sera pre
absorbed with blocked and non-blocked platelets.
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Fig 67 Levels of anti-platelet membrane antibodies in
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(see Fig 66, p203). Pre-incubation of the platelets with 
a blocking agent removed most of this inhibition. 
However as expected, ELISA for anti-human platelet 
antibody could be inhibited by either blocked or 
unblocked platelets see Fig 67, p203.
6.2.3 Assay of experimental anti-sera
Various rabbit anti-sera raised against
BMFGM,(RABMFGM), XO (RAXO), Platelet Membrane (RAPM) and 
BSA (RABSA), (Materials and Methods Sect 2.8, p81) were 
assayed by using the following ELISA systems.
i Using the BMFGM ELISA (Materials and Methods Sect 3.3 
(i), p86), the above anti-sera were assayed, along with 
their corresponding pre-imraune sera (from dilutions of 
1:50-1:2000), using a commercially available goat anti- 
rabbit-Polyvalent antibody-HRP conjugate.
Fig 68a, p206, shows that both RABMFGM and RAXO sera 
gave strong responses, whereas RABSA showed a moderate 
response and RAPM showed no response.
ii Using the ELISA to detect anti-XO antibodies 
(Materials and Methods Sect 3.3 (ii), p88), the antisera 
used in i above, at the same dilutions and using the 
same conjugate were assayed.
Fig 68b, p206, shows that RAXO and RABMFGM both gave
strong responses, whereas RABSA and RAPM did not.
iii Using the ELISA to detect anti-platelet membrane 
antibodies (Materials and Methods Sect 3.3 (iii), p88), 
the anti-sera used in i and ii were similarly assayed.
Fig 68c, p206, shows that RAPM gave a strong response,
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Fig 68 Assays of different rabbit anti-sera raised 
against; BMFGM, BXO, platelet membrane (PM), and BSA.
Key: -
■ = rabbit anti-BMFGM antisera 
• - ' ' anti-XO
▼ = '' anti-PM
A '' anti-BSA
The unfilled symbols represent the pre-immune 
equivalents of the above anti-sera.
a. ELISA using BMFGM as coating antigen
b. ELISA using BXO as coating antigen
c. ELISA using PM as coating antigen





a. a n t i - B M F G M  b. a n t i - X O
- L o g  a n t i - s e r u m  diln
c. a n t i  — P I -M e m b  d . a n t i —B S A
Lo g a n t i - s e r u m  di ln
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RABSA a weak response,and RABMFGM and RAXO no response 
at all.
iv An ELISA to detect anti-BSA antibodies was developed 
from the BMFGM ELISA (Materials and Methods Sect 3.3
(i), p86), by using BSA to coat the microtitre plates,
in place of BMFGM (lOyg protein/ml carbonate buffer). 
Again the same sera were assayed as in i, ii, and iii.
Fig 68d, p206, shows that RABSA gave a strong response, 
whereas RABMFGM, RAXO, and RAPM did not.
Pre-immune rabbit sera for all RABMFGM, RAXO, RAPM, and
RABSA gave little response in any of the ELISA*S 
outlined above.
6.3 Platelet aggregation experiments.
Various pre-immune and post-immune rabbit antisera 
were available i.e. those prepared for the purposes of 
Sect 6.2.3 above and two others; Rabbit anti-Citrate 
Synthase (RACS), and Rabbit anti-Isocitrate
Dehydrogenase (RAID), (provided by colleagues in the 
Biochemistry Dept). These antisera, along with their 
corresponding pre-immune sera were tested for their 
ability to aggregate freshly prepared, pooled PRP 
(Materials and Methods Sect 4.4, p96). Equal volumes of 
each (50 yl) were added to PRP (0.5ml).
Fig 69, p208, shows that all anti-sera tested caused 
platelet aggregation, whereas, no pre-immune sera had 
any effect.
Fractions of IgG were prepared from RABMFGM, RAXO, and
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Fig 69  Platelet segregation using a variety of pre-,
and post-immune rabbit sera.
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Fig 70 Platelet aggregation using pre-, and post-immune 












RAPM, as well as from their corresponding pre-imraune 
sera (Materials and Methods Sect 2.5, p77). Each IgG
preparation (50yl, 4mg/ml PBS) was added to washed
platelets (0.5 ml), and platelet aggregation was 
monitored. Fig 70, p209, shows that only IgG prepared 
from RAPM sera caused aggregation whereas IgG prepared 
from RABMFGM, RAXO, and the three pre-immune sera had no 
effect.
6.4 Western blotting of SDS-PAGE patterns of Platelet 
membrane, followed by Immunoblotting.
Platelet membrane, prepared according to the method of 
Barber and Jamieson (1976), was subjected to SDS-PAGE
(75ug protein / lOOyl track) and transferred to
nitrocellulose sheets. The transferred bands were 
incubated with either serum (1:25), or IgG (1:100), 
followed by detection using an appropriate conjugate 
(1:1000), Materials and Methods Sects 4.1 and 4.2, 
p89,93.
Human sera stained several bands when immunoblotted 
against SDS-PAGE patterns of human platelet membrane; 
prominent amongst these is a band at Mr 39,000 possibly 
corresponding to Fc receptor see Fig 71, p211. Affinity 
purified anti-BMFGM immunoglobulins showed little 
staining when immunoblotted against human platelet 
membrane see Fig 72, p212. Rabbit anti-BMFGM anti-sera
stained a number of bands when immunoblotted against 
human platelet membrane, but many of these bands were 
also stained by other rabbit anti-sera, Fig 73, p213.
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Fig71 Immunoblot of huraan sera against platelet membrane 
(using goat anti-human polyvalent HRP conjugate).
39*
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Fig 72 Immunoblot profile of affinity purified anti-BMFGM 





2. Human IgG minus BMFGM antibody
3. BMFGM affinity antibody
4. Blank (no IgG)
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Fig 73 Iromunoblot-profile of rabbit anti-sera against
platelet membrane (using goat anti-rabbit polyvalent 
antibody as conjugate).
1 2 3 4 5 6 7 8
1,2 Rabbit anti-BMFGM 
3 Rabbit anti-platelet membrane
4- Rabbit anti-BSA
5- Rabbit anti-IDH
6- Normal Rabbit Serum
7- Affinity purified RABMFGM




Davies and coworkers (1974), showed a significant 
elevation of anti-(bovine whole milk) antibodies in the 
serum of MI patients, compared to controls; a difference 
that was even more striking when antibody levels were 
considered in patients who had died from an infarct. 
Their work was, however, refuted by various other groups 
(see Introduction Sect 1.5, p48) and the theory was
largely discredited. After this literature controversy, 
Davies et al (1982), found that their anti-(whole milk) 
antibodies were essentially anti-BMFGM antibodies, and 
it now appeared possible that, if the latter were
assayed directly, then differences between MI and
control sera might be more clearly seen. This was the 
situation at the start of the present work.
An ELISA to detect anti-BMFGM antibodies was
accordingly developed to investigate the relationship 
between anti-BMFGM antibodies and MI. The ELISA was 
optimised (Results Sect 1.1, plOl) in terms of antigen 
(BMFGM) and conjugate concentrations. The assay was 
found to require minimal blocking; neither BSA, nor NGS 
were necessary. The effect of including casein was to 
reduce absorbances of all sera substantially. It seems 
unlikely that anti-BMFGM antibodies are absorbed out by 
casein, as they are known to be directed mainly against 
XO (see later), but it is possible that casein may bind 
to the membrane (Basch et a l ,1985), and block antigenic
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sites, thus preventing the attachment of anti-BMFGM 
antibodies. In fact, some antibodies in human serum do 
bind to a protein on the BMFGM of the same Mr as casein 
(28kD), (see Results Sect 5.2, pl60).
Serum dilutions were also examined (Results Sect 1.1, 
pl02), to determine which gave the most consistent 
results, and assays were done on separate occasions to 
investigate reliability. Although absolute titres did 
vary slightly from day to day (Results Sect 1.3, pill), 
they were always within the same ranges.
Antibody binding to the BMFGM was also shown to be 
specific in that it was Fab' mediated and titres were 
independent of total IgG levels (Results Sect 1.2,
pl07) •
Distributions of IgG anti-BMFGM antibodies in MI and 
Control sera.
By use of the BMFGM ELISA, initial comparisons were 
made of anti-BMFGM antibody levels (Results Sect 2.1, 
pll4) in 462 "New" MI samples (<65 years of age, from 
South Wales and the Bristol area) and 517 healthy 
Control sera (49-64 years of age, from Caerphilly). No 
statistical difference was found between them. Anti-
BMFGM antibody titre distributions in 602 "New", 401 6- 
month, and 428 2-year post infarct serum samples (ages
45-80, and from all regions of South Wales) were similar
(Results Sect 2.2, pll4). In fact, the only statistical 
difference observed was in low titres of anti-BMFGM 
antibody levels (i.e. < 10% Std, Results Sect 2.3,
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pll7), when antibody titres in 6-month and 2-year MI 
samples were actually found to be lower than those of 
the controls. This difference was not observed in the 
case of "new" MI samples. From this observation one 
might expect that new patient samples would have 
statistically elevated levels of IgG anti-BMFGM 
antibody levels (considering samples of <10% Std) 
compared to 6-roonth and 2-year samples. However, this 
was not the case (statistics not shown). Investigations 
on other batches of serum, carried out in the laboratory 
also showed that IgG anti-BMFGM antibodies are higher in 
control compared to MI samples, although this difference 
was never found to be significant (Benboubetra and 
Harrison, personal communication).
These observations were in conflict with Davies* 
hypothesis (1974) in two respects:-
1. IgG anti-BMFGM antibodies were not raised in MI 
patients compared to controls.
2. New patients did not have higher titres than 6-month 
or two year post-infarct patients, as would be expected 
if patients with high titres had a threefold increased 
chance of dying within the first six months after an 
infarct (Davies, 1984).
Origins of samples with respect to region, and age were 
examined, to see if any obvious differences within these 
parameters could explain this inability to repeat 
Davies* findings. However, IgG anti-BMFGM antibody 
levels were found to be similar in each of the five
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regions investigated, and in all the age groups compared 
(Results Sect 2.5, 2.6, pl23).
Distributions of IgG anti-BMFGM levels in some other
disease states
Anti-BMFGM antibody levels were compared in other 
"autoimmune" disease states with those of healthy 
controls (i.e. males aged 49-64, as used in the MI
studies). The anti-BMFGM levels in MND sera were very 
similar to those of the controls, whereas those of ITP 
and MG were elevated, but significantly only in the case 
of MG. A possible explanation for these findings may lie 
in the sex and ages of the samples. The incidence of MG 
is higher in women than in men, the ratio being 3:2
(Newsom-Davies and Vincent, 1982), and 80% of the 
samples tested were those of women. While details of the 
ITP donors were not available, patients, are mainly
middle aged women, and chidren (George et a l , 1985). MND
sufferers, on the other hand, are mainly men with the 
overall proportion 3:2, but in some states of the 
disease can be 5:1 (Clifford-Rose, 1977). 90% of the
MND samples tested were those of men. Rees (1985)
reported that anti-BMFGM antibody levels are higher in 
women than in men, titres being elevated by pregnancy. 
Elevations of IgG anti-BMFGM antibodies have also been 
observed in the serum samples of children (Benboubetra 
and Harrison, personal communication). It is impossible 
to comment further about anti-BMFGM titres in MG or ITP
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without data from age and sex-matched controls. In our 
studies with CHD patients, women have generally not been 
studied, in view of the likelihood (Rees, 1985) of the 
influence of hormonal changes. Concerning MG, it is 
worthwile noting that elevated levels of antibodies to 
other autoantigens commonly occur (Newsom-Davies and 
Vincent, 1982).
There were not enough samples to justify comment upon 
the relevance of anti-BMFGM antibodies in migraine 
sufferers; there appeared to be a distribution of low 
and high titres. In the light of evidence suggesting 
that migraine is linked with allergy (Monro et al,1984), 
it may be more prudent to consider anti-BMFGM IgE levels 
or those IgG subclasses particularly associated with 
allergy.
Comparison of ELISAs carried out at Bath and Carmarthen
Despite the fact that, in the above studies, Davies' 
hypothesis could not be verified, Rees and Thomas (West 
Wales Hospital, Carmarthen) were, in parallel studies, 
finding increases of antibody titres in MI samples 
compared to controls (in one of their studies 65% of MI 
and 35% of controls were positive for anti-BMFGM 
antibody, personal communication). This was particularly 
disturbing in view of the fact that their samples were 
from the same source as ours (Materials Sect 1.2, p69). 
It was decided therefore, to compare the two assays by 
systematically comparing antigens (Dried Milk v BMFGM), 
and conjugates.
On analysis, it became apparent that Carmarthens* use 
of a different conjugate (detecting IgGf IgA and IgM 
human antibodies, rather than IgG alone), was the major 
cause of the discrepancies between the two assay 
systems. Differences were found not to arise from 
different antigen preparations or from different 
treatment of samples (Results Sects. 3.1-3.3, pl29-135).
The BMFGM ELISA was therefore modified to detect 
separately, IgG, IgA, and IgM and polyvalent (all three) 
anti-BMFGM antibodies by using commercially produced 
conjugates, in place of the laboratory-prepared anti IgG 
(Results Sect. 4.0, pl35). IgG, IgA, and IgM anti-BMFGM 
antibodies were detected, and subsequently assayed in MI 
and control sera.
Preliminary analysis, on two sets of 65 "New” male MI 
and 65 male control samples (selected randomly and not 
matched for either age or region), showed, in each set, 
an elevation of polyvalent, and IgM anti-BMFGM antibody 
titres in MI patients compared to controls. No 
difference was found with IgG anti-BMFGM titres (as 
already observed in Results Sect. 2.1, pll4), IgA titres 
in MI patients were decreased compared to controls. The 
difference in IgM anti-BMFGM titres was significant.
These results were verified when 100 MI and 100 
control male samples were assayed as above. The MI 
samples this time were matched in age (45-64 yrs of 
age), and region (South Wales Valleys), with control 
samples (49-64 yrs of age, mainly from Caerphilly). In 
fact, anti-BMFGM titres (IgG) had already been shown not
220
to depend on either of these factors (Results Sect 2.5,
2,6, pl23). Again, elevations of polyvalent and IgM 
antibodies were found in MI patients compared to 
controls. No change was observed in IgG and a slight 
reduction was observed in IgA antibody levels in the MI 
population. As before, IgM levels showed a 
statistically significant difference; the other 
differences were not significant. From the results of 
these investigations it was concluded that IgM anti- 
BMFGM levels were raised in "new” MI patients with 
respect to controls. These results agree with the 
Davies' findings, as outlined in detail below.
An Explanation of Davies' results
Davies' measured anti-BMFGM antibody levels by 
haemagglutination, which depends upon cross-linking of 
antigen-coated sheep red blood cells, by human 
antibodies (Boyden,1951;Rees,1973). All classes of 
antibody are detcted by this assay, but IgM, by virtue 
of its polyvalency, is particularly dominant 
(Roitt,1988). If anti-(BMFGM) IgM antibodies alone (i.e. 
not IgA, IgG etc.) are elevated in MI patients, then 
Davies' earlier finding can be explained, as can my own 
failure (Results Sect. 2.1 - 2.2, pll4) to find
differences between MI and control samples, by using a 
laboratory-prepared conjugate raised against human IgG 
(Results Sect. 3.3, pl35). The later studies at
Carmarthen, by Rees and Thomas, used anti-polyvalent 
conjugate, which detects IgG, IgA, and IgM antibodies.
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These results can also be explained in terms of IgM 
anti-BMFGM elevation in serum. I f too, found an 
increase in anti-BMFGM antibodies in MI patients when 
using a polyvalent conjugate, although it was not 
statistically significant.
The above results clearly support the Davies 
hypothesis (Davies et al,1974), if this is restricted to 
IgM antibodies. Concerning the dismissal by other 
workers (discussed in Introduction Sect.1.5, p48), a
number of points can now be made.
Oster et al (1974) verified Davies findings and used 
the same Haemagglutination assay, although Oster*s
choice of donors has justifiably been criticised (Carr 
et al,1975).
The results of Toivanen et al (1975a) are complicated 
by discrepancies in their Paper (see Introduction Sect 
1.5, p51). Nevertheless, their figures from the text 
(i.e. average anti-milk titres from which negative 
titres have been excluded) do show an elevation of IgM 
antibodies in MI samples, as measured by 
radioimmunoassay. This is commented upon by Poston 
(1975). In fact, Davies (1984) had argued that the 
inability of Toivanen et al to repeat his findings arose 
from the latters* antigen preparation, which lacked the 
cream fraction of milk, containing the BMFGM.
Scott and coworkers (1976) also used the Haem­
agglutination technique, but found no difference in 
antibody levels between MI and control groups. All 
samples were from male patients. Davies (1984) suggested
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that the antigen (National Dried Milk) differed
critically from that (Oster milk) used by his own group, 
but without detailed justification.
Gibney and co-workers (1980) used two methods to 
detect anti-milk antibodies; an ELISA using a conjugate
raised against human IgG antibodies and also the
Haemagglutination assay. Considering the fact that the 
conjugate used in the ELISA was against IgG, it is not 
surprising that no elevations of anti-milk antibodies 
were found in MI patients. In fact, as in my own 
studies, antibody levels appeared to be higher in the 
control groups. However, the fact that the
Haemagglutination assay did not show any difference 
cannot be immediately explained. A large proportion of 
the controls were women (12/37) compared to the MI group 
(4/37). As already mentioned, Rees (1985) showed that 
anti-milk antibody levels in women are higher than in 
men and this factor may have served to elevate the 
antibody levels in the control group of Gibney et a l . 
Alternatively, their antigen, "spray dried milk", may 
lack the antigens present in BMFGM.
Following the finding that IgM anti-BMFGM antibodies 
are elevated in MI sera compared with controls, it was 
clearly important to identify the BMFGM antigen more 
precisely.
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The antigenicity of the BMFGM
To investigate further the antigenicity of the BMFGM 
it was decided to affinity-purify anti-BMFGM antibodies, 
particularly in order to characterise the BMFGM antigens 
by immunoblotting of its SDS-PAGE profile.
Attempts to purify anti-BMFGM antibodies from serum by 
using a batch absorption process were largely 
unsuccesful. Although it was possible to adsorb 100% of 
the anti-BMFGM antibodies onto the membrane, the maximum 
recovery was only 0.3 i 0.1 %. Varying times of
incubation and volumes of affinity eluting agent did not 
improve yields (Results Sect 5.1a, pl48), although,
changing the eluting agent from Gly/HCl to ammonium 
hydroxide boosted the recovery from 0.1% to 0.3% of 
original activity. Poor recoveries could not be 
explained by denaturation, either of the anti-BMFGM
antibody or of the BMFGM itself (Results Sect 5.1a,
pl51) .
In view of these failures, the use of an affinity 
column was investigated. The literature contains few 
methods for affinity purification of antibodies to 
membrane antigens. Steiner (1985) used a column
containing immobilized platelets or platelet membranes 
to separate IgG directed to platelet surface antigens. 
His method of immobilisation of the membranes had been 
developed from that of Sela and Edelman (1977) who used 
glutaraldehyde fixed cells, immmobilised on Sephadex 
beads, to isolate immunoglobulins specific for cell 
surface glycoproteins. Following these procedures,
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Sephadex beads were incubated with Concanavalin A 
followed by BMFGM and the cross-linking agent 
glutaraldehyde. This column matrix was then improved 
upon by using a commercially-available matrix to which 
Con A was already bound (Con A-Sepharose 4B). As the Con 
A content of this matrix (9mg/ml) was higher than that 
used initially (max. lmg/ml), the column could be 
reduced in size from 50ml to 5ral. Nevertheless the % 
recovery of antibody improved and the yield was 
increased further by changing the cross-linking agent 
from glutaraldehyde to dimethylsuberimidate.
Glutaraldehyde is a dialdehyde and theoretically could 
crosslink two proteins, via the £ -amino groups of 
lysine, by formation of Schiff*s bases. The stability of 
proteins cross-linked by this method does not, however, 
agree with the known reversibility of Schiff*s base 
formation, and an alternative mechanism has been 
proposed involving polymerisation products of 
glutaraldehyde (Richards and Knowles,1968).
Glutaraldehyde has also been reported to react with N- 
terminal amino groups of some peptides, and the 
sulfhydryl group of cysteine (Habeeb and Hiramoto,1968). 
Dimethlysuberimidate also crosslinks proteins by 
covalent attachment to lysine groups but is more 
specific in its reaction and so less likely to bind to 
antigenic sites on the membrane, restricting anti-BMFGM 
antibody access. The column recovery was also improved 
by recirculating serum overnight. Following the above 
modifications, an affinity purification procedure was
225
developed which routinely yielded 15-20% of the original 
antibody activity. It was not found possible to generate 
serum, or IgG, free of anti-BMFGM antibody, by using 
this column. All flow through fractions contained 
approximately 25% of the original activity. This was not 
a consequence of overloading of the column (Results Sect 
5.1b, p 156) and it may be that it reflects the presence 
of a fraction of anti-BMFGM antibodies with low avidity 
for BMFGM. Certainly, in the experimental situation, 
injection of large amounts of antigen will give rise to 
low affinity antibodies (Roitt,1988).
Sela and Edelman (1977) affinity-purified antibodies 
from serum and from an IgG preparation with equal 
success. Although this was also the case with the BMFGM 
column (Results Sect 5.1b, pl56), after 5 purifications 
of serum, the column became blocked by a white 
precipitate. This was never experienced when IgG was 
used as a purification source. It appears that this 
precipitation is caused by some component of serum, 
possibly CICs or even IgM; IgM, in fact, was never j 
detected in the affinity-purified fraction, although IgM 
anti-BMFGM antibodies clearly exist (Results Sect 4.0, 
pi35 ) .
A number of affinity-purified anti-BMFGM antibody 
batches were prepared; low titre sera produced low 
amounts of affinity purified IgG, as expected (Results 
Sect 5.lb, pl60).
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Information concerning the antigenicity of the BMFGM 
came primarily from Western blotting analysis of SDS- 
PAGE profiles of the BMFGM (Results Sect 5.2, pl60). 
Human sera and affinity-purified antibodies bound to a 
band of approximately 150kD; corresponding to the 
enzyme, xanthine oxidase (XO). Higher titre sera stained 
more intensely than those of lower titre. Some lower MWt 
bands at 28, 36, 45, 59 and 66kD, were also stained,
most noticeably in pooled sera. A polypeptide of 170kD 
was stained with some sera and with affinity-purified 
antibodies. It is possible that some of these stained 
bands result from milk serum proteins, adsorbed to the 
BMFGM. Casein (M.Wt 28kD), for example, is a known 
contaminant of the BMFGM (Basch et al , 1985), and anti- 
BSA antiserum was shown to cross-react with BMFGM 
(Results Sect 6.2.3, p204). The molecular weight of BSA 
is 67.5kD.
In contrast to human sera, which stained only a few 
bands in addition to that at 150kD, RABMFGM IgG 
immunostained most polypeptides of the BMFGM, as did the 
affinity-purified fraction.
These differences between rabbit anti-serum and human 
serum may indicate that:
1. Ingested BMFGM is the source of the human antibodies, 
but only a limited number of proteins, primarily XO, are 
absorbed and exposed to the immune system in immunogenic 
forms. SDS-PAGE profiles of dried milk which correlates 
with BMFGM as an antigen (Results Sect 3.1, pl29) 
suggest that low molecular weight fragments are still
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antigenic. The persistence of bovine milk XO activity 
has also been reported after gastric digestion in vivo 
and in vitro (Zikakis et al, 1976).
2. It is possible that the antibodies are, in fact, 
against endogenous XO, and fortuitously cross-react with 
the BMFGM.
Although IgG anti-BMFGM antibodies were affinity 
purified to increase the specificity of Western blots of 
the BMFGM, they did in fact give results comparable with
those from whole human serum.
It will be interesting to see if IgM and IgA anti- 
BMFGM antibodies show the same response on immunoblot 
profiles of the BMFGM.
Investigation of anti-XO antibodies in human sera.
From the results, discussed above, it appeared that
anti-BMFGM antibodies, at least the IgG fraction, were
primarily directed against XO and so it was decided to 
assay anti-XO antibodies directly. For this purpose, an 
ELISA was used and, for this, purified XO was required. 
The enzyme prepared by the method of Nakamura and 
Yamazaki (1982) showed acceptable parameters and could 
be successfully used as antigen in ELISA for IgG and IgA 
anti-XO antibodies. Assay for IgM anti-XO antibodies 
was, however, complicated by high background responses 
in all sera tested. These background levels were found 
to be associated with the presence of a band on SDS- 
PAGE, of the purified XO, with M.Wt 83kD, which could be 
removed by further purification of XO on a folate 
affinity column (Results Sect 5.3, pl67).
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The receptor, secretory component, present on 
glandular epithelial cells is involved in mediation of 
transport of polymeric IgA and IgM into external 
secretions (Mostov et al, 1984). Two or three types of 
this receptor may be present in the animal. For the 
rabbit, polypeptides of MWt 77,80 and 83kD have been 
detected (Brandtzaeg,1974;Kuhn and Kraehenbuhl,1979). 
The bovine receptor is present on intestinal, liver, and 
mammary gland membranes. The membrane bound form has 
been reported to have a M.Wt of 93kD (Beale and 
Hopley,1986), and has been shown to bind bovine and 
human IgM. cDNA sequences predict a Mwt of 82,041D of 
this receptor (Mostov et a l , 1984). If the 83kD
contaminant in my XO preparation arises from this 
receptor, perhaps as a proteolytic fragment, it would 
explain why only IgM antibodies show a high background, 
in that total IgM binding to secretory component could 
be superimposed upon specific anti-XO binding. Although 
this receptor has not been demonstrated on BMFGM, it 
seems likely that, as secretory component is found on 
the mammary cell apical membrane, and BMFGM is derived 
from the latter, then secretory component will be 
present on the BMFGM also.
It might seem that the 83kD protein is most likely to 
be a proteolytic fragment of XO. Although Jarasch et 
al(1981) report a proteolytic fragment of XO, occuring 
at 85kD, other reports (Nagler and Vartanyan, 1976) have 
cited major proteolytic fragments on SDS-PAGE of 20, 42 
and 92kD. In the present work, the 83kD polypeptide,
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stained positively for carbohydrate (Results not shown), 
whereas XO did not and in view of the fact that cavine 
XO is known to contain no carbohydrate (Johnson et 
a_l,1985), it would seem that the 83kD band arises from 
another source.
ELISA comparisons of IgG, IgA, and IgM anti-XO and 
anti-BMFGM antibodies in the same serum samples showed 
significant correlations between anti-XO and anti-BMFGM 
titres (Results Sect 5.5, pl73), further supporting the 
idea that XO is a major antigenic component of the 
BMFGM. The correlation coefficient was less when 
comparing IgM than with IgG and IgA levels; again, this 
may reflect non-specific binding by a secretory 
component-like receptor, in the case of the anti-BMFGM 
ELISA.
IgG, IgA, and IgM anti-XO antibody levels were 
compared in 100 MI samples and 100 controls (age and 
region matched).
The results obtained were very similar to those obtained 
with 100 MI and 100 control sera tested for anti-BMFGM 
antibodies (Results Sect. 4.2, pl44), again indicating
that XO is the major antigen of the BMFGM. IgM anti-XO 
antibody levels were significantly raised in MI patients 
compared to controls, whereas those of IgG, and IgA were 
not (Results Sect 5.6,pl73).
An alternative pool of MI sera was available from the 
Royal United Hospital (RUH), Bath, Avon. These samples 
had been collected, in general, within 24h, following an
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MI, at the Coronary Care Unit; this was much earlier 
than the 15-30 days that were usual for the above South 
Wales samples. These RUH samples (56) were compared with 
controls (44) who had been hospitalised, with no 
evidence of heart or liver disease, or cancer. A highly 
significant increase in IgM antibodies was seen in MI 
patients; this was more significant (p = 0.1%) than the 
above analysis <p = 5%) of South Wales samples.
Concerning the RUH 24h post infarct samples, it is 
unlikely that an elevation of IgM anti-XO antibodies 
resulted from the infarct itself. Fig 74, p231, shows 
that, for a primary response to antigen, IgM antibodies 
can take up to 10 days to appear, and after a second 
exposure to antigen take about 3 days. It is possible, 
of course, that an IgM response could have occurred to a 
sub-clinical event, preceding the heart attack. 
Alternatively, it may be that IgM anti-XO antibody 
levels are permanently elevated in those people 
susceptible to MI. The MI samples from South Wales, as 
had been stated, were taken 15-30 days post-infarct and 
still showed elevation of IgM anti-BMFGM and anti-XO 
levels compared with controls (Results Sect 4.2 and 5.6, 
pl44,173). At this stage IgM antibodies generated in 
response to the MI might well be expected to have fallen 
away with time and indeed IgG levels would be probably 
be elevated; this was never observed. Overall, the 
implications are that the immunological disturbance we 
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It is true that the elevation of IgM levels in MI 
patients was more significant in more recently infarcted 
patients and this could reflect a slow decrease in anti- 
XO IgM levels after infarct or pre-infarct events. 
Alternatively this higher significance may simply be the 
result of more stringent selection of control subjects 
in the RUH samples. The controls available from the 
Caerphilly-Speedwell study were taken from the 
population at large and, inevitably, some of these 
samples would be from donors with some previous evidence 
of Ischaemic Heart Disease. This could not conveniently 
be checked. Time did not allow assay of either IgA, or 
IgM anti-BMFGM antibodies in 6-month or 2-year samples, 
to see whether or not the elevation of IgM antibodies 
could be detcted in these samples, with respect to 
controls. Certainly, IgG anti-BMFGM levels were shown 
not to change when comparing "New" with 6-Month samples 
and 6-month with 2-year samples.
General antibody levels and Myocardial Infarction.
It has been shown that a biphasic response exists in 
the IgG fraction in some patients (30/45) after an MI 
(Ebringer et al,1971). An initial fall, with lowest 
level at day 5, is followed by an increase. By the 
fourth week after an MI, serum IgG levels return to 
normal (Finkelstein et a l ,1963). Serum IgA, and IgM have 
been reported not to change (Ebringer et a l ,1971). In 
Myocardial Ischaemia, however, there is no obvious fall 
or rise in IgG levels, but the average IgG level is
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significantly higher than in controls (15.48 mg/ml 
compared to 12.59 mg/ml). For MI patients, this average 
is 12.65 mg/ml. Gray et al (1978) have reported an 
increase in levels of total IgG and IgM in patients with 
old proven infarcts, while the level of IgM was raised 
in patients with peripheral vascular disease. 
Interestingly, total IgE levels have been reported to be 
elevated in MI patients (Criqui et a l , 1987) (in
contrast to IgG), and to increase gradually after 
infarction, reaching a sustained maximum by Day 7. This 
is followed by a drop to initial levels by the end of 
week 3. In some patients, IgE elevation persists 
(Szczeklik et al, 1988).
Autoantibodies against cardiac tissue are known to 
appear in the 2nd and 3rd weeks after an MI (Ehrenfeld 
et al , 1961), and eventually to decrease in most
patients (Heine et al, 1966). This coincides with an
overall elevation in antibody levels as discussed above. 
Post-cardiac injury syndrome, frequently found after 
cardiac surgery (Engle and Ito, 1961), and in 0-6% of 
acute MI cases, is associated with actin and myosin 
autoantibodies (De Scheerder et a l ,1985). IgG antibodies 
to cardiolipin are also reported in young post MI 
patients, and are high risk markers for recurring events 
(Hamsten et al ,1986). Interestingly, Davies and 
coworkers, 1974 report an attempt to measure antibodies 
against extracts of human heart, but only 5/53 were 
positive, and in these cases, titres fell with recovery, 
in contrast to the persistent elevation of anti-BMFGM
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antibody levels subsequent to infarct (Davies et a l f 
1974) .
Work reported here (Results Sect 1.2, pl07) showed
that IgG anti-BMFGM antibody levels do not correlate 
with total IgG levels, and so are not necessarily 
affected by the patterns mentioned above.
Anti-XO antibodies in human sera
Anti-XO antibodies in human sera have been documented 
elsewhere and not in the context of heart disease. 
Jarasch et al, (1986) showed high levels in normal human 
serum, estimating that they can account account for 0.2- /  
8% of the total IgG. However, only antibodies of the IgG 
class were reported and no association with any disease 
state was found. In the present work, levels of 
affinity-purified IgG-BMFGM antibodies, ranged from 
0.08mg/ml to 1.17mg/ml (Results Sect 5.1b,pl59). If one 
assumes an average total IgG count of ll-12mg/ml 
(Johnstone and Thorpe, 1982), and that most of the 
affinity purified antibodies are directed against XO, 
then this agrees very well with the data of Jarasch et 
al. Experimental antibodies to bovine XO have been used 
to show that most of the XO present in bovine organs is 
present in the BMFGM and endothelial cells of small 
capillaries and vessels (Jarasch et al, 1981).
Oster and coworkers too (1974), reported anti-XO 
antibodies in human sera and, in fact, found that levels 
(assayed by haemagglutination) were elevated in 
atherosclerotic patients (see Fig 75, p235).
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Fig 75 Immunoassay of serum xanthine oxidase.
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This and related reports are discussed in more detail 
below.
Xanthine Oxidase and Heart Disease.
The main aim of the above paper was to support Oster’s 
hypothesis that ingested bovine XO finds its way into 
the human bloodstream. Oster (1968) advanced a novel 
mechanism for human atherosclerosis. He postulated that 
X0f derived from bovine milk, may be deposited in 
arterial and myocardial walls, and, by oxidising fatty 
aldehydes, lead to depletion of membrane plasmalogens. 
The resulting membrane damage would stimulate cell 
proliferation, scar formation, cholesterol ester 
deposition and ultimate development of the 
atherosclerotic lesion (Oster, 1971,1972,1973a).
Earlier work (Oster and Mulinos, 1944) had shown that 
organs normally devoid of plasmalogens i.e. the liver 
and small intestine, had an abundance of XO. The normal 
human myocardium contains little or no XO (Eddy et 
a_l,1987) but XO was, nevertheless, reported in
atherosclerotic lesions, and in the infarcted myocardium 
(Ross et al, 1973). Moreover Oster and Hope-Ross (1966) 
found that, in the case of a fatal MI, plasmalogens 
disappear from the infarcted area, 2h after the onset of 
pain. They surmised that the pain of an MI was produced 
by plasmalogen depletion in the myelin sheath of nerve 
terminals in the heart (Oster and Ross, 1975). Further 
support for Oster1s theory came from observations that 
patients with clinically manifest atherosclerosis
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obtained relief by administration of the XO inhibitors 
allopurinol (Oster, 1968), and folic acid (Oster 
1973b).
Oster concluded that the most likely source of XO was 
dietary. Cows* milk and certain dairy products contain 
the active enzyme in abundance (Zikakis and Wooters, 
1980), and activity may be retained during digestion 
(Zikakis et al,1976). Oster argued that human anti-XO 
antibodies may represent attempts by the body to inhibit 
the enzyme (Oster,1976). Oster (1976) proposed that milk 
fat globules containing XO can readily cross the 
intestinal barrier, and that the XO may be active. 
Homogenisation of milk creates microglobules, and after 
pasteurisation, as much as 66% of XO may still be in its 
active state (Greenbank and Pallansch,1962), 118%
according to Zikakis and Wooters (1980)], Oster
concluded that "the dietary origin of the 
atherosclerotic lesion is proportional to the biological 
availability of XO in youth".
Reports by the F.D.A.(Carr et a l ,1975) and Deeth
(1983) concluded that the evidence supporting Oster*s 
hypothesis was inconclusive. Many aspects of his work 
were criticised, particularly his evidence that active 
bovine XO could enter and survive in the bloodstream 
(Volp and Lage,1977). Although retention of enzymic 
activity may remain in doubt, it has become clear that 
ingested large protein molecules do reach the
bloodstream (Introduction Sect. 3.0, p60) and it has
been shown that titres of anti-XO antibodies increase
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with increasing milk consumption (Rzucidlo and Zikakis, 
1979), however serum XO activity itself does not appear 
to increase with increasing milk consumption (McCarthy 
and Long,1976)•
In recent years, interest in the possible involvement 
of XO in heart disease has arisen for apparently totally 
different reasons. Endogenous XO has been proposed to be 
a source of oxygen radicals (Hearse et al,1986) which 
damage myocardial tissue during a period of re­
oxygenation after a hypoxic period (Granger et 
al,1981;Chambers etal,1985; McCord 1985). XO exists in 
mammals in two forms (Battelli,1980), a dehydrogenase 
form (D-form) which uses NAD + as electron acceptor, and 
an oxidase form, using O 2 as the acceptor. During a 
period of ischaemia, xanthine oxidase (D-form), is 
rapidly converted to the oxidase form (Chambers et 
a_l, 1985; Engerson et al,1987) which will reduce 
molecular oxygen to either superoxide or hydrogen 
peroxide (Link and Riley,1988).
The breakdown of ATP in the ischaemic heart causes 
accumulation of hypoxanthine, a substrate for XO while 
reperfusion provides the O 2 (Eddy et a l ,1987; Abd- 
ElFattah et al,1988) see Fig 76, p239. Several recent
studies indicate that allopurinol and oxypurinol, 
competitive inhibitors of XO are protective in the 
reperfused dog heart (Charlat et__al,1986;Hearse et 
al,1986;Werns et al,1986), although other workers 
dispute these findings (Puett et__al,1987;Kinsman et 
al.1988).
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Fig 76 The proposed mechanism by which xanthine oxidase 
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However, the relevance of this hypothesis to the human 
myocardium remains controversial. Several species, 
including rabbits and pig have undetectable amounts of 
myocardial XO. The XO content of human myocardium is 
unclear, reported amounts varying from trace amounts to 
excess (Eddy et al, 1987). As mentioned above, it has
been reported that XO is confined to the capillary 
endothelial cells of heart muscle, at least from a 
bovine source (Bruder et al ,1983; Jarasch et a l ,1981) .
IMMUNOLOGICAL CROSS-REACTIVITY BETWEEN THE BMFGM AND 
PLATELET MEMBRANE
Davies and Rees anticipated that antibody to the BMFGM 
would cross-react with other cell membranes, including 
possibly the human platelet membrane, long suspected of 
playing a role in atherogenesis.
Davies and coworkers (1982) demonstrated evidence of 
such cross-reactivity as follows: They showed that an 
immune serum raised to BMFGM in rabbits caused 
aggregation of platelets, recorded both visually, and by 
means of a platelet aggregometer, whereas pre-immune 
serum had no effect. Also rabbit anti-BMFGM antibody, in 
post-immune serum was shown, by immunofluorescence, to 
bind to platelets, whereas that from pre-immune serum 
had no effect (Davies,1984;Rees,1985).
Rees (1985) hypothesised that anti-BMFGM antibodies 
may bind to platelets, thus assisting their removal from 
the circulation. This would effectively increase 
platelet turnover and there would be a greater
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proportion of fresh, active platelets in the 
circulation. It would follow therefore that MI patients, 
with high levels of anti-BMFGM antibodies, would have 
higher levels of active platelets. This, in fact, was 
demonstrated by Rees (1982).
In the present studies, it was decided to investigate 
these proposed cross-reactivities in more detail.
The platelet membrane is now thought to contain over 
120 different proteins; no great surprise considering 
the many functions it must fulfil (Capron et 
a_l, 1985;George et a l , 1985 ) . Although the platelet is not 
considered an effector cell of the immune system, it is 
known to react with antibodies in different ways. 
Platelet antigens can be divided into two groups:-
1. Platelet-specific antigens - these make platelets 
susceptible to attack by antibodies arising 
spontaneously, e.g. post-transfusion and in pregnancy 
(Shulman,1964;Von dem Borne,1980).
2. Non-platelet specific antigens - e.g. the ABO system 
(Moreau and Andre, 1954), HLA (Aster et al,1973), Tn and 
T (Cartron and Nurden,1979), Senescent (Kay, 1981), and 
Fc receptors (discussed below)
Human platelets are known to possess an Fc receptor 
for IgG, FcyR (Israels et al ,1973; Karas et a l ,1982), 
and for IgE (Capron,1985).
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Three different types of FcyR have been distinguished by 
using monoclonal antibodies (Anderson and Looney,1986):-
FcyRI - (72kD), found on monocytes,
FcyRII - (40kD), found on neutrophils, monocytes,
eosinophils, platelets and B-cells,
FcyRIII - (50-70kD), found on neutrophils, large 
granular lymphocytes and macrophages.
Because of the large volume of platelets in the blood, 
these constitute the major source of the Fey RII 
receptor. The blood concentration of this receptor, 
provided by platelets, is 0.7nM (0.22nM by neutrophils,
0.014nM by monocytes and 0.02nM by B-cells). The 
receptor has a low affinity for monomeric IgG and
preferentially binds immune complexes (Karas et
al,1982). Immune complex-induced aggregation in 
platelets appears to reach maximal intensity when the 
immune complex is formed from a four fold antigen 
excess and up to 20 fold antibody excess (Battersby et 
ad,1984). All sub-classes of human IgG activate human 
platelets whereas IgM, IgA, and IgD or bovine IgG do not
(Pfueller and Luscher, 1972; Henson and Spielberg,
1973) .
The role of FcyRII is thought to be to aid removal of 
CICs from the circulation by delivery to the reticulo­
endothelial system.
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It is possible, therefore, that anti-BMFGM antibodies 
may bind to platelets by means of their Fc portion, and 
not via their Fab' portions as originally anticipated by 
Davies and others (1982).
Between 8,000 and 50,000 molecules of IgG per platelet 
have been detected on platelet membranes and in platelet 
lysates (Kelton and Gibbons, 1982). It has been assumed 
that they were mainly Fc associated. However, it has 
been shown that IgG is also contained in platelet a- 
granules (George and Saucerman,1988).
Development of a platelet ELISA
An ELISA was developed to meaure anti-platelet 
membrane antibodies. The method of Horai and co-workers 
(1981), involving the use of monolayers of whole 
platelets as antigens was found to be unreliable for two 
reasons: the first was that a high background could not 
be eliminated (i.e. conjugate was binding non- 
specifically); the second was that results were variable 
and no standard curve could be produced. Thomas (West 
Wales hospital, Carmarthen) reported similar findings 
(personal communication). It was thought that loosening 
of the platelets adhering to microtitre wells might 
occur during the washing procedures and lead to 
inconsistencies, but the use of poly-l-lysine, or Ca2* 
in the ELISA buffer did not improve matters. Platelets 
are known to contain surface IgG and it was considered 
possible that these were contributing to the high
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background levels, but pre-washing of the platelets did 
not lead to improvement (Results Sect 6.1a, pl85).
In view of the lack of promise of the above assay, the 
ELISA of Winiarski and Ekelund (1986), which uses 
preseparated platelet membranes, was further 
investigated and developed as follows:-
1. The results of Winiarski and Ekelund had suggested 
non-specific binding of sera, as titres produced by 
using serum or F(ab ' ) 2 were not always comparable. NRS 
was accordingly included in the buffers and this was 
found to reduce the effect (Results Sect 6.1(iii), 
pl87) .
2. The membrane preparation, used by the above authors, 
involved sonication which, although very quick, did not 
produce consistent results. It was shown (Results Sect. 
6.1b, pl91), that the SDS-PAGE profile of the platelet 
membrane varied with sonication time and, more subtly, 
preparations showing identical SDS-PAGE patterns, gave 
different background levels in the ELISA. Sonication has 
been reported to cause membrane damage (Freifelder, 
1982). The method of preparation of platelet membranes, 
described by Barber and Jamieson, (1970), was found to 
be an improvement and produced a consistently low 
background when used to coat ELISA microtitre wells.
3. The original ELISA used 50yg membrane protein/ml 
coating buffer; this was reduced to lOyg/ml. It is 
possible that the authors' method of measuring membrane 
protein was not as sensitive as that used in the 
laboratory, which was specifically modifed for membrane
protein estimation (Methods Sect 3.1(ii), p84).
4. Carbonate buffer, used in coating the platelet 
membrane onto the microtitre plates, was found to give a 
wider range of absorbances, compared to using 
formaldehyde to coat platelet membranes to wells. It may 
be that formaldehyde interferes with antibody binding to 
membrane.
The platelet ELISA was used in various ways to show 
that affinity purified anti-BMFGM antibodies did not 
bind specifically to the platelet membrane and that 
anti-BMFGM antibody titres did not correlate with anti- 
platelet membrane) antibody titres (Results 
Sect.6.2.1, pl97). In attempts to demonstrate the
validity of the ELISA for anti-(platelet membrane) 
antibodies, ITP sera were compared with controls. 
Although ITP sera did show higher responses than 
controls, the difference was shown not to be significant 
(Results Sect 6.2.1, pl97). There is some controversy, 
however, over the role of anti-platelet antibodies in 
ITP (van Leeuwen et al,1981), as some workers support a 
role for immune complex involvement (Trent et 
al,1980;Walsh et al,1984).
If time had allowed it would have been more 
appropriate to prepare IgG fractions from sera to assay, 
as then there would have been no interference from 
immune complex binding, and specific anti-(platelet 
membrane) binding would have been observed.
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Demonstration of the lack of specific immunological 
cross-reactivity between BMFGM and Platelet membrane
Incubation of platelets with human serum could be 
shown to inhibit the BMFGM ELISA, but this inhibition 
was largely removed when the platelets were pre-blocked 
with normal rabbit serum, suggesting that the inhibition 
was largely the result of immune complex binding 
(Results Sect 6.2.2, p201). Platelets used as inhibitors 
in the platelet ELISA showed only a slight loss of 
inhibition when pre-blocked.
Experimental antisera also showed no cross-reactivity 
between anti-BMFGM and human platelet membrane (Results 
Sect 6.2.3, p204). Rabbit anti-BMFGM and anti-XO
antisera showed no response in the platelet membrane 
ELISA and conversely, anti-(platelet membrane) antisera 
showed no response on either the BMFGM or the XO ELISAs. 
Rabbit anti-BSA antisera did respond slightly in the 
BMFGM and platelet membrane ELISAs suggesting that BSA 
may be on the BMFGM and a cross-reacting protein, 
possibly human serum albumin, may be present on the 
platelet membrane.
Immunoblotting of human serum onto SDS-PAGE profiles 
of platelet membrane highlighted a band at 39kD, likely 
to be the Fc receptor. Affinity-purified anti-BMFGM IgG 
gave little staining, and RABMFGM sera only stained 
bands that were also stained by other experimental anti­
sera. No evidence of any antigenic determinants, as seen 
with immunoblot profiles against the BMFGM, was evident.
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Certainly, no cross-reacting protein of 150kD was 
present on the platelet membrane.
One of the experiments cited by Rees (Davies,1984; 
Rees,1985) as evidence of antigenic cross-reaction of 
the BMFGM with the platelet membrane was repeated. He 
found that the addition of post-immune rabbit anti-BMFGM 
antisera aggregated platelets, whereas serum from pre- 
immune rabbits did not. In the present work, a variety 
of other pre- and post-immune sera were tested in the 
same way (Results Sect 6.3, p207), and it was shown that 
platelet aggregation occurred for all post-immune sera 
tested. It seemed unlikely that the platelet membrane 
cross-reacted with all of these antigens. This platelet- 
induced reaction most probably resulted from immune 
complex formation, as all of the anti-sera were 
collected 5-6 days after injection of the animal with 
antigen (see Fig 77, p249, in fact the lag phase of 
appearance of antibody would be even shorter, than 
shown here). In support of this idea was the finding 
that IgG purified from anti-BMFGM and anti-XO antisera 
did not aggregate platelets, whereas IgG prepared from 
anti-platelet membrane antisera did.
A pilot experiment, not described in the Results 
section showed that the addition of whole dried milk, to 
equal volumes of PRP, from different samples, resulted 
in aggregation of some PRP and not others. Subsequently, 
the plasma was separated from platelets for each sample 
and assayed for IgG anti-BMFGM levels. Interestingly, 
out of the 25 samples tested, the 6 samples that
contained platelets which aggregated had the highest 
anti-BMFGM titres. • This would be consistent with 
formation of immune complexes, in the high titre plasma, 
that bring about aggregation.
It is possible that, depending on relative
concentrations of anti-BMFGM (XO) antibody and antigen, 
CICs may be formed in vivo. Certainly anti-BMFGM (XO) 
antibodies constitute a large proprtion of total IgG. 
CICs have been reported to be increased in MI patients 
(Fust et a l ,1978;Smith et al,1983); an elevation that 
apparently does not result from neo-antigen formation 
from the myocardium (Smith et al,1983). These complexes 
contain IgG, IgA, and IgM antibodies (Triolo et
a_l,1984). Increased levels of CICs, by binding to
platelets, are likely to accelerate turnover of the 
latter (Rees, 1985) and to raise the levels of fresh, 
more active platelets. An increase of platelet activity 
in MI patients is well documented
(Tofler,1987;Elwood,1988). This could explain increases 
in platelet adhesiveness (Davies and Lloyd 1967).
Davies (1958) also reported reductions in the RBC 
migration times of MI patients. Although RBCs do not
have an Fc receptor to bind CICs, they have a high 
affinity receptor, CR1, for a complement component C3b, 
often bound to soluble CICs. CR1 binds C3b-CICs and 
serves in the transport of the complexes in the 
circulation to the sites of their elimination in the 
liver (Medof,1982;Cornacoff et a l ,1983). CIC bound RBCs 
would have reduced migration times.
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Fig 7 7 Formation of soluble immune-complexes after
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CONCLUDING REMARKS
CONCLUDING REMARKS
This final section attempts to summarise the progress 
made in the course of this work, to outline the many 
remaining uncertainties and to suggest how these might 
be resolved.
At the start of the project, Davies* hypothesis, 
linking anti-(cows* milk) antibodies with MI was largely 
discredited. There were however, reasons to question the 
validity of refuting publications and to believe that a 
repeat of Davies* experiments, with certain 
modifications might lead to more clear cut differences 
between Mis and controls. Although, in several surveys, 
Davies had consistently found elevated antibody titres 
in MI patients, these elevations were not always shown 
to be significant. He, himself, felt that significant 
elevations were most likely to be found when patients 
sera were assayed soon after the MI, i.e. before those 
with higher titres died. Another factor was Davies* 
later finding that anti-(cows* milk antibodies), as 
assayed by him, were largely anti-BMFGM antibodies. In 
view of these considerations, it seemed likely that a 
careful analysis of anti-BMFGM antibody titres, assayed 
by ELISA, rather than the less precise haemagglutination 
method, in patients with recent Mis might show more 
clearly any true differences from controls.
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Accordingly, a large scale study was carried out, in 
conjunction with the MRC Epidemiology Unit at Cardiff, 
assaying IgG anti-BMFGM antibodies, but, surprisingly at 
the time, MI titres were not shown to be higher than 
those of controls. However, subsequent smaller numbers 
of subjects, showed that IgM anti-BMFGM antibodies were /
significantly elevated in MI patients. This finding, to 
a large extent, confirms Davies* results and explains 
differences between his data and those of dissenting 
groups.
The question then arose as to the nature of the 
immunogen giving rise to human anti-BMFGM antibodies. 
Western blots of human sera and affinity-purified anti- 
BMFGM antibodies on SDS-PAGE patterns of BMFGM 
pinpointed the enzyme, xanthine oxidase, as the major
C'
antigenic target. In accordance with this, two separate, 
carefully controlled studies showed IgM anti-XO 
antibodies to be significantly elevated in MI patients.
Having established a clinical significance of raised 
anti-BMFGM antibody levels and the association, even 
identity, of these antibodies with anti-XO antibodies, 
it remained to examine Davies' and Rees' belief that 
anti-BMFGM antibodies might interact with human 
platelets with pathogenic consequences. The overall 
conclusions, from competition ELISAs, Western blotting v 
and platelet aggregation experiments was that there was 
no specific antigenic cross-reactivity of this type, 
although it may be that anti-BMFGM antibody-containing 
immune complexes bind non-specifically to platelets and 
effectively activate them.
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These results serve to explain roost of Davies'
findings and those of relevant papers from other groups.
The basic question, of course, concerns the origin and
role of human anti-XO antibodies. The presence, in roost
humans, of circulating IgG anti-XO antibodies has been
reported (Oster et a l ,1974;Bruder et a l ,1984;Jarasch et
al,1986). The work in this thesis confirms their
presence in remarkably high levels and additionally
established the occurance of IgA and IgM anti-XO
antibodies. Most importantly, the latter antibodies were
*
found to be elevated in patients following MI.
Anti-XO antibody levels have been reported to
correlate with ingestion of milk products (Rzucidlo and 
Zikakis, 1979), and bovine milk would seem to be the 
obvious source of such antibodies. Oster's hypothesis of 
initiation of atherosclerosis had depended on the 
presence, in the circulation, of bovine milk-derived 
xanthine oxidase and it was the likliehood of this that 
was mainly attacked by the critical FDA report (Carr et 
a_l,1975). In fact, studies by others (Warsaw et a l ,1975) 
have established that proteins of up to 80kD commonly 
find their way through the gut, even of adults. It is 
quite conceivable that, at least, proteolytic fragments 
of bovine milk-derived XO could be absorbed from the gut 
and provoke an immune response. Oster (1976) argued in 
favour of the absorption of whole fat globules with 
BMFGM but my own data would suggest otherwise, in that 
Western blots of human antibodies showed few
*see Appendix
polypeptides in addition to XO itself. If the entire 
BMFGM had constituted an immunogen, then many more bands 
as shown with rabbit anti-BMFGM antisera, might be 
expected.
A number of groups have failed to demonstrate the 
presence of significant amounts XO activity in normal
human serum (Shamma'a et a_l, 1973; McCarthy and
Long,1976). XO activity, however, is known to be 
elevated in acute liver injury (Giler et a l ,1975) but 
not in MI, as measured by these workers. It may be that 
only inactivated enzyme or proteolytic fragments find 
their way into the bloodstream. Alternatively, in view 
of the high levels of anti-XO antibodies, it is possible 
that any free XO is rapidly cleared in the form of 
circulating immune complexes.
It does appear conceivable that digested bovine XO 
could give rise to the anti-XO antibodies, clearly 
abundantly present in blood. It is also conceivable that 
active XO, in the form of immune complexes, could be 
deposited in blood vessels and initiate endothelial 
membrane damage; possibly not by plasmalogen depletion, 
as propsed by Oster (1971), but by generation of free 
radicals. Antibodies which bind to XO do not reduce all 
of the enzymes* activity (Ultmann et al,1962; Bruder et 
a_l,1984). The XO detected by Oster and coworkers (Ross 
et al,1973) in atherosclerotic plagues might have arisen 
in this way. It could be argued that those individuals 
who absorb higher levels of XO generate higher levels of 
anti-XO antibodies and have higher risk of pathogenic
effects from active immune complex deposition. Why then 
is correlation of anti-XO antibody levels and MI seen 
for IgM but not IgG ?
IgG anti-XO antibody titres are considerably higher 
than those of IgM antibodies. On the other handf IgM 
antibodies are more efficient in immune complex
formation (Roittf1988). It may be that those individuals 
who, for some reason, generate and maintain higher IgM 
responses to bovine XO are particularly at risk.
The above discussion does not consider endogenous XO, 
which is certainly present in human liver and intestine 
(Parks and Granger,1986). It may be that the 
particularly high and prevalent levels of anti-XO
antibodies, in most humans, arise through bovine X0- 
induced breaking of tolerance to autoantigens, as has 
been proposed for viral or bacterial induction of 
certain autoimmune diseases. Bruder et al (1984) suggest 
that two populations of anti-XO antibodies may exist in 
human sera: The first against bovine XO; the second
against human XO.
Their evidence for endogenous origin of anti-XO
antibodies is that various animal species produce anti- 
XO antibodies; and bovine IgG anti-XO antibodies do not 
cross-react with the human form of the enzyme. For
evidence of a bovine source of the enzyme, they show 
that antibodies are also present in serum which cross- 
react with other proteins of the BMFGM that human IgG 
anti-XO antibodies will precipitate both human and 
bovine XO from the MFGM, and that some sera bind BXO 
with greater affinity than human XO from milk globules.
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Despite the widespread occurrance of such antibodies 
and their quantity in sera, unlike any other auto­
antibody (Guilbert et al,1982), they support the 
hypothesis that XO antibody formation is due to a self­
immunisation of the enzyme, being a multiple event. In 
fact the same could be true of bovine XO, being 
repeatedly "administered" from the diet.
Most human anti-XO antibodies are IgG and have not 
been shown to be elevated in MI patients. IgM anti-XO 
antibodies are, however, raised following MI and the 
most important question concerns their origin. Their 
levels were shown most clearly to be raised in serum 
taken from patients within 24h of MI. This is certainly 
a faster response than would be expected if the 
antibodies arose from endogenous XO, released in the 
infarct itself. It may be that the response reflects a 
pre-clinical event prior to the infarct proper and 
careful studies of antibody levels in serial samples, 
following MI, might shed some light on this. If the IgM 
response was a consequence of the MI or a preceding 
event, a subsequent rise in IgG anti-XO antibodies might 
be expected. This was certainly not evident in the "new" 
(2-3 weeks post MI) samples although it may be that any 
such rise could be missed against a high background 
level of exogenously-induced anti-XO antibodies.
A further question arises in connection with the idea 
that XO, newly exposed in MI, initiates production of 
IgM antibodies. This question concerns the occurrance of 
XO in humans. XO has been known to occur in human liver
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and intestine, and was shown by Jarasch et al (1981) to 
be present in capillary endothelial cells, but not 
arteries, of cows. If the same were true of humans, it 
could well be that infarct-associated damage in the 
myocardium would expose endogenous XO to the immune 
system. It happens that the presence of XO in human 
heart is currently hotly debated in connection with its 
proposed role as the initiator of free radical damage 
following an MI. Most recent opinion (Downey et a l ,1988) 
is largely against its significant presence in the human 
heart. Demonstration that IgM anti-XO antibodies arise 
in response to myocardial XO would clearly contradict 
this opinion; conversely, confirmation of the absence of 
XO in human heart would argue against the idea that the 
IgM response is secondary to MI.
What experiments could help to answer these many 
uncertainties? Assays of IgG and IgM anti-XO antibodies 
in serial serum samples, taken from patients in the 
days, weeks and months following an MI, may well help to 
resolve the question of whether the IgM response is 
secondary to MI. The purification and study of human XO 
antibodies, also might help answer this question. Human 
and bovine XO could be used in competition ELISAs, to 
determine the specificities of both IgM and IgG 
concerning the possibility that MI is initiated by X0- 
induced endothelial damage, a search for circulatory 
immune complexes containing XO might prove profitable.
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In conclusion, this thesis has served to resolve many 
of the apparent contradictions surrounding Davies* 
findings and hypothesis of MI and may even have gone 
some way toward validating the ideas of Oster. However 
very many questions remain and perhaps this work will 
help to stimulate their solution.
APPENDIX
Although it has been possible to show an elevation of 
IgM anti-BMFGM antibodies, and more specifically IgM 
anti-XO antibodies in MI patient compared to controls, 
this does not exclude the possibility that the observed 
elevation of IgM is in fact due to rheumatoid factor in 
MI patients. Rheumatoid factor is an autoantibody, mainly 
IgM, which reacts with IgG. Immune complexes arising from 
such a combination are characteristically found in the 
joints of sufferers of Rheumatoid Arthritis.
If rheumatoid factor is, in fact, elevated in MI 
patients this would also explain why, in the ELISA 
measuring specifically IgG or IgA antibodies to either 
BMFGM or XO, no difference was found between MI and 
control samples. However, in the ELISA measuring IgM 
antibody levels to either BMFGM or XO , any IgG binding 
to the antigen would of course have an IgM antibody 
(rheumatoid factor) associated with it. This would be 
detected as well as any IgM anti-BMFGM or IgM anti-XO 
antibody.
Reference:-
Chantler, S. and Diment, J.A. (1981) in " Imunoassays for 




Abd-ElFattah, A.S., Jessen, M.E., Lekven, J., Doherty. 
N.E., Brunstig. L.A., Wechsler. A.S. (1988). 
Circulation. 7]}, (5), 224-235.
Abildgard, C.F. and Simone, J.V. (1967). Seminars in 
Hematology. 4, 424-452.
Alberts, B., Bray, D., Lewis, J., Raff, M . , Roberts, K. 
and Watson, J.D. (1983). "Molecular Biology Of the 
Cell". Garland Publishing, Inc. New York and 
London.
Al-Khalidi, U.A.S., Nasrallah, S., Kachadurian, A.K. and 
Shammea, M.H. (1965). Clin. Chira. Acta. 11_, 72-77. 
Anderson, C.L. and Looney, R.J. (1986). Immumol. Today. 
7, 264-266
Anderson, M . , Cawston, T., Cheeseman, G.C. (1974).
Biochem. J. 139, 653-660.
Anderson, M. and Cheeseman, G.C. (1971). J. Dairy. Res. 
38, 409-417.
Anitschkow, N. and Chalatov, S. (1913). Centralblatt fur 
Allgemeine Pathologie. 24, 1.
Annand, J.C. (1967). J. Atheroscler. Res. 7, 797-801. 
Annand, J.C. (1986). Atherosclerosis. j[9, 347-351. 
Arfors, K.E., Rutili, G., Svensjo, E., (1979). Acta.
Physiol. Scand. (suppl). 463, 93-103.
Ascherson, F.M. (1840). Translation in "Foundations of 
Colloid Chemistry." by Hatschek, E. (1925). E.
Benn Ltd. London.
Aster, R.H., Miscovich, B.H. and Rodey, G.E., (1973). 
Transplantation. 1J>, 205-210.
259
Baillie, M. (1793). "The Morbid Anatomy Of Some Of The 
Most Important Parts Of The Human Body."
Barber, A.J., and Jamieson, G.A. (1970). J. Biol. Chem.
245, 6357-6365.
Bargmann, W. and Knoop, A. (1959). Z. Zellforsch.
Mikrosk. Anat. 4j), 344-388.
Barrett-Connor, E. and Khaw, K.T. (1988). Circulation. 
78, 539-545.
Basch, J.J., Greenberg, R., Farrell, H.M.Jr. (1985).
Biochem. Biophys. Acta. 830, 127-135.
Battelli, M.G. (1980). FEBS Letts. 113, 47-51.
Battersby, B., Sherwood, T., Winocour, P., Virella, G.
(1984). J. Clin. Lab. Immunol. 1_5, 57-61. 
Baumgartner, H.R. (1963). Z. Ges. Exp. Med. 137, 227-
235.
Beale, D. and Hopley, J. (1986). Biochem. J. 233, 37-40. 
Beaumont, J.L. and Beaumont, V. (1978) "Immunological 
Aspects of Atherosclerosis in "Atherosclerosis 
Reviews Vol 3" ". (Pasletti, R. and Gotto, A.M.
Jr. Eds.) Raven Press, New York.
Begg, T.B., Wade, J.M., and Bronte-Stewart, B. (1966).
J. Atheroscler. Res. 6, 303-312.
Benboubetra, M. and Harrison, R. Dept of Biochemistry, 
University of Bath, Claverton Down, Bath, U.K. 
Benditt, E.P. and Benditt, J.M. (1973). Proc. Nat. Acad.
Sci. U.S.A. 70, 1753-1756.
Bizzozero, G. (1882). Virchows. Arch. Path. Anat. 90, 
261-332.
Bjorkerud, S. and Bondjers, G. (1971). Atherosclerosis. 
13, 355-363.
260
Bjorkerud, S. and Bondjers, G. (1972). Atherosclerosis. 
15, 285-300.
Bloom, W. and Fawcett, D.W. (1975). "A textbook of 
Histology”. Saunders, Philadelphia 
Bondjers, G. and Bjorkerud, S. (1973). Atherosclerosis. 
17, 85-94.
Bowman, W.C. and Rand, M.J. (1980). ’’Textbook of
Pharmacology”, Blackwell Scientific Publications, 
Cambridge.
Boyden, S.J. (1951). J. Exp. Med. 93^ , 107-120.
Bradford, M.M. (1976). Anal. Biochem. 7_2, 248-254. 
Bradley, D.D., Wingerd, J., Petitti, D.B., Krass, R.M.
and Ramcharan, S. (1978). New. Engl. J. Med. 299,1, 
17-20.
Brandtzaeg, P. (1974). J. Immunol. 112, 1553-1559. 
Briley, S.M. and Eisenthal, R. (1974). Biochem J.
143, 149-152.
Brown, M.S., Faust, J.R., and Goldstein, J.L. (1975). J.
Clin. Invest. 5j>, 783-793.
Brown, M.S. and Goldstein, J.L. (1984). Scientific 
American. 251 (5), 58-66.
Brown, M.S. and Goldstein, J.L. (1986) Science. 232, 34- 
47.
Bruder, G., Heid, H.W., Jarasch, E-D. and Mather, I.H.
(1983). 23, 218-225.
Bruder, G., Jarasch, E.D. and Heid, H.W. (1984). J.
Clin. Invest. 74, 783-794.
Bylock, A., Bondjers, G., Jansson, I., Hansson, H.A., 
(1979). Acta. Pathol. Microbiol. Scand. 87 (sect 
A), 201-209.
261
Caerphilly and Speedwell Collaborative Group. (1984). J.
Epidemiol, and Comm. Health. 3fJ, 259-262.
Capron, A., Araeisen, J.C., Joseph, M . , Auriault, C., 
Tonnel, A.B. and Caen, J. (1985). Int. Archs. 
Allergy. Appl. Immunol. 77, 107-114.
Carr, C.J., Talbot, J.M. and Fisher, K.D. (1975). 
Contract No. FDA 223-75-2090 (Div. Nutrition,
Bureau of Foods), FASEB Life Sciences Research 
Office, Bethesda.
Carruthers, A. and Melchior, D.L. (1983). Biochemistry.
22, 5797-5807.
Carstairs, K.C. (1965). J. Pathol. Bacteriol. 90, 
225-231.
Cartron, J.P. and Nurden, A.T. (1979). Nature. 282 
621-623.
Cathcart, M.K., Morel, D.W. and Chisolm, G.M. (1985). J.
Leuk. Biol. 3jJ, 341-350.
Challacombe, S.J. and Tomasi, T.B. Jr. (1980). J. Exp.
Med. 152, 1459-1462.
Chambers, D.E., Parks, D.A., Patterson, G . , Roy, R., 
McCord, J.M., Yoshida, S., Parmley, L.F. and 
Charlat, M.L., O fNeil, P.G., Abernathy, D.R., Egan,
J.M., Michael, L.H., Roberts, R. and Bolli, R.
(1986). Circulation. 74^ , 11-19.
Clark, D.A., Schroeder, J.S., Gniepp, R.B., Stinson,
E.B., Dore, E., Shumway, N.E. and Harrison, D.C.
(1973). Am. J. Pathol. 54^ , 563-576.
Clark, S.L. (1959). J.Biophys. Biochem. Cytol. 5, 41-50. 
Clifford Rose, F.(1977). In "Motor Neurone Disease." Ch 
1, ppl-13, (Clifford Rose, Ed). Pitman Press.
262
Cochrane, C.G. and Hawkins, D. (1968). J. Exp. Med. 127, 
137-154.
Cooper, G.W. (1970). In "Regulation of Hematopoiesis." 
(Gordon, A.S. Ed.) VolII p 1611, Appleton-Century- 
Crofts, New York.
Copley, A.L. (1979). Folia. Haematol. 106, 732-764. 
Cornacoff, T.B., Herbert, L.A., Smead, W.L. and Vanaman, 
M.E. (1983). J. Clin. Invest. 71_, 236-247.
Coudrier, E., Reggio, H. and Louvard, D. (1983).
EMBO.J. 2, 469-475.
Crawford, T. and Levene, C.I. (1953). J. Pathol.
Bacteriol. 66, 19-23.
Crell, J.F. (1740). Cited by Long, E. in
"Atherosclerosis" (1953). (Cowdry, E.V. Ed).
MacMillan, New York.
Criqui, M.H., Lee, E.R., Hamburger, R.N., Klauber, M.R.
and Coughlin, S.S. (1987). Am. J. Med. J52, 964-968. 
Cronkite, E.P. (1958). Brook Haven Symp. in Biol. 10, 
96-120.
Cunningham, M.J. and Pasternak, R.C., (1988).
Circulation. 77, 964-966.
Cunningham-Rundles, C., Brandeis, W.E., Good, R.A. and
Day, N.K. (1978). Proc. Nat. Acad. Sci. U.S.A. 75,
3387-3389.
D'Angelo, V., Villa, S. and Mysliewiec, M. (1978).
Thrombosis and Haemostasis, 3j?, 535-536.
Davies, D.F. (1958). Clin.Sci. _17, 563-573.
Davies, D.F. (1959). Clin.Sci. If), 263-268.
263
Davies, D.F. (1969). J. Atheroscler. Res. _10, 253- 
259.
Davies, D.F. (1984). In ’’Health Hazards of Milk.’’
pp 201-212, (Freed, D.L.J., Ed), Balliere, Tindall. 
Davies, D.F. and Clark, A. (1961). Clin.Sci. ^0, 279- 
287.
Davies, D.F. and Clark, A. (1968). J. Atheroscler.
Res. 6), 724-730.
Davies, D.F., Davies, J.R. and Richards, M.A. (1969). J.
Atheroscler. Res. 9, 103-107.
Davies, D.F., Johnson, A.P., Rees, B.W.G., Elwood, P.C.
and Abernethy, M. (1974). Lancet, i., 1012-1014. 
Davies, D.F. and Lloyd, V. (1967). Cardiovasc. Res. 1, 
108-110.
Davies, D.F., Rees, B.W.G. and Davies, P.T.G. (1980).
Lancet, i, 1190-1191.
Davies, D.F., Rees, B.W.G. and Davies, P.T.G. (1982).
International Laboratory. 1^ 2, 22-24.
Dawber, T.R. (1980) "The Framingham Study: An
epidemiological investigation of cardiovascular 
disease." Harvard. Univ. Press, Cambridge, Mass. 
Dawson, R.M.C., Elliot, D.C, Elliot, W.H. and Jones, 
K.M. (1974). In "Data for Biochemical Research." 
Oxford Univ. Press.
Deeth, H.C. (1983). J. Dairy. Sci. 66>, 1419-1435. 
DeScheerder, I., Vandekerckhove, J., Robbrecht, J., 
Algoed, L., De Buyzere, M . , DeLanghe, J., 
DeSchrijver, G. and Clement, D. (1985). Am.
J.Cardiol. 56, 631-633.
264
Digby, J., Harrison, R., Jehanli, A., Lunt, G.G. and
Clifford-Rose, F. (1985). Muscle Nerve 8, 595-605.
Dowben, R.M., Brunner, J.R. and Philpott, D.E. (1967).
Biochem. Biophys. Acta. 135, 1-10.
Downey, J.M., Hearse, D.J. and Yellon, D.M. (1988). J.
Mol. Cell. Cardiol. 2J0 (suppl) , 55-63.
Duguid, J.B. (1946). J. Pathol. Bacteriol. f)8, 207-212.
Duguid, J.B. (1948). J. Pathol. Bacteriol. 6j0, 57-61.
Eastham, E.J., Lichauco, T., Grady, M.I. and Walker,
W.A. (1978). J. Pediatr. 93, 561-564.
Ebringer, A., Rosenbaum, M . , Pincus, N. and Doyle, A.E.
(1971). Am. J. Med. 50, 297-301.
Eddy, L.J., Stewart, J.R., Jones, H.P., Engerson, T.D., 
McCord, J.M., Downey, J.M., Cunningham-Rundles, C., 
Brandeis, W.F. and Good, R •A. (1987). Proc. Nat. 
Acad. Sci. U.S.A. 7^* 3387-3389.
Egger, J., Carter, C.M., Wilson, J., Turner, M.W. and 
Soothill, J.F. (1983). Lancet iJL, 865-869. 
Ehrenfeld, E.N., Gery, I. and Davies, A.M. (1961).
Lancet, i, 1138-1141.
Eisenberg, M.S., Bergner, L., Hallstrom, A.P. and
Cummings, R.O. (1986). Scientific American. 254, 
25-31.
Ellis, F.R. (1974). Lancet, ii, 400.
Elwood, P.C., Beswick, A. and Cartwright, J. (1988). Br. 
J. Haematol. ^4 (suppl) 45 (abstract).
265
Engerson, T.D., McKelvey, T.G., Rhyne, D.B. , Boggio,
E.B., Snyder, S.J. and Jones, H.P. (1987). J. Clin. 
Invest. 7j), 1564-1570.
Engle, M.A. and Ito, T. (1961). Am. J. Cardiol. ]_,
73-82.
Faggiotto, A. and Ross, R. (1984). Arteriosclerosis. 4, 
341-356.
Faggiotto, A., Ross, R. and Harker, L. (1984).
Arteriosclerosis. 4 r 323-340.
Ferguson, A. (1977). Gut. 1JJ, 921-937.
Finkelstein, A.E., Woerner, T.E., Smith, J.C., Bayles, 
T.B. and Levine, H.D. (1963). Am J. Med. 3j), 163-
174.
Fisher, R.B. (1954). In "Protein Metabolism." Methuen, 
London.
Florey, H. (1960). Br. Med. J. 2, 1329-1335.
Forrester, J.S., Litvack, F., Grundfest, W. and Hickey, 
A. (1987). Circulation. 7_5, 505-513.
Franke, W.W., Heid, H.W., Grund, C., Winter, S., 
Freudenstein, C., Schmid, E., Jarasch, E.D.,
Keenan, T.W., (1981), J. Cell. Biol. 89, 485-494. 
Freifelder, D. (1982). In "Physical Biochemistry".p688.
W.H. Freeman and Co, New York.
Fust, G., Szondy, E., Szekely, J., Nanai, I. and Gero,
S. (1978). Atherosclerosis. 29, 181-190.
266
Gajdusek, C.M., Dicorleto, P., Ross, R. and Schwartz, 
S.M. (1980). J. Cell. Biol. 85, 467-472.
George, J.N., Nurden, A.T. and Phillips, D.R. (1984).
New. Eng. J. Med. 311, 1084-1098.
George, J.N., Nurden, A.T. and Phillips, D.R. (1985). 
"Platelet Membrane Glycoproteins." Plenum Press, 
New York.
George, J.N. and Saucerman, S. (1988). Blood. 72, 
362-365.
Gerrity, R.G. (1981). Am J. Pathol. 103, 181-200.
Gibney, M.J., Gallagher, P.J., Sharratt, G.P., Benning, 
H.S., Taylor, T.G. and Pitts, J.M. (1980). Athero­
sclerosis. 37, 151-155.
Giler, S., Sperling, O., Brosh, S., Urea, I. and DeVries 
,A. (1975). Clin. Chim. Acta. 63, 37-40.
Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, 
J.D., Castelli, W.P., Knoke, J.D., Jacobs, D.R., 
Bangdiwala, S. and Tyroler, H.A. (1989). 
Circulation. 7_9 (1), 8-15.
Gorlin, R . , Fuster, V. and Ambrose, J.A. (1986).
Circulation. 1_A, 6-9.
Granger, D.N., Rutili, G. and McCord, J.M. (1981).
Gastroenterology. 81, 22-29.
Gray, M.V., Hill, J.D., and Mitchell, J.R.A. (1978).
Atherosclerosis, 3^ 1, 377-381.
Greenbank, G.R. and Pallansch, M.J. (1962). J. Dairy.
Sci. 45, 958-961.
Greenwalt, D.E., Johnson, V.G. and Mather, I.H. (1985).
Biochem. J. 228, 233-240.
Gregoriardis, G. (1976). New. Eng. J. Med. 295, 704-710.
267
Guilbert, B . , Dighiero, G. and Avrameas, S. (1982). J 
Immunol. 128, 2779-2787.
Gunther, M., Aschaffenburg, R., Matthews, R.H., Parish, 
W.E. and Coombs, R.R.A. (1960). Immunology. 3, 296- 
306.
Habeeb, A.F.S.A. and Hiramoto, R. (1968). Arch. Biochem.
Biophys. 126, 16-26.
Haerem, J.W. (1975). Am. Heart. J. 9£, 562-568. 
Hamburger, F. (1901). "Biologisches uber die 
Eiweeisskerperder kuhmilch und uber 
sauglingsnahrung wien klin wochen schr", 1_4, 1202. 
Hamburger, R.N., Casillas, R., Johnson, R . , Mellon, M . , 
O'Conner, R.D. and Zeiger, R. (1987). Annals of 
Allergy. 5j) (2), 175-178.
Hamsten, A., Norberg, R., Bjorkholm, M. , De Faire, U.
and Holm, G. (1986). Lancet. _i, 113-115.
Hancock, K. and Tsang, V.C.W. (1983). Anal. Biochem.
133, 157-162.
Hannson, G.K. and Bjornheden, T., Bylock, A. and
Bondjers, G. (1981). Exp. Mol. Pathol. ,34# 264- 
280.
Hannson, G.K., Bondjers, G . , Bylock, A. and Hjalmarsson, 
L. (1980). Exp. Mol. Pathol. .33, 302-315.
Hannson, G.K., Starkenbaum, G.A., Benditt, E.P. and
Schwartz, S.M. (1984). Proc Nat Acad Sci, U.S.A.
81, 3103-3107.
Harkavy, J. and Perlman, E. (1964). N.Y. State. J. Med. 
64, 1287-1296.
268
Harrison, R. and Behan, P.O. (1986) in "Clinical
Neurochemistry." vol 1. (Bachelard, H., Lunt, G.G. 
and Marsden. D., Eds). Acad. Press.
Haust, M.D. (1971). Human Pathology. 2, 1-30.
Hayslett, H.T. (1976). In "Statistics Made Simple".
(Murphy, P. Ed). Chaucer Press, Bungay.
Hearse, D.J., Manning, A.S., Downey, J.M. and Yellon, 
D.M. (1986). Acta. Physiol. Scand. 126, 65-78. 
Heine, W.I., Friedman, H., Mandell, M.S. and Goldberg,
H. (1966). Am. J. Cardiol. 17, 798-803.
Heird, W.C. and Hansen, I.H. (1977). Pediatr. Res. 11, 
406.
Heller, T., Bailey, L. , Gott, M. and Howes, M. (1987)
In "Coronary Heart Disease - reducing the risk". 
John Wiley and sons Ltd, Chichester.
Hemmings, W.A. (1978). In "Antigen Absorption by the 
Gut. "MTP Press Ltd, Lancaster.
Henson, P.M. and Spielberg, H.L. (1973). J. Clin.
Invest. 52 ,^ 1282-1288.
Hodgson, J. (1815). In "Treatise on the diseases of 
arteries and veins."
Hopkins, P.N. and Williams, R.R. (1981).
Atherosclerosis. 4J), 1-52.
Horai, S., Claas, F.H.J. and van Rood, J.J. (1981) 
Immunol. Letts. 3^, 67-72.
Huang, C.M. and Keenan, T.W. (1972). Biochem.Biophys.
Acta. 274, 246-257.
Huang, R.T.C. (1973). Biochem. Biophys. Acta. 306, 82- 
84.
269
Hudson, L. and Hay, F.C. (1976) "Practical Immunolgy."
Blackwell Scientific Publications, Oxford.
Hutchins, P. and Walker-Smith, J.A. (1982). In "Clinics 
in Immunology and Allergy." Vol^, No 1 pp43-77.
Israels, E.D., Wisli, G., Paraskevas, F. and Israels, 
L.G. (1973) Thromb. Diath. Haemorr. j29, 434-444. 
Iverius, P.H. (1973). In " Atherogenesis:Initiating 
Factors." CIBA Symp. No 12, 185-196, Elsevier.
Jackson, R.L. and Gotto, A.M.Jr. (1976). In
Atherosclerosis Reviews." Vol 1, pp 1-21,
(Paoletti, R. and Gotto, A.M. Jr, Eds). Raven 
Press, New York.
Jaffe, E.A., Hoyer, L.W. and Nachman, R.L. (1973).
Proc. Nat. Acad. Sci. U.S.A. l ± r 1906-1909.
Jarasch, E.D., Bruder, G. and Heid, H.W. (1986). Acta 
Physiol. Scand. suppl. 548, 39-46.
Jarasch, E.D., Bruder, G., Keenan, T.W. and Franke W.W.
(1977). J. Cell. Biol. 73, 223-241.
Jarasch, e.d., Grund, C., Bruder, G., Heid, H.W.,
Keenan, T.W. and Franke, W.W. (1981)* Cell. 2j), 67- 
82.
Jenkins, P.J., Harper,.R.W. and Nestel, P.J. (1978).
Br. Med. J. ii, 388-391.
Jenner, E. (1778). in "Dr Jenner of Berkeley:Letter to 
Heberden", p68, (Fisk, D. Ed). Heinneman, London.
270
Jewell D.P. and Trulelove, S.C. (1972). Gut. JL3, 796- 
801.
Joel, D.D. , Sordat, B.f Hess, M.W. and Cottier, H. 
(1970). Experentia. 26^ , 694 (Abstract).
Johnson, S.A. (1971). In "The Circulating Platelet" 
(Johnson, S.A. Ed). Academic Press, New York.
Johnson, D.A., Gautch, J.W., Sportsman, J.R. and Elder, 
J. (1984). Gene. Anal. Tech. 1, 3-8.
Johnson, V.G., Greenwalt, D.E., Heid, H.W., Mather, I.H. 
and Nadara, P.J. (1985). Eur. J. Biochem. 151, 237 
-244.
Johnstone, A. and Thorpe, R. (1982). "Immunochemistry in 
Practice." Blackwell Scientific Publications,
Oxford.
Kabat, E.A. (1968). "Structural Concepts in Immunology 
and Immunochemistry". Holt, Rinehart and Winston 
Inc, New York.
Karas, S.P., Rosse, W.F. and Kurlander, R.J. (1982). 
Blood. 60, 1277-1282.
Kaser-Glanzmann, R., Jakabova, M., George, J.N. and
Luscher, E.F. (1977). Biochem. Biophys. Acta. 466, 
429-440.
Kay, M.M.B. (1981). Nature. 281, 491-494.
Keenan, T.W. (1974). Biochem. Biophys. Acta. 337, 255- 
270.
Keenan, T.W. and Huang, C.M. (1972). J. Dairy. Sci.
55, 1586-1596.
Keenan, T.W., Morre, D.J., Olson, D.E., Yunghans, W.N. 
and Patton, S. (1970). J. Cell. Biol. 44, 80-93.
Kelton, J.G. and Gibbons, S. (1982). Semin. Thromb. 
Haemost. £), 83-104.
Kennel, W.B., Hjortland, M.C., McNamara, P.M. and
Gordon, T. (1976). Ann. Inerm. Med. 8J5, 447-452.
Keys, A. (1970). Circulation. ^1 Suppl I, 11-1211.
Keys, A. (1980). "Seven Countries: a multivariate
analysis of death and CHD" . Harvard Univ. Press, 
Cambridge, Mass.
King, N. (1955). Tech. Commun. No2, of Commonwealth 
Bureau of Dairy Science, ppl-99.
Kinsman, J.M., Murray, C.E., Richard, V.J., Jenning,
R.B. and Reimer, K.A. (1988). J. Am. Coll. Cardio 
12, 209-217.
Kirkwood, E. and Lewis, C. (1989). In "Understanding 
Medical Immunology". John Wiley and Sons Ltd, 
London.
Kobylka, D. and Carraway, K.L. (1973). Biochem. Biophy 
Acta. 307, 133-140.
Korenblat, P.E., Rothberg, R.M., Minden, P. and Farr, 
R.S. (1968). J. Allergy. 41, 226-235.
Kuhn, L.C. and Kraehenbuhl, J-P. (1979). J. Biol. Chem 
254, 11066-11071.
Laegreid, A., Otnaess, A.K. and Fuglesang, J. (1986).
Pediatric. Res. 20, 416-421.
Laemmli, U.K. (1970). Nature. 227, 680-685.
272
Lang, B., Vincent, A. and Newsom-Davies, J. (1982). J.
Immun. Meth. 51, 371-381.
LeFevre, M.E. and Joel, D.D. (1984). ’’Intestinal
Toxicology." pp45-56. (Schiller, C.M. Ed), Raven 
Press, New York.
Leibovich, S.J. and Ross, R. (1976). Am. J. Pathol. 84, 
501-514.
Lev, R. and Orlic, D. (1973). Gastroenterology. 65, 60- 
68.
Levine, R.F. (1982). Br J. Haematol. 52^ , 173-180.
Levy, L. (1967). In "Advances in Exp. Med. and Biology: 
The reticuloendothelial system and 
atherosclerosis." Vol _1. (DiLuzio, N.R. and 
Paoletti, R. Eds). Plenum Press, New York.
Lin, W. and Kasamatsu, H. (1983). Anal. Biochem.128, 
302-311.
Linder, E. (1981). J. Immunol. 126, 648-658.
Link, E.M. and Riley, P.A. (1980). Biochem. J. 249, 
391-399.
Lippard, V.W., Schloss, O.M. and Johnson, P.A.(1936).
Am. J. Dis. Child. 51, 562-574.
Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, 
R.J. (1951). J. Biol. Chem. 193, 265-275.
L.R.C.P. (The Lipid Research Clinics Program) (1984). J. 
Am. Med. Assoc. 251, 351-364.
MacDonald, V.E. and Savoca, K.V. (1985). Int. Clin. 
Prod. Rev. (Jan/Feb), 8-18.
273
McCarthy, R.D. and Long, C.A. (1976). J. Dairy. Sci.
59, 1059-1062.
McCord, J.M. (1985). New. Engl. J.Med. 312,
159-162.
McDonald, L. (1960). Proc. Roy. Soc. Med. 5J1, 35-38. 
McGill, H.C.Jr. (1984). Arteriosclerosis. 4, 443-451. 
Marchand, F. (1904). Ver handlung der Kongres fur innere 
Medizin. 2^, 23-59.
Markwell, M.A.K., Haas, S.M., Tolbert, N.E. and Bieber, 
L.L. (1981). Meth. in. Enzymol. T 2 f 296-303.
Matel, M.B., Dubois, P. and Got, R. (1973). Biochem.
Biophys. Acta. 311, 565-575.
Mather, I.H. (1978). Biochem. Biophys. Acta. 514,
25-36.
Mather, I.H. and Keenan, T.W. (1975). J.Memb. Biol. 21, 
65-85.
Mather, I.H., Sullivan, C.H. and Madara, P.J.(1982),
202, 317-323.
Medof, M.E., Iida, K., Mold, C. and Nussenzweig, V.
(1982). J. Exp. Med. 156, 1739-1754.
Minick, C.R. (1976). Ann. New. York. Acad. Sci. 275, 
210-226.
Minick, C.R. and Murphy, G.E. (1973). Am. J. Pathol.
73, 265-300.
Mitchell, J.R.A. (1978). British Medical Bulletin. 34, 
105-106.
Mitchell, J.R.A. and Schwartz, C.J. (1965). In "Arterial 
Disease", pp50-65, (Davis, F.A. Ed). Blackwell 
Scientific, Philadelphia.
Monacada, S., Gryglewski, R.J., Bunting, S. and Vane, 
J.R. (1976). Nature. 261, 663-665.
Monro, J., Carini, C. and Brostoff, J. (1984). Lancet, 
ii, 719-721.
Moore, S. (1974). "Vascular Injury and Atherosclerosis" 
Marcel Dekker Inc, New York.
Moore, S., Friedman, R.J., Singal, D.P., Blajchman,
M.A. and Roberts, R.S. (1976). Thromb. Haemost. 35 
70-81.
Moreau, P. and Andre, A. (1954). Nature. 174, 88-90
Morrisey, J.H. (1981). Anal. Biochem. 117, 307-310.
Morton, R.K. (1954), Biochem. J. 5^ 7, 231-237.
Mostov, K.E., Friedlander, M. and Blobel, G. (1984). 
Nature. 308, 37-43.
Mowat, A.M. (1987). Immunology Today. 8 (3), 93-98.
Moxey, P.O. and Thier, J.S. (1975). Gastroenterology. 
68, 1002-1009.
Murano, G. and Bick, R.L. (1980). In "Basic Concepts of 
Hemostasis and Thrombosis: Clinical and laboratory 
evaluation of thrombohemorrhagic phenomena." CRC 
Press Inc, Boca Raton.
Nachman, R.L. and Weksler, B. (1980) in "The Cell
Biology of Inflammation" (Weissman, G. Ed). 145- 
160, Elsevier, Amsterdam.
Nagler, L.G. and Vartanyan, L.S. (1976). Biochem. 
Biophys. Acta. 427, 78-90.
Nakamura, M. and Yamazaki, I. (1982). J.Biochem. 92, 
1279-1286.
275
Newman, R.A. and Harrison, R. (1973). Biochem. Biophys.
Acta. 298, 798-809.
Newsom-Davies, J. and Vincent, A. (1982). in "Clinical 
Aspects of Immunology" 4th edn, Vol2^ pplOll 1068 
Lachmann, P.J. and Peters, D.K. Eds). Blackwell 
Scientific Publications.
Nielsen, C.S. and Bjerrum, O.J. (1977). Biochem.
Biophys. Acta. 446, 496-509.
Nishino, Y., Nishino, T. and Tsushima.K (1981). FEBS. 
Lett. 131, 369-372.
Oliver, M.F. and Boyd, G.S. (1959). Lancet, i^ i, 690-694. 
O.P.C.S. Monitor (1982). "Death by cause (DH2) 1982". 
Public office of population censuses and surveys, 
London.
Oster, K.A. (1968). Cardiol. Digest. 3, 29-34.
Oster, K.A. (1971). Am J. Clin. Res. 2 , 30-35.
Oster. K.A. (1972). In "Myocardiology" Vol l.,pp 803- 
813, (Bajusz, E. and Rona, G. Eds). Univ. Park. 
Press, Baltimore.
Oster, K.A. (1973a). in "Myocardial Metabolism." pp 73- 
80, (Dhalla, N.S. Ed). Univ. Park. Press,
Baltimore.
Oster, K.A. (1973b). Medical Counterpoint. j>, 26-36. 
Oster, K.A. (1976). Am. Lab. S r 47-49.
Oster, K.A. and Hope-Ross, P. (1966). Am. J. Cardiol.
17, 83-85.
Oster, K.A. and Mulinos, M.G. (1944). Pharmacol. Exp. 
Theor. 84, 132-138.
276
Oster, K.A., Oster, J.B. and Ross, D.J. (1974). Am. Lab. 
6 , 41-47.
Oster, K.A. and Ross, D.J. (1975). Recent. Adv. Stud.
Cardiac. Struct. Metab. 10, 401-410.
Owen, R.L. (1977). Gastroenterology, 72, 440-451.
Paganelli, R., Levinsky, R.J., Brostoff, J., Wraith,
D.C. (1979) Lancet, i, 1270-1272.
Page, C.P. (1988). Trends in Pharra. Sci. 9, 66-71. 
Palmer, L.S. and Samuelson, E. (1924). Proc. Soc. Exp.
Biol. Med. 21, 537-539.
Parish, W.E., Barrett, A.M., Coombs, R.R.A., Camps, F.E.
and Gunther, M. (1960). Lancet. i_i, 1106-1110. 
Parker, R.E. (1973). In "Introductory Statistics for 
Biology". Edward Arnold Ltd, London.
Parks, D.A. and Granger, D.N. (1986). Acta. Physiol.
Scand. Suppl. 548, 87-99.
Patton, S. and Keenan, T.W. (1975). Biochem. Biophys.
Acta. 415, 273-309.
Patton, S. and Trams, E.G. (1971). Febs. Lett. 14, 230- 
232.
Pfueller, S.L. and Luscher, E.F. (1972). J. Immunol.
109, 517-525.
Phillips, D.R. and Agin, D.P. (1977). Biochem. Biophys.
Res. Commun. 75, 940-947.
Playfair, J.H.L. (1982). "Immunology at a Glance".
Blackwell Scientific Publications, Oxford.
Poole, J.C.F., Sanders, A.G. and Florey, H.W. (1958).
J. Pathol. Bact. 75, 133-158.
277
Poston, R.N. (1975). Lancet, ii., 502-503.
Poston, R.N. and Davies, D.F. (1974). Atherosclerosis. 
19, 353-367.
Powell, J.T., Jarlfors, U. and Brew. K. (1977). J. Cell. 
Biol. 72, 617-627.
Puett, D.W., Forman, M.B., Cates, C.V., Wilson, B.H., 
Hande, K.R., Friesinger, G.C., Virmani, R.
(1987). Circulation. 7j>, 678-686.
Raz, A.M., Minkes, M.S. and Needleman, P. (1977)
Biochem. Biophys. Acta. 488, 305-311.
R.C.G.P. (Royal College of General Practitioners)
(1986). ’’Morbidity statistics from general practice 
1981-1982. Third national survey" HMSO, London.
Rees, B.W.G. (1973). Med. Lab. Tech. 30, 167-177.
Rees, B.W.G. (1985). PhD Thesis."The Interaction of 
Platelets and Exogenous Antigenic Factors in 
Coronary Heart Disease." Open University.
Rees, B.W.G. Dept of Haematology, West Wales Hospital, 
Carmarthen, Wales, U.K.
Reid, J., Research and Development Division, Flow Lab, 
Second Avenue, Industrial Estate, Irvine, Scotland 
U.K.
Reidy, M.A. (1985). Lab. Invest. j^ 3, 513-520.
Reidy, M.A. (1986). In "Biology and Pathology of
Platelet Vessel Wall Interactions." (Jolles. G . , 
Legrand, Y.J. and Nurden.A. Eds). Proc. Rhone 
Poulenc Sante Inserm conference. Academic Press, 
London.
278
Reidy, M.A. and Schwartz, S.M. (1984). Exp. Mol. Pathol. 
41, 419-434.
Reimer, K.A. and Jennings, R.B. (1985). Circulation. 71, 
1069-1075.
Reinhardt, M.C., Paganelli, M.D. and Levinsky, R.J.
(1983). Ann. Allergy. 51^ , 311-312.
Rhodes, R.S. and Karnovsky, M.J. (1971). Lab. Invest.
25, 220-229.
Richards, F.M. and Knowles, J.R. (1968), J. Mol. Biol. 
37, 231-233.
Richman, L.K., Graef, F.A.S., Yarchsan, R. and Shober,
W. (1981). J.Immunol. 126, 2079-2083.
Robson, C. (1973). In "Experiment, Design and Statistics 
in Psychology". (Foss, B.M. Ed). Chaucer Press, 
Bungay.
Roitt, I. (1977). "Essential Immunology". Blackwell 
Scientific Publications.
Roitt, I. (1988). "Essential Immunolgy". Blackwell 
Scientific Publications.
Roitt, I., Brostoff, J. and Male, D. (1985).
"Immunolgy". Gower Medical Publishing C, New York 
and London.
Rosenberg, R.D., Reilly.C. and Fritze, L. (1985). Ann.
New York. Acad. Sci. 454, 270-278.
Ross, D.J., Ptaszynski, M. and Oster, K.A. (1973). Proc.
Soc. Exp. Biol. Med. 144, 523-526.
Ross, P.J., Sharnick, S.V. and Oster, K.A. (1980). Proc.
Soc. Exp. Biol. Med. 163, 141-146.
Ross, R. (1986). New. Eng. J. Med. 314, 488-500.
279
Ross, R., Glomset, J., Kariya, B. and Harker, L.A
(1974). Proc. Nat. Acad. Sci. U.S.A. Tit 1207-1210. 
Rothberg, R.M. (1969)- J. Pediatr. 7^, 391-399.
Rudel, L.L., Bond, M.G. and Bullock, B.C. (1985). Ann.
New York. Acad. Sci. 454, 248-253.
Ruttenberg, E.J., Steerenberg, P.A., Brosi, B.J.M. and 
Buys, J. (1976). J. Imm. Meth. 1^ ), 67-83.
Rutter, J.V., Harrison, R . , Jehanli. A. and Lunt, G.G. 
(1986). Biochem. Soc. Trans. 1236, 619th meeting. 
Cambridge, U.K.
Rzucidlo, S.J. and Zikakis, J.P. (1979). Proc. Soc. Exp. 
Biol, and Med. 160, 477-482.
Saphir, O. and Gore, I. (1950). Arch. Pathol. 4j), 418- 
425.
Schloss, O.M. (1924-1925). Harvey Lectures. _10, 156-187. 
Schwartz, S.M. and Benditt, E.P. (1976). Proc. Nat.
Acad. Sci. 7^, 651-653.
Scott, B.B., McGuffin, P., Swinburne, M.L. and 
Losowsky, M.S. (1976). Lancet. i_i, 125-126.
Seely, S. (1981). Medical Hypoth. 1_, 907-918.
Segall, J.J. (1977). Brit. J. Prev. Soc. Med. 31, 81-85. 
Seifert R.A., Schwartz, S.M. and Bowen-Pope, D.F.
(1984). Nature. 311, 669-671.
Sela, B. and Edelman, G.M. (1977). J. Exp. Med. 145, 
443-449.
Shamma'a, M.H., Nasrallah, S.M. and Al-Khalidi, U.A.S. 
(1973). Dig. Dis. 18, 15-22.
280
Shaper, A.G., Pocock. S.J., Walker, M . , Cohen, N.M.,
Wale, C.J. and Thompson, A.G. (1981). Brit. Med. J. 
2, 179-186.
Shimamoto, T. (1963). J. Athero. Res. 3^, 87-102. 
Shimamoto, T. and Nuraano, F. (1969). In "Atherogenesis" 
(International Congress series, No 201). Excerpta 
Medica, Amsterdam.
Shimokado, K., Raines, E.W., Madtes, D.K., Barret, T.B., 
Benditt, E.P. and Ross, R. (1985). Cell. 4_3, 277- 
286.
Shekelle, R.B., Shryock, A.M., Oglesby, P., Lepper, M., 
Stamler, J., Liu, S.and Raynor, W.J. (1981). New. 
Eng. J. Med. 304, 65-70.
Shiner, M. and Ballard, J. (1972) Lancet, i., 1202-1205. 
Shulman, N.R. (1964). Ann. Intern. Med. 6J), 507-521. 
Siegel, S. (1956). In "Nonparametric statistics For the 
Behavioural Sciences". McGraw Hill Book Co. Inc,
New York.
Silk, D.B.A. (1974). Gut. 15, 494-495.
Smith, G.W., McArthur, C.J. and Simpson, I.J. (1983). J.
Clin. Lab. Immunol. 3J2, 197-199.
Sniderman, A., Shapiro, S., Marpole, D., Skinner, B., 
Teng, B. and Kwiterovich, P.O. Jr. (1980). Proc. 
Nat. Acad. Sci. U.S.A. 77, 604-608.
Stamler, J., (1963). In "Atherosclerosis and its
origin", pp 231-262. (Sandler, M.and Bourne,G.H. 
Eds). Acad. Press, New York.
Steiner, M. (1985). Biochem. Biophys. Res. Commun. 129, 
206-212.
281
Stryer, L. (1981). "Biochemistry". W.H.Freeman and 
Co, San Francisco.
Switzer, R.C., Merril, C,R. and Shifrin, S. (1979).
Anal. Biochem. 98, 238-241.
Szczeklik, A., Sladek, K., Szczerba, A. and Dropinski,
J. (1988). Circulation. 71_, 1245-1249.
Tangen, 0., Berman, H.J. and Marfey, P. (1971). Thromb.
Diath. Haemorrh. Z5, 268-278.
Taussig, M.J. (1979). In "Processes in Pathology", 
Blackwell Scientific Publications.
Taylor, K.B. and Truelove, S.C. (1961). Br. Med. J. 2, 
924-929.
Thiery, J.P. and Bessis, M. (1956). Rev. Hemat. 1_, 162-
175.
Thoma, R. (1883). Virchows. Archiv. 104, 209.
Thomas, E. Dept of Haematology, West Wales Hospital, 
Carmarthen, Wales, U.K.
Thompson, C.B., Eaton, K.A., Princiotta, S.M., Rushin, 
C.A. and Valeri, C.R. (1982). B r . J. Haematol. 50, 
509-519.
Thompson, J.G. (1969). Lancet. i_i, 1088-1092.
Thompson, M.P., Brunner, J.R., Lindqvist, K. and Stine, 
C.M. (1961). J. Dairy. Sci. 44, 1589-1596.
Tofler, G.H., Brelinska. and Schafer, A.I. (1987). New.
Eng. J. Med. 316, 1514-1518.
Toivanen, A., Vilijanen, M.K. and Savilahti, E. (1975a). 
Lancet, ii, 205-207.
282
Toivanen, A . , Vilijanen, M.K. and Savilahti, E. (1975b).
Lancet, jli, 927.
Towbin, H. and Gordon, J. (1984). J. Immunol. Meth. 12, 
313-340.
Towbin, H . , Staehelin, T. and Gordon, J. (1979). Proc.
Nat. Acad. Sci. U.S.A. 76^ , 4350-4354.
Trent, R., Clancy, R., Danis, V. and Basten, A. (1980).
Br. J. Haematol. 44^ , 645-654.
Triolo, G . , Traina, M . , Giardina, E., Rinaldi, A. and
Raineri, A. (1984). J. Clin. Lab. Immunol. 1J3 (1), 
35-39.
Uhlenhuth, G. (1900). Deutsche. Med. Woch. 26^ , 734. 
Ultmann, J.E., Feigelson, P. and Harris, S. (1962).
J. Immunol. 8J3, 113-120.
Underdown, B.J. and Schiff, J.M. (1986). In "Annual 
Review of Immunology". pp389-417.(Paul. W.E., 
Fathman, C.G. and Metzger, H. Eds), Annual Reviews 
Inc. California.
Van Es, L.A., Daha, M.R., Valentijn, R.M. and Kauffman, 
R.H. (1984) Neth. J. Med. 27, 350-358.
Van Leeuenhoek, A. (1674). Phil. Trans. 9, 102.
Van Leeuwen, E., Von Dem Borne, A., Van Der Plas Van 
Dalen, C. and Engelfriet, C. (1981). Scand. J. 
Haematol. 26, 285-291.
Vemura, K., and Pisa, Z. (1985). World Health 
Statistics Quarterly. ^8, 142-162.
283
Vincent, A. (1979). J. Clin. Path. 13, 97-106.
Vines, G. (1989). New Scientist. No 1653, 44-49.
Virchow, R. (1856). In "Phlogose und Thrombose im 
Gefass-system Gesammelte Abhandlungen zur 
wissenschaftlichen Medizin" p458. Meidinger, 
Frankfurt.
Vogel, J. (1847). In " the Pathological Anatomy of the
Human Body”. Cited By T. Crawford. (1955). Lean and 
Blanchard, Philadelphia.
Volp, R.F. and Lage, G.L. (1977). Proc. Soc. Exp. Biol.
Med. 154, 488-492.
Von dem Borne, A.E.G.K., Van Leeuwen, E.F., Von Riesz,
L.E., Van Boxtel, C.J. and Engelfriet, C.P. (1981). 
Blood. 17, 649-656.
Von Haller, A. (1755). Opuscula Pathologica Observatio, 
LI.
Von Rokitansky, C. (1844). In "Handbuch der
PathologischenAnatomie" Vol 2. Braunmuller and 
Seidel, Vienna.
Walker, W.A. (1975). Pediatr. Clin. North. Am. 12, 731- 
746.
Walker, W.A. (1978). Arch. Dis. Chid. 53, 527-531. 
Walker, W.A., (1979). Ciba. Found. Symp. 70, 201-219. 
Walker, W.A. (1985). Pediatrics (suppl) . 75./ 167-171. 
Walker, W.A. and Isselbacher, K.J. (1974).
Gastroenterology. 17, 531-550.
Walker, W.A. and Isselbacher, K.J. (1977). New Eng. J. 
Med. 297, 767-773.
284
Walsh, C . , Nardi, M. and Karpatkin, S. (1984), New. Eng.
J. Med. 311, 635-639.
Walstra, P. (1966). Neth. milk. Dairy. J. 23, 99-110. 
Walstra, P. (1974). Neth. milk. Dairy. J. _28, 3-9. 
Warburg, O. and Christian, W. (1940). Biochem. J. 303, 
40.
Warsaw, A.L., Walker, W.A. and Isselbacher, K.J. (1974).
Gastroenterology. 66, 987-995 
Weiler, I.J., Hickler, W . , Sprenger, R. (1983). Am J.
Repro Immunol. 4, 95-98.
Weisgraber, K.H., Rail. S.C. Jr, Mahley, R. W., Milne, 
R.W., Marcel, Y.L. and Sparrow, J.T. (1986). J. 
Biol. Chem. 261, 2068-2076.
Weiss, H.J., Hoyer, L.W., Pickles, F.R., Varna, A. and 
Rogers, J. (1973). J. Clin. Invest. 52, 2708-2716. 
Wells, N. (1982). In "Coronary Heart Disease:the scope 
for prevention". Office of Health Economics, 
studies of current health problems: no 73, London. 
Wells, N. (1986). In "Coronary Heart Disease: The need
for action". Office of Health Economics, studies of 
current health problems; no 86, London.
Werns, S.W., Shea, M.J. and Lucchesi, B.R. (1986).
Circulation, 73, 518-524.
Wilson, S.J. and Walzer, N. (1935). Am. J. Dis. Child. 
50, 49-57.
Wiman, K., Curman, B., Tragard, R.L., Peterson, P.A.
(1979). Eur. J. Immunol. 9 (3), 190-195.
Winiarski, J. and Ekelund, E. (1986). J. Exp. Immunol. 
63, 459-465.
285
Wintrobe (1974). In "Clinical Haematology". Lea and 
Febiger, Philadelphia.
Wiseman, G. (1964). In "Absorption from the Small
Intestine". Academic Press, New York and London. 
Wolinsky, H., Goldfischer, S., Daly, M.M., Kasak, L.E. 
and Coltoff-Schiller, B. (1975). Circ. Res. 36, 
553-561.
Wooding, F.B.P. (1971). J. Cell. Sci. 9, 805-821. 
Wooding, F.B.P. (1973). J. Cell. Sci. 13, 221-235. 
Woolf, N. (1982). In "Pathology of Atherosclerosis".
(Crawford, T.Ed). Butterworths and Co Ltd, London 
and Frome.
Zak, F.G., Halpern, M. and Adlerberg, D. (1952).
Angiology. 3, 289.
Zikakis, J.P., Rzucidlo, S.J. and Biasotto, N.O.
(1976). J. Dairy. Sci. 6J), 533-541.
Zikakis, J.P. and Wooters, S.G. (1980). J. Dairy. Sci. 
63, 893-904.
Zittle, C.A., Dellamonica, E.S., Custer, J.H., Rudd, 
R.K., (1956). J. Dairy. Sci. ^9, 528-535.
